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Regulation of Parkin Protein Levels by L-3,4-dihydroxyphenylalanine 
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 Parkinson's disease (PD) is a debilitating neurodegenerative disorder, affecting roughly 
2% of those over the age of 80. Though most cases of PD are "sporadic", arising without a 
family history, a minority of cases have a clear autosomal dominant or recessive inheritance 
pattern. The most common known cause of autosomal recessive PD is homozygous inactivation 
of PARK2, which codes for the E3 ubiquitin ligase parkin. In addition, there is evidence that 
parkin inactivation may play a role in the pathogenesis of sporadic PD as well. As such, 
strategies aimed at increasing parkin activity hold therapeutic promise for sporadic PD. 
 Though much work has examined the functions of parkin, and, more recently, the 
mechanisms by which it is activated, substantially less is known about how parkin levels are 
regulated in the cell. This is particularly true for activated parkin. Understanding these regulatory 
mechanisms is critical for the effective development of therapeutic strategies based on 
upregulation of parkin activity. The work presented in this dissertation provides new insights into 
these regulatory mechanisms. 
 We show that relatively high doses of the dopamine precursor L-3,4-
dihydroxyphenylalanine (L-DOPA) decrease parkin protein levels in vitro, analogously to 
previous findings using other cellular stressors. Characterizing this effect, we show that L-DOPA 
increases parkin degradation and that this occurs independently of L-DOPA's conversion to 
dopamine and of L-DOPA-induced cell death. Furthermore, we define two distinct pathways by 
which L-DOPA decreases parkin: an oxidative stress-dependent pathway and an oxidative stress-
independent pathway. We show that the former overlaps with the previously defined mechanism 
of PINK1-mediated parkin activation. Specifically, parkin's association with PINK1-generated 
phosphorylated ubiquitin (phospho-Ub) leads to its proteasomal degradation downstream of 
oxidative stress, but not via autoubiquitination. Despite the involvement of PINK1 in parkin loss 
from L-DOPA treatment, we do not observe evidence of mitochondrial parkin activity after L-
DOPA treatment, indicating that, surprisingly, parkin loss does not depend on this activity. 
Additionally, we provide evidence against the involvement of Trib3 and NADPH oxidases in 
parkin loss from L-DOPA. Finally, we provide preliminary evidence that parkin knockdown 
does not sensitize cells to L-DOPA-induced death. 
 Taken together, the findings in this dissertation contribute to the understanding of parkin 
regulation. Our observation that parkin's association with phospho-Ub leads to its degradation 
following L-DOPA treatment is of particular interest because it may represent the steady-state 
mechanism by which levels of activated parkin are kept in check. In light of this, an attractive 
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Chapter 1 Introduction 
 This dissertation describes findings about the regulation of the Parkinson's disease-related 
ubiquitin ligase parkin by L-DOPA. As such, this chapter provides relevant background 
information about Parkinson's disease, parkin characteristics and regulation, and L-DOPA. 
1.1 Parkinson's disease 
1.1.1 Overview 
 Parkinson's disease (PD), is the second most-common neurodegenerative disease in the 
world [1]. The incidence of PD increases with age, peaking between the ages of 70 and 79 [2], 
[3]. Accordingly, ~0.05% of those between the ages of 40 and 49 and ~2% of those over 80 are 
affected [4]. Though most cases of PD are sporadic, 15-25% of patients report having a family 
history of the disease [5]. PD is more prevalent in men than in women, though the reason for this 
remains unclear [3]. Although PD has been recognized as a clinical entity by Western medicine 
for 200 years [6], we still lack a full understanding of the disease etiology, and there is currently 
no cure and no treatment to halt or slow disease progression [3]. While there are several 
treatments to treat PD symptoms (including L-DOPA, the "gold standard" treatment), their 
benefit diminishes over time [7], [8]. 
 Though PD has traditionally been thought of as a movement disorder, new diagnostic 
criteria for PD have recently been proposed that reflect an advancing understanding of the 
disease [3], [9], [10]. Under these new criteria, similarly to previous diagnostic iterations, 
"Clinically Established PD" is defined by the presence of specific motor symptoms, namely 
slowness of movement (bradykinesia), rigidity, and/or tremor at rest [9]. Additionally, however, 
supporting evidence that can help establish a diagnosis of PD now includes decreased sense of 
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smell and cardiac denervation [9]. The inclusion of the latter two symptoms in the most recent 
diagnostic criteria reflects a growing understanding that PD encompasses many non-motor 
symptoms. These include, in addition to the two mentioned above, autonomic dysfunction, sleep 
disturbance, cognitive impairment, and mood disorders [11].  
 Neuropathologically, PD is defined by loss of dopaminergic neurons from a region of the 
midbrain called the substantia nigra pars compacta (SNpc) and by the presence of aggregates 
inside neuronal cell bodies and neurites throughout the central and peripheral nervous systems, 
collectively called Lewy pathology [3], [12], [13]. Dopaminergic neurons of the SNpc modulate 
movement via their projections to the striatum [3], [14], and, accordingly, loss of these neurons 
in PD underlies the cardinal motor symptoms of the disease [12]. There is evidence that loss of 
SNpc neurons begins with degeneration of their terminals in the striatum, a "dying-back" process 
[15]. Accordingly, by the time the motor symptoms of the disease begin to appear, about 50-70% 
of dopaminergic striatal terminals and 30% of cell bodies in the SNpc have been lost [15]. 
 The functional significance of the other neuropathological hallmark of PD, Lewy 
pathology, has been more difficult to pin down. The most abundant component of Lewy bodies 
and neurites is the protein α-synuclein [16], [17], though various other proteins, including 
ubiquitin, have also been found to be present [18]. Braak and colleagues first proposed the idea 
that, in PD, Lewy pathology spreads through the brain in a characteristic pattern, beginning in 
the brainstem and olfactory bulbs, and that disease severity correlates with the extent of 
propagation [13], [19]. This idea has been the subject of considerable debate [20]–[24]. On the 
one hand, a substantial proportion of PD patients do exhibit Lewy pathology in keeping with 
Braak's staging [21], and there is substantial evidence that α-synuclein can spread between 
neurons (discussed below). However, many patients don't exhibit pathology that matches the 
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staging scheme [20], [21], and the correlation between extent of Lewy pathology and clinical 
symptoms is tenuous, with one study finding that half the people with advanced stage Lewy 
pathology did not display PD symptoms [25]. Furthermore, the experimental design of the 
original Braak study has been questioned because it seems that early-stage cases were screened 
for pathology in the DMV prior to inclusion [24]. 
 Like Braak's staging scheme, the possible relationship between Lewy pathology and 
toxicity has been an evolving question [23], [26]–[28]. Though it remains unresolved, 
accumulating evidence suggests that Lewy pathology may actually serve a protective function, 
capturing and segregating small, toxic oligomers of α-synuclein from the rest of the cell [27]–
[30].  
 While loss of dopaminergic neurons of the SNpc is considered to be the 
neuropathological hallmark of PD, other neuronal populations are often lost as well [31]. Loss of 
some of these populations is thought to underlie some of the non-motor symptoms of the disease. 
For example, degeneration of dopaminergic neurons of the enteric nervous system is thought to 
underlie constipation associated with the disease [31], [32]. Additionally, nearly all PD patients 
exhibit some loss of the sympathetic neurons that innervate the heart, which frequently results in 
orthostatic hypotension [31], [33], [34]. In the central nervous system, other neuronal 
populations that are very commonly lost in PD include norepinephrine neurons of the locus 
coeruleus (LC) and neurons of the dorsal motor nucleus of the vagus (DMV) [31], though the 
clinical consequences of these losses are not clearly defined [35], [36]. In the case of the LC, 
neuronal loss appears to exacerbate the degeneration of SNpc neurons and possibly contribute to 
the development of dementia from PD [35], [37]. In the case of the DMV, degeneration may 
contribute to gastrointestinal dysfunction and increased inflammation [36]. 
  4 
1.1.2 Disease Etiology 
 Though our understanding of PD etiology continues to improve, we still don't fully 
understand how the disease arises. Age is the greatest risk factor for developing PD, but whether 
the mechanisms that underlie PD are distinct from normal aging or, conversely, represent 
accelerated aging, has been debated for decades [38], [39]. Despite this, there is general 
agreement that PD is probably a multifactorial disease, with concurrent dysfunction and interplay 
between multiple biological pathways necessary for its development [3], [38], [40], [41]. 
1.1.2.1 Environmental underpinnings 
 A long-standing hypothesis about PD etiology is that exposure to environmental toxins 
promotes neurodegeneration. This idea was first thrust into the spotlight with the discovery that 
accidental intravenous injection of the compound 1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine 
(MPTP) by drug users led to acute parkinsonism with a very striking similarity to PD [42], [43]. 
MPTP and its metabolite, MPP+ (1-methyl-4-phenylpyridinium), are structurally quite similar to 
the pesticide paraquat, which prompted epidemiological studies that examined the possible 
connection between PD and pesticide exposure [44]. Over time, it became apparent that, indeed, 
there does appear to be a positive correlation between pesticide exposure and PD [44]–[46], with 
one recent meta-analysis reporting a ~50% increased risk of PD associated with pesticide 
exposure [46]. MPP+ and many pesticides interfere with mitochondrial respiration [47]–[49], an 
observation that provided the first compelling evidence that mitochondrial dysfunction plays a 
role in PD pathogenesis.  
  5 
1.1.2.2 Genetic underpinnings 
 The last twenty years have seen tremendous advancement in our understanding of the 
genetic underpinnings of familial PD [50], and, from this work, it has become apparent that 
many of the mechanisms underlying familial and sporadic PD are shared [3]. 
 The first gene to be linked to PD was SNCA, which codes for α-synuclein [51]. The 
discovery that α-synuclein is the primary component of Lewy pathology [16], [17] further 
emphasized its central role in PD. In addition to missense mutations, whole-gene duplications 
and triplications of SNCA also lead to PD, with the latter causing a more aggressive disease than 
the former [52]–[54]. This indicates that excess amounts of normal α-synuclein cause PD, which 
is consistent with evidence that α-synuclein misfolding underlies its pathogenicity [27], [28]. 
 Mutations in SNCA and two other genes, LRRK2 and VPS35, lead to PD with an 
autosomal dominant inheritance pattern [50], [55]. Conversely, mutations in the genes PARK2 
(encoding parkin), PINK1, and PARK7 (encoding DJ-1) lead to PD with an autosomal recessive 
inheritance pattern and an early onset [50], [55]. Many mechanisms have been proposed to 
explain the pathogenicity of mutations in the these genes, and there is overlap among them and 
with mechanisms that had previously been implicated in PD pathogenesis [3], [27], [56]–[65]. 
The most salient of these mechanisms are promotion of α-synuclein oligomerization, 
neuroinflammation, dysregulated autophagy, oxidative stress, and mitochondrial dysfunction. 
These mechanisms are briefly discussed below. 
1.1.2.3 α-synuclein oligomerization 
 One of the most established mechanisms underlying PD pathogenesis is α-synuclein-
mediated toxicity. α-synuclein normally exists as an unfolded monomer and/or in a homo-
tetramer, but, in the pathogenic process, it aggregates into small oligomers, which gradually give 
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rise to fibrils with beta sheet structure, and finally, to Lewy pathology [27], [28]. It is currently 
believed that the oligomeric α-synuclein species mediate its toxicity [27], [28]. 
 Though idea that Lewy pathology is itself toxic has fallen into disfavor, evidence exists 
to support Braak's hypothesis that Lewy pathology spreads from one brain region to another. One 
of the earliest pieces of evidence of α-synuclein propagation between neurons was the finding by 
two groups that grafts of fetal tissue implanted in PD brains could develop Lewy pathology [66], 
[67]. Subsequently, this propagation has been demonstrated in cell culture and animal models 
[68]. Though the precise nature of the α-synuclein species that gets transmitted (i.e. fibril, 
oligomer, etc.) is unclear, propagation involves α-synuclein secretion by one cell, uptake by 
another, and "seeding" of α-synuclein aggregates in the recipient cell [68].  
 Many mechanisms have been proposed for α-synuclein-mediated toxicity in PD. These 
include interference with proteasomal and lysosomal protein degradation, membrane 
permeabilization, mitochondrial impairment, disruption of ER-Golgi transport, and disruption of 
α-synuclein's normal function in synaptic vesicle trafficking [3], [27], [68], [69]. Additionally, 
there is accumulating evidence from in vitro and in vivo models and even patient samples that α-
synuclein can evoke a pathogenic immune response [63], [70]. 
1.1.2.4 Neuroinflammation 
 There is an evolving appreciation that pathological immune activation is a key 
contributor to neurodegeneration in PD. Various studies have found evidence of increased 
microglial activation and peripheral immune cell infiltration in the PD brain [63]. Additionally, 
levels of pro-inflammatory cytokines are increased in the serum and CSF of PD patients [63]. In 
PD animal models, activation of a neuroimmune response has been found to cause degeneration 
of dopaminergic neurons [63], [71], [72]. Additionally, neuroinflammation has been shown to 
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promote α-synuclein aggregation [71]. Recently, Matheoud et al. suggested a novel mechanism 
by which increased neuronal stress could lead to neuroimmune-mediated degeneration [64]. The 
authors found evidence that stress from elevated heat and the inflammogen LPS leads immune 
cells to present mitochondrially-derived antigens on their surface. Furthermore, they found that 
the PD-linked proteins parkin and PINK1 oppose this process. This suggests that loss of function 
of PINK1 and parkin, which leads to PD, could promote neuronal degeneration via enhanced 
mitochondrial antigen presentation and subsequent attack by T cells. In support of this 
possibility, parkin null mice, which lack a neurodegenerative phenotype, were found to have 
selective degeneration of SNpc neurons after chronic LPS administration [73]. 
1.1.2.5 Dysregulated autophagy/lysosomal function 
 Another mechanism that is now widely recognized to contribute to PD pathogenesis is 
dysregulation of the autophagy-lysosomal system [3], [65]. There is evidence that this system is 
impaired in the SNpc of PD patients [74]–[76]. Such impairment might be expected to lead to 
toxicity from aberrant protein accumulation. In line with this possibility, several studies have 
demonstrated that deletion of key autophagy genes in mice leads to neurodegeneration and 
concomitant accumulation of proteins in inclusion bodies [65], [77], [78]. In the case of PD, 
there is evidence that impaired autophagy and lysosomal function leads to α-synuclein 
accumulation [3]. For example; reduced activity of the lysosomal enzyme glucocerebrosidase 
leads to elevated α-synuclein levels both in vitro and in vivo [3], [79]. This observation is 
particularly relevant to PD because inactivating mutations in GBA, with codes for 
glucocerebrosidase, are a strong risk factor for development of PD [79]. Similarly, a PD-causing 
mutation in the gene VPS35 has been found to elevate α-synuclein by decreasing Lamp2a, the 
lysosomal receptor for chaperone-mediated autophagy [80]. 
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1.1.2.6 Oxidative stress 
 Another pathological change that has been well-documented in PD is an increase in 
oxidative stress, defined as a shift in the balance between production of reactive oxygen species 
(ROS) and antioxidant defense mechanisms toward the former [81]. PD patients have been 
observed to have increased markers of lipid and RNA oxidation in their cerebro-spinal fluid 
(CSF), and their brains display elevated levels of lipid peroxidation, protein modification by 
carbonyls, and DNA oxidation [82]–[84]. Oxidative stress has long been theorized to contribute 
to PD pathogenesis [85]–[87]. This is partly because many of the neurons that degenerate in the 
disease, including those of the SNpc, are catecholaminergic [31], and catecholamines (including 
dopamine, epinephrine, norepinephrine) are susceptible to autoxidation, generating ROS and 
reactive quinone products that can lead to oxidative stress [88]. Additionally, metabolism of 
dopamine, epinephrine, and norepinephrine by monoamine oxidase (MAO) leads to hydrogen 
peroxide formation, which can be converted to the highly reactive hydroxyl radical [89]. There is 
evidence to support the idea that dopamine-derived oxidative stress contributes to the demise of 
SNpc neurons. For example, two recent studies reported that transgenic mice that lack a 
neurodegenerative phenotype developed SNpc degeneration after exposure to measures that 
increased cytosolic dopamine content [90], [91]. One of these measures was administration of L-
DOPA [91], the precursor to dopamine. L-DOPA remains the gold standard of treatment for PD 
motor symptoms [7], so the fact that it promoted neurodegeneration in a PD mouse model raises 
concerns regarding its possible toxicity in PD patients. This question, of whether L-DOPA 
exposure hastens the degenerative process in PD, has been a perennial one in the field, and one 
that remains unresolved (discussed in Section 1.3).  
  9 
1.1.2.7 Mitochondrial dysfunction 
 As mentioned in Section 1.1.2.1, the first line of evidence that mitochondrial dysfunction 
is involved in PD pathogenesis came from the observation that MPP+ interferes with 
mitochondrial function via inhibition of mitochondrial complex I. Subsequently, systemic 
exposure of rats to relatively low doses of the complex I inhibitor rotenone was shown to cause 
selective degeneration of SNpc neurons and α-synuclein aggregation [92]–[94]. This selective 
degeneration is striking because rotenone is lipophilic and thus can cross into all cells if injected 
systemically [92]. Given that rotenone is a mitochondrial complex I inhibitor, the fact that it can 
so faithfully reproduce two hallmark features of PD is compelling evidence that mitochondrial 
dysfunction contributes to disease pathogenesis. 
 There is additional evidence implicating mitochondrial dysfunction as a pathogenic 
mechanism in PD. For one, different studies have reported decreased mitochondrial complex I 
activity in various tissues from PD patients [57]. Additionally, there is evidence of increased 
deletions and mutations in mitochondrial DNA from the SNpc of PD patients [57]. Finally, the 
discovery that the PD-linked genes PINK1 and parkin have central roles in mitochondrial quality 
control (discussed in Section 1.2.3) suggests that mitochondrial dysfunction could play a key role 
in PD arising from their loss [95]. 
 Mitochondrial dysfunction plays a prominent role in two recent models to explain the 
selective degeneration of certain neuronal populations in PD. These models propose that specific 
characteristics make these neuronal populations particularly vulnerable to mitochondrial 
dysfunction [96], [97]. First, these populations tend to have extensively branched, poorly 
myelinated axonal arbors [96]; second, they often exhibit slow, rhythmic "pacemaking" activity 
in conjunction with oscillations in intracellular calcium concentration [97]. Both of these 
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characteristics are energetically costly: extensive axonal arbors, because they require the upkeep 
of a vast number of synaptic terminals [96]; pacemaking activity, because it requires repeated 
extrusion of calcium from the cell at the expense of ATP [31], [97]. As such, these cells are 
likely to have a low respiratory reserve and may therefore be particularly sensitive to 
mitochondrial dysfunction.  
1.1.3 Conclusion 
 PD is a progressive neurodegenerative disorder, the exact etiology of which remains 
incompletely understood. However, there's evidence for the involvement of multiple pathological 
mechanisms in PD, supporting a model of PD as a multi-factorial disease (Fig. 1.1). 
Additionally, there is evidence that the pathological mechanisms implicated in PD can promote 
one another. For example, α-synuclein misfolding can interfere with autophagy and 
mitochondrial function and induce neuroinflammation [3], [27], [63], [98], mitochondrial 
dysfunction can cause oxidative stress [99], oxidative stress and autophagy/lysosomal 
dysfunction can induce α-synuclein aggregation [3], [80], [100], and neuroinflammation can 
induce oxidative stress [101]. As such, decreasing the pathological effects of one of these 
mechanisms may decrease the pathological effects of the others. We propose that elevation of 
parkin activity in sporadic PD would be useful in this regard (Fig. 1.1). As discussed below, 
parkin has been shown to have a broad neuroprotective capacity, possibly derived from its 
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Figure 1.1. Mechanisms involved in PD and the therapeutic potential of parkin activity. 
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1.2 Parkin 
1.2.1 Parkin genetics 
1.2.1.1 Nature of disease-causing PARK2 mutations 
 The gene that encodes parkin, PARK2, was first discovered in 1998, when Kitada et al. 
traced a 2960 bp cDNA clone to a region of chromosome 6 that had been previously shown to 
segregate with PD in an autosomal recessive pattern [102]. The authors showed that PARK2 
contains 12 exons and very long introns; the entire gene spans 1.4 Mb [103]. Subsequently, over 
100 confirmed pathogenic mutations in PARK2 have been identified (compiled in the Parkinson 
Disease Mutation Database) [104]. These include deletions, exon duplications, nonsense 
mutations, and point mutations throughout the gene. The disease penetrance of homozygous or 
compound heterozygous PARK2 mutations appears to be 100% [105]. The facts that large 
deletions, nonsense mutations, and frameshift mutations in PARK2 are pathogenic and that the 
disease phenotype is recessive in most affected families first suggested that pathogenic mutations 
in PARK2 cause a loss of parkin function [106]. Indeed, this has been borne out for many 
mutations in in vitro and in vivo studies [106]–[109].  
 Inactivating PARK2 mutations generally lead to parkin inactivation due to deletions or 
substitutions of residues important for catalysis, E2 binding, or proper folding [106]. However, 
the pathogenicity of some PARK2 mutations appears to be more complex than a direct 
inactivation of parkin activity [109], [110]. For example, Chaugule et al. found that some 
missense mutations in parkin's N-terminal ubiquitin-like domain (Ubl) disrupt parkin's 
autoinhibited conformation and actually increase its autoubiquitination activity [110]. Two of the 
Ubl mutants from this study were previously shown to have shorter half-lives than wild-type 
parkin, so it was proposed that the pathogenicity of missense Ubl mutations arises from a lack of 
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stability of the resulting parkin protein [110], [111]. Given that Ubl mutants showed enhanced 
autoubiquitination activity, Chaugule et al. hypothesized that pathogenic Ubl mutants accelerate 
their own proteasomal degradation.  
 Altogether, there are multiple lines of evidence to support loss of function as the 
mechanism by which mutations in PARK2 lead to PD, though the means by which these 
mutations lead to parkin inactivation are varied.  
1.2.1.2 Heterozygous PARK2 mutations as a risk factor for PD 
 The recessive nature of PARK2 mutations was brought under scrutiny by several studies 
of families from 1999 to 2001 in which apparently heterozygous mutation carriers were affected 
by PD [112]–[114]. Since then, the question of whether heterozygocity for a PARK2 mutation 
predisposes to PD has not been resolved, though there seems to be slightly more evidence that it 
does. The original studies that reported a possible pathogenic effect of heterozygous mutations in 
PARK2 did not exhaustively analyze the locus for mutations, and it was suggested that some (if 
not all) of the apparent heterozygotes could actually be compound heterozygotes. To address this 
possibility, West et al. more comprehensively analyzed the PARK2 locus of 20 PD patients that 
were apparently heterozygous for PARK2, some of whom had a family history, and concluded 
that 9 of them indeed appeared to be heterozygous for PARK2 mutations [115]. The PARK2 
mutations for each of these 9 cases had been previously found in compound heterozygous or 
homozygous form in PD patients, suggesting that they were pathogenic. However, it's possible 
that the presence of PARK2 mutations in these patients was coincidental and did not contribute to 
the development of PD. Despite this caveat, the study by West et al. lent more credence to the 
idea that heterozygous PARK2 mutations could predispose to PD. 
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 Subsequently, multiple studies tried to shed light on the pathogenicity of heterozygous 
PARK2 mutations by comparing the frequencies of these mutations in PD patients and age-
matched controls. The rationale was that, if they were pathogenic, heterozygous PARK2 
mutations would be expected to be overrepresented in the patient population [116]. The results 
from these studies have been conflicting. In some cases, mutation frequency was found to be 
similar between patients and controls [117]–[120]; in others, patients were found to have an 
increased mutation frequency [121]–[124]; finally, some studies observed an increased mutation 
frequency in patients only when stratifying by mutation type [125], [126]. Most of the above 
studies grouped all mutations together in their analyses and did not statistically analyze the 
relative frequencies of specific mutations, likely due to a lack of statistical power [126]. This is a 
weakness of such studies, because not all mutations will inevitably be pathogenic [106], [126]. 
An association between pathogenic mutations and PD could be obscured if non-pathogenic 
mutations make up a substantial fraction of the total mutations found. Another weakness of such 
studies is the lack of clinical follow-up of controls. It's feasible that some of the people in the 
control group would eventually go on to develop PD [127]. In line with this possibility, the 
authors of one study that examined the frequency of heterozygous PARK2 mutations in controls 
discovered that one of their control subjects displayed mild signs of parkinsonism when re-
evaluated three years later [128].  
 Though large-scale studies comparing mutation frequency in PD patients and controls 
have not yielded conclusive evidence on the question of whether heterozygous PARK2 mutations 
predispose to PD, small studies examining mutation carriers for clinical and neurological 
changes have provided some evidence in favor of heterozygocity as a risk factor. For example, a 
group that examined the degree of striatal dopamine uptake (a measure that's significantly 
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decreased in PD) in PARK2 mutation carriers found that striatal dopamine uptake in 
asymptomatic heterozygotes was between that of PD patients and that of controls [129], [130].  
Similarly, a recent study found that self-reported asymptomatic PARK2 and PINK1 mutation 
carriers displayed a subtle motor abnormality, though the authors didn't separate their results for 
PARK2 and PINK1 [131]. Altogether, these studies suggest that carriers of some heterozygous 
PARK2 mutations may possess a subtle, preclinical version of PD abnormalities, which, in 
combination with other factors, could develop into PD. 
1.2.1.3  Differences between PARK2-linked PD and sporadic PD 
 Although PD arising from PARK2 mutations shares a fundamental characteristic with 
sporadic PD, namely motor dysfunction arising from loss of dopaminergic neurons of the SNpc, 
there are various differences between the two disorders. Perhaps the most obvious difference is 
age at onset. Whereas the average age at onset for sporadic PD is around 60 years [132], most 
patients with PARK2 mutations begin to show symptoms in their 30's or 40's [133]. In fact, the 
likelihood of detecting a pathogenic PARK2 mutation in a patient is inversely proportional to age 
at onset [134], with PARK2 mutations underlying as many as 77% of cases with a family history 
and an age at onset of less than 30 years [133].  
 In addition to differing age at onset, there are often other clinical and neuropathological 
differences between sporadic PD and PARK2-linked PD. Clinically, PARK2 patients tend not to 
exhibit some of the non-motor symptoms that are common in sporadic PD, such as decreased 
sense of smell and dementia [135]. Neuropathologically, sympathetic denervation of the heart is 
less pronounced in PARK2 patients [136], [137], and Lewy pathology tends to be absent [135], 
[138]. Interestingly, presence of Lewy pathology has been found to correlate with age at onset in 
patients with PARK2-linked PD [138]. One hypothesis to explain this observation postulates that 
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the underlying PARK2 mutations in patients with Lewy pathology result in an incomplete loss of 
parkin function, and residual parkin ubiquitination activity contributes to both Lewy pathology 
and later disease onset [138].  
 The differences between sporadic and PARK2-linked PD have led to the idea that they 
represent two distinct disorders [138], [139]. While it's clear that they are not exactly the same 
disease, the more important question is whether the pathological process that leads to 
degeneration of dopaminergic neurons is the same in both. There is evidence that it is. Parkin has 
been shown to be post-translationally inactivated in sporadic PD (discussed in Section 1.2.5), 
and, given that its genetic inactivation leads to degeneration, its inactivation in sporadic PD 
could be reasonably proposed to contribute to the neurodegenerative process in the latter. 
Furthermore, mitochondrial dysfunction is likely to be an important etiological component for 
both PARK2-linked and sporadic PD. Parkin's key role in mitochondrial quality control 
(discussed in Section 1.2.3) suggests that mitochondrial dysfunction is a contributing factor in 
PARK2-linked PD pathogenesis. Similarly, as discussed in Section 1.1.2.7, mitochondrial 
dysfunction in the pathogenesis of PD has been well-established. In light of this evidence, it may 
be the case that post-translational inactivation of parkin plays a key role in the loss of 
dopaminergic neurons in sporadic PD but not in other aspects of the disease. In this model, the 
non-motor symptoms frequently present in sporadic PD but absent in PARK2-linked PD could 
stem from additional pathological mechanisms. 
1.2.2 Parkin structure and function 
1.2.2.1 General properties  
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 Parkin is an E3 ubiquitin ligase consisting of 465 amino acids [102], [140], [141]. It's 
expressed throughout the brain and in many non-neural tissues [102], [142]–[144], and there is a 
high degree of homology between human parkin and that of rats (85% homologous [145]) and 
mice (83% homologous [146]). Parkin belongs to the RING-between-RING (RBR) family of 
ubiquitin ligases [147]. Like all RBRs, it contains a canonical RING domain, called RING1, an 
in-
between RING domain (IBR), and a catalytic domain called RING2 (Figure 1.2) [147]. In 
addition, parkin contains a unique domain called RING0. All four of these domains coordinate 
two zinc ions using 7 cysteines and a single histidine residue, but only RING1 does so in the 
cross-brace fashion that defines RING domains [148], making it the only true RING domain in 
parkin [140]. In addition to the RING domains, parkin contains a ubiquitin-like domain (Ubl) at 
 
Figure 1.2. Parkin structure. A. Domains of parkin. B. Structure of full-length rat parkin. Zinc ions are 
represented by grey balls. Catalytic cysteine, C431, is indicated. From J. F. Trempe et al., “Structure 
of parkin reveals mechanisms for ubiquitin ligase activation,” Science (80-. )., vol. 340, no. 6139, pp. 
1451–1455, 2013. Reprinted with permission from AAAS.  
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its N-terminus, joined to the rest of the protein by a long linker. The Ubl has 62% sequence 
similarity with ubiquitin and is structurally nearly identical [102], [149]. 
 Substrate ubiquitination by parkin involves multiple steps [150]. First, an E2 ubiquitin 
conjugating enzyme loaded with ubiquitin docks at a recognition site in RING1; parkin has been 
found to interact with multiple E2s [151], [152]. The ubiquitin is then transferred to the catalytic 
cysteine of parkin, Cys431, in RING2. Finally, parkin transfers the ubiquitin onto a lysine 
residue on the substrate. It remains unclear how parkin recognizes its substrates [153], [154]. 
Nevertheless, it's known that parkin mediates both mono-ubiquitination of its substrates as well 
as poly-ubiquitination using various linkage types [152], [155]. 
 Like other RBR ligases, parkin is normally autoinhibited [150], [153]. This is likely the 
result of several interactions between its domains. First, the Ubl interacts with residues in RING1 
and the IBR [156]–[158]. There is evidence from multiple studies that this interaction is 
inhibitory, likely by preventing parkin's interaction with ubiquitin-loaded E2 [110], [157]–[159]. 
Second, a portion of the linker between the IBR and RING2 called the repressor element of 
parkin (REP) binds to and obscures the E2 binding site in RING1 [156], [160], [161]. Finally, 
RING0 appears to block the catalytic cysteine in RING2 [156], [160], [161]; however, this idea 
has been challenged [158]. 
1.2.2.2 Parkin activation 
 Parkin becomes fully activated when two things occur: phosphorylation on Ser65 in the 
Ubl domain and non-covalent binding to a ubiquitin molecule that has itself been phosphorylated 
on Ser65 (phospho-Ub) [155], [157], [162]–[169]. The latter interaction involves RING0, 
RING1, and the IBR domains of parkin and the phosphate group, hydrophobic Ile44 patch, and 
carboxy terminus of phospho-Ub (Fig. 1.3) [170], [171]. Either one of these events alone 
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partially activates parkin [164], [165], [167], [168], and each promotes the occurrence of the 
other [155], [157], [158], [170], [172]. How parkin phosphorylation and binding to phospho-Ub 
relieves its autoinhibition is an area of ongoing research.  
 Both events result in a weaker association of the Ubl domain with the rest of the protein 
[157], [158], [171]–[173], consistent with an inhibitory role for this association. Both early and 
recent work has indicated that the Ubl fully dissociates from the RING1 domain upon full parkin 
activation [157], [158], [172]–[175]. An early line of evidence for this was the fact that parkin's 
Ubl has been found to interact with various proteins via the same residues that it uses to interact 
with RING1 [175]–[179], implying that the latter interaction must be severed to allow for the 
former interactions. Very recently, two structural studies have demonstrated that, indeed, the 
phosphorylated Ubl domain dissociates from RING1 in fully activated parkin [180], [181]. 
Furthermore, these studies showed that, following its dissociation from RING1, the 
phosphorylated Ubl domain associates with RING0, displacing the RING2 domain and exposing 
parkin's active site.  
 Many of the above studies predicting or demonstrating dissociation of the Ubl domain 
from RING1 have suggested that parkin's association with phospho-Ub leads to this dissociation. 
However, this idea has been challenged by Kumar et al., who determined the crystal structure of 
parkin bound to phosphorylated ubiquitin [171]. This study found that, surprisingly, the Ubl 
domain stays bound to RING1 after parkin binds phospho-Ub, suggesting that both parkin 
phosphorylation and its association with phospho-Ub are necessary for Ubl dissociation. As this 
finding is contradiction to the predictions of the above studies, further work will be necessary to 
understand exactly how the Ubl comes to dissociate from RING1. 
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 Less controversial is the effect that parkin binding to phospho-Ub has on its IBR domain. 
Four studies have solved crystal structures of parkin bound to phospho-Ub [170], [171], [180], 
[181], and all reveal that phospho-Ub binding induces a large movement of parkin's IBR domain 
away from its Ubl domain (Figure 1.3). This movement appears to destabilize the inhibitory 
interactions of the REP with RING1 and of RING0 with RING2 [170]. Furthermore, the second 
study to describe this effect found that the gap between the Ubl and IBR created by IBR 
displacement functions as a novel binding site for ubiquitin [171]. The authors found that 
ubiquitin interaction with this site is necessary for efficient parkin activity, and they proposed a 
 
 
Figure 1.3. Movement of parkin IBR domain upon phospho-Ub interaction. Structure of parkin bound 
to phospho-Ub (colored) superimposed on the structure of autoinhibited parkin (grey). Arrow 
indicates movement of IBR domain. From A. Kumar et al., “Parkin-phosphoubiquitin complex 
reveals cryptic ubiquitin-binding site required for RBR ligase activity,” Nat. Struct. Mol. Biol., vol. 
24, no. 5, pp. 475–483, 2017.  Reprinted with permission from Springer Nature. 
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model in which two activated parkin molecules cooperate during parkin-mediated ubiquitination. 
In this model, an E2 charged with ubiquitin interacts with one molecule of parkin while the 
ubiquitin that it's charged with interacts with the ubiquitin-binding site in a second molecule of 
parkin. Then, the ubiquitin is transferred from the E2 to the catalytic cysteine in the first parkin 
molecule (Figure 1.4). This mechanism, if confirmed, could reflect a more general ability of 
RBR ligases to cooperate in trans [150]. 
 To date, only one kinase, PINK1, has been found to phosphorylate parkin and ubiquitin at 
Ser65, [164], [165], [167], [168]. However, other ubiquitin/parkin kinases are expected to exist 
Figure 1.4. Model of parkin cooperation proposed by Kumar et al., 2017. Parkin is shown in green; 
phospho-Ub in orange. An E2 conjugated with ubiquitin (Ub) binds to one molecule of parkin while 
the conjugated ubiquitin binds to the gap between the Ubl and IBR of a second molecule of parkin. 
The ubiquitin will then be transferred from the E2 to the catalytic cysteine (C431) in the first parkin 
molecule. Image of parkin structure from the RCSB PDB (www.rcsb.org) of PDB ID 5N2W (A. 
Kumar et al. (2017) Parkin-phosphoubiquitin complex reveals cryptic ubiquitin-binding site required 
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[182]. The discovery of PINK1 as an activator of parkin arose from studies on the role of these 
two proteins during the process of mitophagy, which is described in the next section. 
 Importantly, a recent study found that phospho-Ub levels are upregulated in the 
substantia nigra of patients with Lewy body disease, a category that includes PD [183]. This 
suggests that there is an increased need for parkin activity in sporadic PD and that interventions 
to enhance this activity could be therapeutic. 
 Of note, there has been no evidence of parkin reverting back to an autoinhibited state 
following its activation. But, intriguingly, a recent study found that parkin is degraded in an 
activated state following mitochondrial depolarization [162]. This finding raises the possibility 
that modulation of parkin activity is mediated by degradation and not deactivation. If this is the 
case, understanding the mechanism behind such degradation will be critical for understanding 
how parkin activity is modulated and how to increase this activity therapeutically.  
1.2.3 Parkin functions 
 Parkin has been reported to participate in numerous pathways, and its neuroprotective 
capacity is very well-documented. However, a major outstanding question in the field is which 
parkin function is most relevant for its neuroprotection against PD [59], [184].  
Answering this question is challenging in part because parkin knockout mice don't 
display nigrostriatal degeneration, despite some evidence of abnormal neurotransmission and 
mitochondrial impairment [185]–[189]. However, CRE-mediated deletion of parkin in the SNpc 
of adult mice has been found to induce neurodegeneration [190]. This suggests that 
developmental compensatory mechanisms may prevent neurodegeneration in parkin knockout 
mice, which would imply that other E3 ubiquitin ligases or molecular pathways can carry out 
parkin’s protective role(s) in mice. It remains to be determined what these compensatory 
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mechanisms may be, though one possibility is an upregulation of antioxidant defenses [188], 
[191]. Such compensatory mechanisms are not apparent in humans (because homozygous loss of 
parkin function causes PD with complete penetrance (Section 1.2.1.1)), which indicates that 
pathways that interface with parkin’s activities are not identical between humans and mice. 
Intriguingly, a recent study reported that human dopaminergic neurons contain more intracellular 
dopamine than mouse dopaminergic neurons, which appears to make them more vulnerable to 
oxidative stress, lysosomal dysfunction, and a-synuclein aggregation [91]. It’s possible that this 
difference in dopamine content also contributes to the different vulnerability of human and 
mouse dopaminergic neurons to degeneration from parkin loss. 
1.2.3.1 Initiation of mitophagy 
 Parkin's best-characterized role is in the initiation of mitophagy, the process by which 
damaged mitochondria are selectively degraded via the autophagy-lysosomal pathway [192]. 
1.2.3.1.1 Historical background 
 The first hint that parkin plays a role in mitochondrial maintenance came from a study in 
Drosophila [193]. In this study, parkin null flies exhibited severe locomotor defects and male 
sterility, and both of these impairments appeared to be due to mitochondrial pathology. 
Subsequent Drosophila work confirmed these findings and gave the first indication that parkin 
and PINK1 function in a common pathway [194]–[196]. These studies found that PINK1 null 
flies exhibit a phenotype remarkably similar to that of parkin null flies, that double knockouts of 
PINK1 and parkin do not have a more severe phenotype than the individual mutants [194], [195], 
and that overexpression of parkin can rescue the PINK1 null phenotype [194]–[196], but not vice 
versa [194], [195]. These observations suggested that PINK1 functions upstream of parkin in a 
pathway regulating mitochondrial integrity. 
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 The next clue about the function of parkin in mitochondrial maintenance came from a 
study from Richard Youle's group in 2008 [197]. The authors found that depolarization of the 
mitochondrial inner membrane from exposure to the protonophore carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) led to a translocation of parkin, which is normally cytosolic, to 
the mitochondria in multiple cell types. Furthermore, they showed that mitochondria are 
degraded by autophagy following parkin translocation and that this autophagic degradation 
depends on the presence of parkin. This study was the first to show that parkin activity can lead 
to mitophagy. 
 Soon after this study linked parkin with mitophagy, and consistent with the early findings 
in Drosophila, many groups implicated PINK1 in mitophagy as well [107], [108], [198]–[201]. 
Collectively, they showed that mitochondrial PINK1 expression and kinase activity are necessary 
for parkin translocation to mitochondria and for parkin-mediated mitophagy. 
 In the 8 years after these studies came out, parkin-mediated mitophagy has enjoyed 
considerable scientific attention. According to PubMed.gov, 140 articles were published in 2017 
with the terms "parkin" and "mitophagy" in the title or abstract, almost 6 times more than the 
number published in 2010. This attention has quickly expanded our understanding of parkin-
mediated mitophagy. The current model of this process is summarized below. 
1.2.3.1.2 Model of parkin-mediated mitophagy 
1.2.3.1.2.1 Initial steps 
 The classic model of parkin-mediated mitophagy begins with loss of mitochondrial 
membrane potential (depolarization) as a trigger. Depolarization leads to two rapid 
consequences: mitochondrial fragmentation and stabilization of PINK on the outer mitochondrial 
surface [198], [202].  
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 Mitochondrial fragmentation following depolarization is a consequence of enhanced 
mitochondrial translocation and activity of the mitochondrial fission protein Drp1 [197], [202], 
[203]. In addition, depolarization-induced cleavage of the inner membrane fusion protein Opa1 
and subsequent degradation of the outer membrane fusion proteins mitofusin-1 and -2 (Mfn1 & 
2) appear to play a role in preventing fragmented mitochondria from re-fusing [204]–[206]. 
Mitochondrial fragmentation is critical, but not sufficient, for mitophagy to proceed [197], [206], 
[207]. 
 The other rapid consequence of depolarization is stabilization of PINK1, which acts like a 
"flag" for damaged mitochondria [95], [208]. PINK1 normally has a very short half-life [95], 
[208]. Under basal conditions, it's targeted to mitochondria via an N-terminal mitochondrial 
localization signal, imported through the outer mitochondrial membrane (OMM) via the 
translocase of the OMM (TOM) complex, and passed into the translocase of the inner 
mitochondrial membrane (TIM)23 complex in the inner mitochondrial membrane (IMM) [95], 
[208]. Then, PINK1's N-terminus is cleaved sequentially by the mitochondrial processing 
peptidase (MPP) in the mitochondrial matrix and by the presenilin-associated rhomboid-like 
protease (PARL) in the IMM [95], [208]. Following cleavage by PARL, PINK1 is released into 
the cytosol, where it is degraded proteasomally via the N-end rule pathway [95], [208], [209]. 
 Upon mitochondrial depolarization, PINK1 is stabilized on the outer mitochondrial 
surface [95], [208]. This happens because depolarization prevents protein import through the 
TIM23 complex [210]–[212], so PINK1 cannot enter it and therefore fails to be cleaved. On the 
mitochondrial surface, PINK1 dimerizes and associates with the TOM complex [95], [208]. The 
PINK1 dimers autophosphorylate in trans at Ser228, an event that is necessary for subsequent 
recognition and phosphorylation of ubiquitin and parkin's Ubl by PINK1 [175], [213]. 
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1.2.3.1.2.2 Positive-feedback OMM ubiquitination 
 Upon its stabilization, PINK1 phosphorylates both parkin and ubiquitin that are bound to 
proteins on the outer mitochondrial surface, though the relative order of these events is 
controversial [163], [170], [175]. Either way, this triggers a positive-feedback loop of parkin 
recruitment to the mitochondrion and parkin-mediated ubiquitination of OMM proteins (Figure 
1.1) [208]. The first step, mitochondrial parkin recruitment, occurs because of parkin's affinity 
for phospho-Ub [155], [164], [214]. As discussed in Section 1.2.2.2, parkin is partially activated 
by phospho-Ub, so its binding to the latter on the mitochondrial surface serves the dual function 
of attaching it to the mitochondrion and partially activating it. If not already phosphorylated by 
PINK1, phospho-Ub-bound parkin is then efficiently phosphorylated by the latter to yield a fully 
active parkin molecule [157], [172]. From here, activated parkin builds ubiquitin chains on 
various OMM proteins [208]. These ubiquitin chains then serve as substrates for the  
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Figure 1.5. Schematic of positive-feedback OMM ubiquitination by parkin. Each new cycle involves 
parkin binding to phospho-Ub on the mitochondrion and building ubiquitin chains that are phosphorylated 
by PINK1. From “The ubiquitin signal and autophagy: an orchestrated dance leading to mitochondrial 
degradation,” EMBO Rep., vol. 17, no. 3, pp. 300–316, 2016. Reprinted with permission from John Wiley 
and Sons. 
  28 
next round of PINK1-mediated phosphorylation, which leads to more parkin recruitment and 
activation, starting the cycle over again. From this description, it's evident that both parkin and 
PINK1 activity are crucial for mitochondrial parkin translocation.  
 Once on the mitochondrial surface, parkin ubiquitinates many OMM proteins using K6, 
K11, K48, and K63 ubiquitin linkages [155], [215]–[218]. However, a recent study found Mfn1 
and 2 to be early and preferred parkin substrates during mitophagy [219]. According to this 
study, parkin-mediated poly-ubiquitination and proteasomal degradation of Mfn2, specifically, 
seems to be required for efficient parkin-mediated ubiquitination of other OMM proteins. Mfn2 
degradation following its ubiquitination has been shown to depend on its extraction from the 
OMM by the AAA+ ATPase p97 [206], [219], [220]. In line with the evidence that Mfn2 
degradation is required for the ubiquitination of other OMM proteins, p97 activity is necessary 
for mitophagy to proceed [206], [219], [220].  
1.2.3.1.2.3 Final steps 
 It's unknown whether p97 plays a role in the extraction of any other proteins from the 
OMM aside from Mfn1 and 2 during mitophagy, but it's clear that many mitochondrial proteins, 
especially on the OMM, are subject to proteasomal degradation following their ubiquitination 
[221], [222]. Parkin has been shown to mediate disruption of the OMM during mitophagy, 
potentially allowing for the ubiquitination of normally-inaccessible inner mitochondrial proteins 
[215], [218], [222]. However, despite the parkin-mediated structural collapse, it appears that the 
deeper a protein resides in the organelle, the more likely it is to be degraded lysosomally, with 
the remains of the mitochondrion [221], [222]. Proteasomal activity seems to be required for 
mitophagy to proceed [206], [219], [221]. Although one group has challenged this idea, their 
method of assessing mitophagy leaves room for several interpretations [222]. Thus, even though 
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ultimate lysosomal degradation is central to the definition of mitophagy, proteasomes also play a 
key role in this process upstream of autophagosomal engulfment.  
 Parkin-mediated poly-ubiquitination of mitochondrial proteins plays another critical role 
during mitophagy, namely, the recruitment of autophagy receptors [223]. These receptors act as a 
bridge between the mitochondrion and a growing autophagic membrane. Canonically, this is due 
to their ability to interact with both ubiquitin and lipid-conjugated LC3/GABARAPs [224]. Four 
autophagy receptors have been implicated in parkin-mediated mitophagy: p62, OPTN, NDP52, 
and TAX1BP1 [107], [225]–[228]. The presence of these receptors is critical for mitophagy to 
occur, though the relative importance of each appears to be cell-type specific [223]. The process 
by which these autophagy receptors lead to mitochondrial engulfment is not well understood 
[223]. For instance, a recent study has challenged the belief that LC3/GABARAPs are necessary 
for autophagosome formation around the mitochondrion [229]. Instead, the authors found 
GABARAPs to be important for autophagosome-lysosome fusion, suggesting that autophagy 
receptors can recruit the phagophore through a novel mechanism. In addition to elucidating the 
mechanism behind phagophore recruitment, more work will be needed to understand which 
types of ubiquitin chains are preferentially recognized by autophagy receptors, whether ubiquitin 
phosphorylation increases or decreases the affinity of these receptors for ubiquitin chains, and 
the process by which the phagophore closes to become an autophagosome [223], [229]. In the 
final step of mitophagy, the nascent autophagosome fuses with a lysosome and the mitochondrial 
remains are degraded by lysosomal proteases [223]. 
1.2.3.1.3 Parkin loss as a consequence of mitochondrial depolarization 
 Although the mechanism of parkin-mediated mitophagy has garnered considerable 
attention, a notable absence in the model described above is parkin's fate after its mitochondrial 
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recruitment. Most studies examining mitophagy rely on parkin overexpression, and in these cases 
parkin levels are usually unchanged following mitochondrial depolarization [199], [206], [230]. 
This lack of effect on parkin levels is likely an artefact of high parkin expression. This is because 
studies employing endogenous parkin, as well as work from Ted Fon's group using 
overexpressed parkin, have demonstrated that parkin protein levels decrease following 
mitochondrial depolarization [162], [201], [231]–[235]. However, despite documentation of this 
effect, its significance and the mechanism by which it takes place remain largely unclear. 
 Rakovic et al. demonstrated in 2010 that endogenous parkin loss following mitochondrial 
depolarization is proteasomal [201]. In a follow-up study in 2013, they postulated that parkin's 
proteasomal degradation following mitochondrial depolarization is mediated by its 
autoubiquitination [231]. In fact, multiple studies have reported parkin poly-ubiquitination 
following mitochondrial depolarization, though only Rakovic et al. examined endogenous parkin 
[199], [206], [231], [232], [236]. However, the suggestion by Rakovic et al. and most of these 
other studies that parkin poly-ubiquitination is the result of its auto-ubiquitination, while likely, 
has not been rigorously tested. Moreover, the requirement of parkin poly-ubiquitination for its 
proteasomal degradation, as suggested by Rakovic et al., has also not been demonstrated. In fact, 
Durcan et al. provided evidence in 2014 that parkin poly-ubiquitination actually protects it from 
degradation following depolarization [232]. Additionally, there is indirect evidence that parkin 
ubiquitination by the ubiquitin ligase Nrdp1 may underlie its loss from mitochondrial 
depolarization [235]. 
 Similarly unclear is how depolarization-induced parkin loss is connected to the process of 
mitophagy. Durcan et al. and another study from the same group found parkin degradation to 
correlate with mitophagy induction and implied that these two processes may be linked [232], 
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[233]. However, Rakovic et al. found that mitochondrial depolarization could induce parkin loss 
even in the absence of mitophagy [231]. In contrast to Durcan et al., Rakovic et al. proposed a 
model in which proteasomal parkin loss due to autoubiquitination prevents it from ubiquitinating 
OMM proteins and inhibits mitophagy. Though these two models are diametrically opposed as to 
how parkin loss relates to mitophagy induction, they both suggest that parkin activity is involved 
in its loss following mitochondrial depolarization: in one case, by poly-ubiquitinating 
mitochondrial proteins during mitophagy induction; in the other case, by poly-ubiquitinating 
itself for proteasomal degradation. 
1.2.3.1.4 Physiological relevance of parkin-mediated mitophagy 
 Much of what we know about the process of mitophagy comes from treating non-
neuronal cells that overexpress parkin with extreme depolarizing agents like CCCP, which leads 
to total mitochondrial clearance in a substantial fraction of cells after 24 hours [107], [221], 
[230]. This raises the question of how relevant this mechanism is to cells under physiological and 
disease-relevant conditions, particularly to neurons. Parkin translocation to mitochondria in 
primary and iPSC-derived neurons upon whole-cell mitochondrial depolarization has been 
demonstrated by several studies, although this process is significantly slower than in 
immortalized cells [230]. However, it seems that only one study has examined mitophagy 
induction downstream of whole-cell-depolarization-induced parkin translocation, and the authors 
did not observe mitophagy induction [231]. This study found that, despite evidence of parkin 
translocation, depolarization-induced mitophagy did not occur in iPSC-derived neurons, 
undifferentiated SH-SY5Y cells, or fibroblasts with endogenous parkin levels. However, upon 
parkin overexpression, mitophagy could be induced in fibroblasts and SH-SY5Y cells, but not in 
neurons. These findings highlight both the unique response of neurons to whole-cell 
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depolarization and the importance of using cells with endogenous parkin levels to query 
mitophagic mechanisms. 
 The lack of mitophagy in neurons in response to whole-cell depolarization may be due to 
their high reliance on oxidative phosphorylation for energy, which would make total clearance of 
the mitochondrial network untenable [237], [238]. In line with this idea, it has been shown that 
forcing cancer cells, which rely primarily on glycolysis for ATP production [239], to derive 
energy from mitochondrial oxidative phosphorylation leads to a substantial delay in 
depolarization-induced parkin recruitment and may even prevent mitophagy [219], [240], [241]. 
Conversely, partially increasing ATP levels in neurons following depolarization has been found 
to promote mitochondrial parkin recruitment [240]. 
 Although the bioenergetics of neurons may preclude mitophagy after an extreme insult 
that concurrently damages all mitochondria, more targeted mitochondrial damage that doesn't 
significantly alter cellular ATP levels may be expected to result in mitophagy. Indeed, this has 
been shown to be the case [242]. Two studies from 2014 demonstrated the existence of parkin-
mediated mitophagy in primary cultured neurons [217], [243]. The first specifically depolarized 
a small subset of mitochondria using laser light and a mitochondrially-targeted photosensitizing 
dye [243]. The second elegantly demonstrated the presence of basal parkin-dependent mitophagy 
in cultured hippocampal neurons without added exogenous stressors; this study made use of a 
mitochondrially-targeted pH-sensitive dye as a readout of mitochondrial delivery to lysosomes 
[217]. 
 Though parkin-mediated mitophagy has been demonstrated to occur with endogenous 
levels of parkin in cultured neurons, it has yet to be convincingly demonstrated in vivo. In 
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addition, as mentioned above, it's unclear if defective mitophagy is the key pathological insult 
underlying PD from parkin loss. 
1.2.3.2 Mitochondrial quality-control mechanisms beyond mitophagy 
 Parkin-mediated mitophagy is the most well-studied parkin function, but parkin activity 
has been found to promote mitochondrial health through several other mechanisms as well.  
 The first is regulation of mitochondrial-derived vesicles (MDVs). The study of MDVs is 
a nascent field; the first study to describe them was published in 2008 [244]. As their name 
suggests, MDVs are single- or double-membraned vesicles that bud off from mitochondria. 
Multiple different types of MDV have been identified; they carry specific mitochondrial cargo 
and are elicited by distinct stimuli [244]. The cellular destinations of MDVs vary as well; they 
have been found to be targeted to peroxisomes and late endosomes/lysosomes [244], [245]. The 
budding off of MDVs doesn't require Drp1, and their delivery to lysosomes is independent of the 
autophagy protein Atg5, making this process distinct from mitophagy [245]. Parkin has been 
shown to positively regulate formation of MDVs induced by antimycin A, a complex III 
inhibitor that generates ROS inside mitochondria [233], [245]. These MDVs contain oxidized 
inner mitochondrial proteins and are targeted for lysosomal degradation [233], [246]. It appears 
that lysosomally-targeted MDVs are a mechanism by which a subset of damaged proteins can be 
degraded when mitochondrial damage is not severe enough to require destruction of the whole 
organelle by mitophagy [233], [244]. The mechanism by which parkin promotes MDV formation 
remains to be determined, though it appears to involve parkin colocalization with budding 
vesicles [233], [244].  
 Of note, as mentioned in Section 1.1.2.4, parkin has recently been found to oppose the 
production of a different class of MDVs involved in mitochondrial antigen presentation [64]. 
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This newly described parkin function places it at an intersection between mitochondrial 
maintenance and the immune response, both of which have been implicated in PD pathogenesis 
(Section 1.1). 
 Another mechanism by which parkin has been found to positively regulate mitochondrial 
function is stimulation of mitochondrial biogenesis by degradation of the transcriptional 
repressor PARIS [59], [190]. Work from the Dawson group showed that PARIS negatively 
regulates the transcription of PGC-1a, a transcriptional coactivator with a major role in 
promoting mitochondrial biogenesis, and that parkin-mediated ubiquitination of PARIS leads to 
its proteasomal degradation [190]. Accordingly, they found that conditional knockout of parkin 
in the SNpc of adult mice led to PARIS-dependent mitochondrial dysfunction and 
neurodegeneration that could be ameliorated by overexpression of PGC-1a [190], [247]. This 
work strongly implicates PARIS in neurodegeneration from parkin loss. However, though there 
has been some support for the connection between parkin loss, PARIS upregulation, and PGC-
1a decrease [248], more work will be needed to confirm PARIS as a key player in 
neurodegeneration from parkin loss and to determine whether the pathogenicity of PARIS 
accumulation intersects with other potentially pathogenic mechanisms from parkin loss.  
 Finally, parkin has been reported to increase the mitochondrial fusion factor OPA1 by 
upregulation of NF-κB signaling [249], [250]. This upregulation was found to be mediated by 
parkin's enhancement of linear ubiquitination of NEMO, an essential activator of NF-κB 
signaling [250]. Parkin-mediated elevation of OPA1 through this pathway was found to protect 
cells from stress-induced death, possibly because of OPA1's role in maintaining mitochondrial 
cristae integrity [249], [250]. 
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1.2.3.3 Non-mitochondrial parkin functions 
 In addition to its mitochondrial roles, many non-mitochondrial functions have been 
assigned to parkin, stemming from a plethora of reported parkin substrates [59]. Parkin has been 
reported to influence synaptic vesicle dynamics and synaptic transmission [251]–[253], 
cytoskeletal components [254]–[256], and cell cycle regulation [257], [258]. In addition, parkin 
activity has been directly linked to prevention of apoptosis: it has been found to prevent 
mitochondrial translocation of the pro-apoptotic Bcl-2 family member Bax by direct 
ubiquitination [249], [259] and to target the pro-apoptotic protein RTP801 for proteasomal 
degradation [260]. 
 Many reported parkin substrates were found before the mechanism of parkin activation 
by PINK1 was discovered [59]. Even after this discovery, most studies reporting on non-
mitochondrial parkin functions don't clarify the mechanism by which parkin's autoinhibition is 
relieved to perform these functions [95]. This is a major gap in our understanding of non-
mitochondrial parkin activity. It remains to be determined whether kinases other than PINK1 can 
phosphorylate parkin and ubiquitin to activate the former. An alternative model is that 
mitochondrial stabilization of PINK1 is upstream of all parkin functions. In this model, extreme 
mitochondrial damage triggers sustained PINK1 stabilization and mitophagy, whereas a transient 
decrease in mitochondrial membrane potential could briefly stabilize PINK1 and lead it to 
phosphorylate a small pool of cytosolic parkin and ubiquitin. One piece of evidence to support 
this second model is that phosphorylated ubiquitin has been observed in the cytosol following 
mitochondrial depolarization [59], [261]. 
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1.2.3.4 Evidence of parkin's pro-survival role 
 Although it isn't clear which of parkin's many proposed functions is critical for the 
survival of dopaminergic neurons, parkin's ability to promote cell survival is extremely well-
documented. This can be inferred from the fact that parkin loss leads to neuronal death in 
humans and in mice (upon conditional knockout), but it has also been demonstrated in many in 
vitro and in vivo studies. Parkin overexpression has been found to protect from, and parkin 
knockdown to sensitize to, cell death from oxidative stress [262]–[267], mitochondrial toxins 
[250], [266]–[269], ER stress [250], [270]–[272], proteotoxic stress [273], excitotoxicity [268], 
[274], and a-synuclein overexpression [275]–[277]. Given this clear pro-survival role, strategies 
aimed at elevating parkin levels and activity have therapeutic promise for PD. Indeed, several 
studies have been undertaken as a first step towards development of such therapeutics [267], 
[278], [279], and other authors have also noted the attractiveness of such strategies [223].  
1.2.4 Regulation of parkin levels 
 In order to develop therapeutic strategies based on parkin upregulation or activation, it's 
critical to first understand the mechanisms by which levels of total and active parkin are 
controlled in the cell. Despite the significant attention that has been paid to elucidating parkin's 
functions, less is known about how parkin levels are regulated [234]. Also, because the 
mechanism of PINK1-mediated parkin activation has only recently been discovered, the vast 
majority of studies examining regulation of parkin levels do not distinguish between total and 
active parkin pools. Nevertheless, there have been some insights into regulation of parkin 
transcription and degradation. These are described below.  
1.2.4.1 Transcriptional parkin regulation 
 One of the first insights into the cellular control of parkin levels came with the 
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observation that parkin transcript levels increase in the brain during development [280], [281]. 
Parkin mRNA levels have been observed to be much higher in neurons than in glial cells [143], 
[280], and, accordingly, the increase in parkin mRNA during brain development has been 
attributed to neuronal maturation [280], [281]. Evidence points to a decrease in the transcription 
factor N-myc as the driving force behind increased parkin expression during this process [281]. 
N-myc has been shown to bind the PARK2 promoter and negatively regulate parkin expression, 
and there is an inverse correlation between parkin and N-myc levels during human brain 
development and differentiation of neuroblastoma cells [281].	
 Another early observation about transcriptional parkin regulation came from a study by 
Imai et al. in 2000 [271]. This study found that ER stress, specifically, increases parkin mRNA 
levels. Subsequently, many studies have described elevation of parkin transcript levels in 
response to a variety of stressors. These include mitochondrial toxins [266], [268], [282], [283], 
oxidative stressors [266], [282], [284], [285], excitotoxins [268], nutrient deprivation [286], 
DNA damage [285], and, in line with Imai et al., ER stressors [283]. However, another study 
found that the DNA damaging agent camptothecin induces a significant decrease in parkin 
mRNA levels, indicating that transcriptional parkin elevation in response to DNA damage is not 
universal [287]. Nevertheless, in aggregate, these studies challenge the suggestion by Imai et al. 
that increased parkin mRNA expression is a targeted response to ER stress and instead suggest 
that such an increase is a more broad response to many cellular stressors, in line with parkin's 
pro-survival role. The mechanism by which stress elevates parkin mRNA appears to center, at 
least in part, on the transcription factor ATF4. ATF4 has been shown to bind to the PARK2 
promoter and positively regulate parkin transcription both basally and under conditions of ER 
stress, oxidative stress, and mitochondrial dysfunction [266], [283]. Conversely, the transcription 
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factor c-Jun was shown to negatively regulate parkin transcription both basally and following ER 
stress [283]. In addition to ATF4, the tumor suppressor protein p53 has been found to be critical 
for upregulation of parkin mRNA following DNA damage and oxidative stress; this effect 
appears to be mediated by stimulation of parkin transcription via p53 binding to an element in 
the first intron in PARK2 [285]. 
 More recently, two studies undertook chemical [278] and genetic [234] screens to 
identify regulators of cellular parkin levels. The first study confirmed N-myc as a negative 
regulator of parkin transcription and also found that JNK kinase inhibitors increase parkin 
transcription, consistent with the previously reported negative role of c-Jun [278], [283]. This 
study also implicated HDAC inhibitors and inhibitors of the cholesterol biosynthesis pathway as 
positive regulators of parkin transcription. The second study identified 53 proteins that positively 
or negatively affect parkin protein expression; among these, the authors highlighted a functional 
network involving the transcriptional repressor THAP11 as a significant negative regulator of 
parkin transcription [234]. 
1.2.4.2 Mechanisms of parkin degradation 
1.2.4.2.1 Parkin stability 
 Examination of parkin turnover rates has yielded conflicting results about parkin stability. 
Some studies report parkin to be a long-lived protein, with minimal degradation after 24 hours 
[111], [288]–[291], while others report a parkin half-life of about 5 hours [292]–[296]. Both 
groups include studies that examined endogenous parkin and studies that analyzed tagged, 
overexpressed parkin. It's possible that cell-type specific differences are responsible for this 
discrepancy. 
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1.2.4.2.2 Mechanisms of constitutive parkin degradation 
 With regard to the mechanisms by which parkin is degraded, it's useful to distinguish 
between constitutive parkin degradation and degradation induced by acute stressors or 
overexpression of exogenous proteins. Studies reporting on the former are less numerous than 
those that examine the latter. However, proteasomal and lysosomal degradation have been 
implicated in basal parkin turnover. The evidence for basal lysosomal degradation of parkin 
comes from a study by Li et al. [297]. The authors show that overexpression of the mitochondrial 
protein p32 leads to lysosomal parkin degradation and implicate this mechanism in the control of 
basal parkin levels by showing that knockdown of p32 increases endogenous parkin protein. It's 
unclear how p32 mediates its effect on parkin. 
 Historically, the first evidence of proteasomal involvement in basal parkin turnover came 
from one of the first studies to identify parkin as a ubiquitin ligase [294]. This study found that 
wild-type parkin coimmunoprecipitated more poly-ubiquitin than disease-associated mutants and 
that it had a shorter half-life than disease-associated mutants. From this, the authors suggested 
that parkin autoubiquitination leads to its proteasomal degradation. Subsequent studies have 
confirmed parkin's ability to autoubiquitinate [156], [296], [298], and many have speculated that 
this targets parkin for proteasomal degradation [110], [231], [249], [298]–[301]. However, this 
has never been directly shown. In fact, a recent study reported that parkin autoubiquitination 
actually protects it from degradation [232].  
 Despite the tenuous evidence connecting parkin autoubiquitination to its proteasomal 
degradation, there are other reasons to suspect proteasomal involvement in the maintenance of 
steady-state parkin levels. Three studies found that treating cells with proteasomal inhibitors 
increased basal parkin levels or prevented its loss in a pulse-chase analysis (albeit all of these 
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studies examined overexpressed parkin) [296], [302]1. More recently, evidence for a possible 
ubiquitin-independent mechanism of proteasomal parkin degradation has come to light. Several 
studies have reported that parkin can bind to the proteasome via its Ubl domain [178], [179], 
[303]. One of these studies found that knockdown of one of parkin's putative interacting partners 
on the proteasome, Rpn13, led to a significant increase in endogenous parkin levels [179]. This 
suggests that parkin binding to the proteasome via its Ubl domain may lead to its proteasomal 
degradation. In support of this possibility, deletion of the Ubl domain in overexpressed parkin 
has been found to increase its expression level compared to that of full-length overexpressed 
parkin [301]. 
1.2.4.2.3 Mechanisms of stress-induced parkin degradation 
 Many studies have found that parkin protein levels decrease in response to a variety of 
stressors (described below), and this decrease appears to play a role in the toxicity of some of 
these stressors. The mechanisms by which such parkin loss takes place are often not well-
characterized. However, it appears that, in most cases, increased parkin degradation is at least 
partly responsible for the decrease in parkin levels, consistent with the increased, not decreased, 
parkin transcription that occurs in response to multiple stressors. Interestingly, a recent study 
found that total parkin protein levels decrease in the brains of aged mice, including the substantia 
nigra, suggesting that age-related stress may cause parkin loss in vivo [304]. 
 Overexpression of several proteins has been reported to induce parkin degradation: a 
polyglutamine-expanded form of the deubiquitinating enzyme ataxin-3, the ubiquitin ligase 
Nrdp1, the POZ/BTB protein NAC1, parkin's activator PINK1, and the stress-induced 
                                               
1 An early study reported a similar finding [392], but the antibodies used in this study were 
subsequently called into question [448]. 
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pseudokinase Trib3 [265], [288], [293], [296], [305], [306]. The ataxin-3 mutant was found to 
increase lysosomal parkin degradation [288], whereas Nrdp1, NAC1, and PINK1 were all 
reported to increase parkin's degradation via the proteasome [293], [305], [306]. In the case of 
Nrdp1, proteasomal parkin degradation appears to be due to direct ubiquitination of parkin by the 
latter. The mechanism by which PINK1 decreases parkin levels is likely the same as that 
triggered by mitochondrial depolarization because the latter induces PINK1 stabilization and also 
causes parkin degradation via the proteasome (discussed in Section 1.2.3.1.3). Finally, it's 
unclear exactly how Trib3 induces parkin loss, but it appears to involve an interaction between 
the two proteins [265]. Importantly, our group has found that Trib3 is elevated in dopaminergic 
SNpc neurons of PD patients [265]. This suggests that Trib3 may decrease parkin in the PD 
brain; accordingly, the number of neurons with high Trib3 expression and low parkin expression 
was higher in PD patients than in controls.    
 In addition to parkin loss from overexpression of specific proteins, decreased parkin 
levels have been observed from in vitro or in vivo exposure to the oxidant 6-hydroxydopamine 
(6-OHDA) [265], [266], the mitochondrial complex I inhibitor MPP+ [266], [307], the complex I 
inhibitor rotenone [308], [309], the topoisomerase inhibitor camptothecin [287], and the oxidant 
hydrogen peroxide [201] (although another group found an increase in parkin protein upon 
exposure to hydrogen peroxide [285]). Additionally, okadaic acid, staurosporine, and 
camptothecin have been reported to induce caspase-mediated parkin cleavage, though it's unclear 
whether this decreased full-length parkin levels [310], [311]. Finally, as mentioned above and 
discussed in Section 1.2.3.1.3, mitochondrial depolarization has been shown to cause 
proteasomal parkin degradation.  
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 Some elements of the pathways by which these varied stressors lead to parkin loss have 
been described. Our group has found that the pseudokinase Trib3 plays a role in parkin loss from 
6-OHDA and that parkin loss from both 6-OHDA and MPP+ is at least partly proteasomal [265], 
[266]. Other studies have found the serine protease HtrA2 to be implicated in parkin loss from 
rotenone treatment [309], the tumor suppressor p53 to be implicated in parkin loss from 
camptothecin treatment [287], and PINK1 to be necessary for parkin loss from hydrogen 
peroxide exposure [201].  
 It's likely that some of the above stressors decrease parkin levels through a common 
mechanism, at least in part, though this needs to be verified experimentally. In particular, parkin 
loss from mitochondrial depolarization is likely to overlap mechanistically with parkin loss from 
6-OHDA, MPP+, rotenone, and hydrogen peroxide treatment because all of these stressors have 
been reported to decrease mitochondrial membrane potential [312]–[317]. In support of this 
possibility, proteasomal parkin degradation has been implicated in parkin loss from 
mitochondrial depolarization, 6-OHDA treatment, and MPP+ treatment. Additionally, the 
involvement of PINK1, which is stabilized by mitochondrial depolarization, in parkin loss from 
hydrogen peroxide is further evidence that peroxide-induced parkin loss overlaps with 
depolarization-induced parkin loss. 
 Several of the studies that reported toxin-induced parkin loss provide evidence that this 
loss plays a role in cell death caused by the toxin. Studies from our group showed that knocking 
down Trib3 or overexpressing ATF4 attenuated both cell death and parkin loss from 6-OHDA 
[265], [266]. Knocking down parkin completely prevented the protective effect of both Trib3 
knockdown and ATF4 overexpression on cell death from 6-OHDA, indicating that parkin 
activity is necessary for cell protection by these interventions. However, knocking down parkin 
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alone either did not exacerbate cell death from 6-OHDA [265] or mildly increased this death 
[266], indicating that cells that survive 6-OHDA treatment do not rely on parkin activity for their 
survival. These findings can be reconciled by the following model: 1) the parkin loss induced by 
6-OHDA decreases levels of active parkin, contributing to cell death, and 2) ATF4 
overexpression and Trib3 knockdown reduce the loss of active parkin, leading to cell protection. 
This model can explain why parkin knockdown had a strong effect on cell protection in the 
context of ATF4 overexpression/Trib3 knockdown but not in the context of 6-OHDA treatment 
alone. In the latter case, parkin knockdown would not significantly enhance cell death from 6-
OHDA because 6-OHDA already decreases active parkin levels on its own. In the former case, 
parkin knockdown would prevent the protective effect of ATF4 overexpression and Trib3 
knockdown on 6-OHDA-induced death because this protective effect converges on preservation 
of active parkin levels. Further evidence in support of this model comes from the fact that 
preventing parkin loss by parkin overexpression has been shown to be significantly protective 
against death induced by 6-OHDA, MPP+, and camptothecin [266], [287]. 
 In summary, cellular stressors frequently have divergent effects on parkin mRNA and 
protein levels: increasing the former and decreasing the latter. Furthermore, there is evidence that 
the stress-induced decrease in parkin protein contributes to cell death. Although the mechanisms 
behind stress-induced and basal parkin regulation have started to be elucidated, much remains to 
be discovered. In particular, future work should attempt to differentiate between regulation of 
total and active parkin levels, because the latter is the critical determinant of downstream parkin 
activity.  
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1.2.5 Inactivation of parkin by stress-induced misfolding and post-translational modification 
 In addition to the many studies that have reported loss of parkin protein levels upon 
cellular exposure to stress, various studies have also reported that cellular stressors can cause 
parkin to misfold and/or be modified post-translationally, rendering it inactive. Given the 
abundant evidence that parkin loss is neurotoxic, parkin inactivation from stress-induced 
misfolding/modification is another mechanism, in addition to parkin loss, by which cellular 
stressors may cause toxicity. 
 Various stressors have been found to cause parkin to misfold, including oxidizing agents 
[302], [318]–[322], mitochondrial toxins [318], proteasomal inhibition [318], [322], [323], and 
heat shock [319]. To assess parkin folding, most studies examine its solubility by sequential 
resuspension of cell lysates in a buffer with mild detergent (designated the soluble fraction) 
followed by a buffer with ~2% SDS (the insoluble fraction). Parkin found in the insoluble 
fraction is considered misfolded. Evidence for this conclusion is several-fold. First, most studies 
report that, in untreated cells, the majority of parkin is found in the soluble fraction [266], [302], 
[318], [319], [322], [323], suggesting that properly folded parkin is soluble. Second, mutations in 
key zinc-binding residues that are predicted to disrupt parkin folding decrease parkin solubility 
[321]. Third, some PD-associated parkin mutants are enriched in the insoluble fraction, 
suggesting that parkin in this fraction is non-functional [111]. Finally, conditions that induce 
parkin movement into the insoluble fraction have also been found to induce cellular parkin 
aggregates by immunofluorescence [302], [318], [324]. Thus, the fact that many stressors 
increase parkin insolubility is strong evidence that they functionally inactivate it by causing it to 
misfold. 
 In addition to causing parkin to misfold, many stressors have been reported to induce 
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inactivating post-translational modifications of parkin. These modifications can be grouped into 
two categories: oxidative modifications of parkin's cysteine residues and inactivating parkin 
phosphorylation. The first category includes s-nitrosylation, sulfonation, and conjugation of 
dopamine to the reactive thiol groups in certain parkin cysteines [320], [324]–[327]. The second 
category includes stress-induced parkin phosphorylation on Y143 by the kinase c-Abl [328], 
[329], on S131 by the p38-mitogen-activated protein kinase [330]. All of these modifications 
have been reported to ultimately inactivate parkin, with the greatest evidence of this in the case 
of s-nitrosylation and parkin phosphorylation by c-Abl.  
 The fact that many stressors lead to both parkin misfolding and parkin modification 
[302], [318], [321], [324], [326], [328] suggests that the latter may cause the former. Indeed, 
there is evidence that this is the case for oxidative parkin modification, but not for parkin 
phosphorylation. Evidence that oxidative modifications lead to parkin misfolding comes from the 
fact that proteins with high cysteine content (like parkin, which has 35 cysteines) tend to be more 
susceptible to misfolding induced by oxidative stress [321]. Furthermore, mutation of specific 
cysteines abrogated dopamine-induced parkin insolubility [321], and sulfonated parkin was only 
found in the insoluble fraction after exposure to MPP+ [324]. Conversely, the ratio of tyrosine-
phosphorylated parkin to total parkin was higher in the soluble fraction compared to the 
insoluble fraction, suggesting that parkin phosphorylation by c-Abl doesn't induce its misfolding 
[328]. 
1.2.6 Evidence of parkin inactivation and loss in sporadic PD 
 Given the well-established inactivating effects of various stressors on parkin and the 
well-documented increase in markers of cellular stress in the PD brain (Section 1.1.2), a logical 
question is whether parkin loss and inactivation occurs in the substantia nigra of PD patients. In 
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the case of inactivation, there is evidence that it does. The strongest evidence for this is the 
observation that levels of tyrosine-phosphorylated parkin are about 3 to 4 times higher 
specifically in the substantia nigra and striatum of PD patients compared to controls by Western 
blotting, a finding that's particularly striking given that neuronal proteins are often lowered in 
lysates of PD substantia nigra tissue due to neuronal death [328], [329]. Given that the activity of 
tyrosine-phosphorylated parkin was found to be significantly impaired, the strong elevation of 
this modification in the PD brain implies that parkin activity is diminished in the latter. 
Accordingly, two of parkin's substrates were found to be specifically elevated in the substantia 
nigra and striatum of PD patients [328], [329]. 
 In addition to tyrosine-phosphorylated parkin, increased s-nitrosylated and sulfonated 
parkin in the PD brain has been reported [324]–[326]. In light of the discussion above, this 
parkin would presumably be misfolded and insoluble. Accordingly, four different studies have 
reported increased levels of insoluble parkin in the PD caudate (which contains dopaminergic 
projections from the SNpc) [318], [320], [324], [331]. However, whether these changes reflect 
decreased levels of active parkin in the SNpc of PD patients is not clear. There are two reasons 
for this. First, it's unclear to what extent misfolded parkin in the striatum is an indicator of 
pathological changes in the dopaminergic neurons of the SNpc. Second, the likely detrimental 
effect of elevated insoluble parkin is a decrease in the levels of soluble, functional parkin in the 
PD brain, but it's not clear if soluble parkin is actually decreased in PD. Of the four studies that 
found increased levels of insoluble parkin in the PD caudate, three report unchanged or increased 
levels of soluble parkin in the PD caudate [318], [320], [324]. However, the fourth study did, 
indeed, find a reduction in soluble parkin levels in the PD striatum (which contains the caudate) 
compared to controls [331]. A further discrepancy is that the first three studies suggest that total 
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parkin levels in the caudate of PD patients would be increased, but two other groups have found 
that caudate/striatal parkin levels are unchanged in PD [332], [333]. These discrepancies, 
coupled with the fact that none of these studies report on the levels of oxidatively 
modified/insoluble parkin in the substantia nigra, make it difficult to make a conclusive 
statement about whether parkin misfolding decreases its activity in PD. Nevertheless, as 
described above, there is strong evidence that parkin activity is impaired in sporadic PD by 
stress-induced phosphorylation. Since parkin has crucial role in maintaining survival of SNpc 
neurons, it's possible that this decreased activity contributes to sporadic PD pathogenesis. 
 With regard to total parkin levels, it's unclear whether a decrease in parkin analogous to 
that seen with many stressors in cell culture and animal models occurs in in the SNpc of sporadic 
PD patients. Even though total parkin levels were found to be unchanged in the striatum of PD 
patients [332], [333], striatal homogenates contain many cell types, so only a fraction of the 
striatal parkin signal would be expected to come from the axons of dopaminergic neurons of the 
SNpc. In evidence of this, qualitative analysis of a Western blot from an early study shows that 
un-normalized parkin appears to be substantially reduced in homogenates of substantia nigra 
from PD patients, whereas it appears to be reduced only mildly or not at all in homogenates of 
PD putamen [334]. The substantially lower parkin levels in nigral homogenates from PD patients 
likely reflect the significant loss of dopaminergic neurons from this region, and the fact that this 
loss isn't readily apparent in putamen homogenates indicates that they are not a reliable proxy for 
the substantia nigra and that the parkin signal in striatal homogenates may come primarily from 
other cell types. 
 Several studies have examined parkin immunoreactivity specifically in dopaminergic 
SNpc neurons of PD patients, but only one has done so quantitatively [265], [334], [335]. The 
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qualitative studies noted that parkin is present in dopaminergic SNpc neurons in sporadic PD 
[334] and that the levels of parkin in these neurons appear grossly comparable between PD 
patients and controls [335]. However, the latter study also noted that there is significant 
heterogeneity in the level of parkin reactivity in dopaminergic neurons, suggesting that a 
quantitative study is needed to conclusively compare dopaminergic neuron parkin levels between 
PD patients and controls [335]. Our lab performed such a study and found that there was a trend 
toward lower parkin levels in dopaminergic neurons of PD patients that did not reach 
significance [265]. However, the number of brains analyzed in this study was small for the 
substantial variation that was encountered in the control samples. A study with more statistical 
power is warranted to determine whether or not the trend towards lower parkin in PD neurons is 
a true effect. 
 A difficulty for interpreting any results regarding parkin levels in dopaminergic neurons 
from post-mortem PD brains is that these neurons are the "survivors" that have been resilient 
enough to escape neurodegeneration. If parkin levels are not decreased in these neurons, it's 
possible that these neurons have survived because their parkin levels have not decreased, while 
neurons in which parkin was lost succumbed to degeneration. Given that parkin activity is 
impaired by phosphorylation in PD, even relatively small decreases in parkin levels could 
negatively impact cell survival. Thus, even if parkin levels are eventually demonstrated not to be 
decreased in dopaminergic neurons from PD patient brains, it will be difficult to prove that 
parkin does not decrease in degenerating neurons. 
 In addition to stress from the degenerative mechanisms underlying PD, dopaminergic 
neurons (and hence, the parkin in these neurons) might also experience stress from the most 
common treatment of PD motor symptoms, L-DOPA. 
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1.3 L-DOPA 
 L-DOPA is the precursor to dopamine, converted efficiently to the latter in the cytosol of 
catecholaminergic neurons by L-amino acid decarboxylase (AADC) (Fig. 1.6). The therapeutic 
efficacy of L-DOPA in PD stems from its ability to replenish striatal dopamine levels, which fall 
due to death of dopaminergic SNpc neurons [184]. Though L-DOPA remains the most effective 
treatment of PD motor symptoms, a majority of patients eventually develop motor side effects 
called dyskinesias [184], [336]. Additionally, a long-standing concern in the field is that L-
DOPA may accelerate the disease process underlying PD [336], [337].  
 There are several reasons for this concern. First, there is evidence that dopamine may 
play a role in the pathophysiology of PD (Section 1.1.2.6), so L-DOPA-mediated dopamine 
elevation could promote the deleterious effects of the latter. Second, L-DOPA itself is capable of 
causing cellular toxicity via its autoxidation, which generates hydrogen peroxide, superoxide, 
and reactive quinone species capable of damaging proteins, lipids, and DNA [81], [338]. 
Because of the clinical implications of a possible disease-accelerating effect of L-DOPA, 
numerous studies have been undertaken to investigate the possible toxicity of L-DOPA in PD. 
Figure 1.7. L-DOPA is converted to dopamine by L-amino acid decarboxylase. 
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Despite these efforts, the question of whether L-DOPA contributes to neurodegeneration in PD 
remains unresolved [336], [337]. 
 The greatest evidence for L-DOPA toxicity has come from in vitro studies. Exposure of 
cultured cells to L-DOPA concentrations on the order of ~100 µM has been widely shown to 
cause cell death (reviewed in [336]). The mechanisms precipitating L-DOPA-mediated toxicity 
in these studies include L-DOPA autoxidation [336], [339], [340], its conversion to dopamine 
[336], [341], [342], and incorporation of L-DOPA into nascent polypeptide chains due to its 
similarity to tyrosine [343]. The concentrations of L-DOPA used in these studies far exceed the 
maximal L-DOPA concentrations observed in the cerebro-spinal fluid (CSF) of PD patients 
taking L-DOPA (~0.5-1 µM) [344], [345], raising the question of how relevant these findings are 
for patients. However, some of the pathological effects reported in vitro have been also found in 
PD patients. Specifically, proteins containing cysteine conjugates of L-DOPA-quinone and with 
directly incorporated L-DOPA have been detected in post-mortem brain tissue of PD patients 
[343], [346], and elevated CSF levels of 3-nitrotyrosine, a proxy for the ROS peroxynitrite, have 
been observed in PD patients following the commencement of L-DOPA therapy [347]. Thus, it's 
feasible that chronic exposure of patients to low L-DOPA concentrations could mimic the 
deleterious effects of acute exposure to a high dose. 
 Animal studies have yielded contradictory results on the question of possible L-DOPA 
toxicity in vivo [336]. Many studies have not observed deleterious consequences from L-DOPA 
administration to healthy animals or those with PD-mimicking lesions [337], [348]–[351], but 
others have found that L-DOPA can increase reactive oxygen species, diminish mitochondrial 
activity, and possibly contribute to dopaminergic neuron death [336], [352]–[355]. 
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 Attempts to evaluate the effects of L-DOPA on disease progression in patients have 
similarly yielded inconclusive results [336], [337]. Studies that examined the effects of L-DOPA 
on PD motor symptom progression or dopamine neuron number post-mortem have not found 
evidence of a deleterious effect of L-DOPA [337]. However, limitations in the designs of these 
studies prevent a firm rebuttal of the possible toxic effect of L-DOPA [337]. Specifically, clinical 
studies have suffered from incomplete randomization and a possibly insufficient wait time after 
L-DOPA termination to assess motor symptoms [337], [356], [357], and the pathology study had 
a relatively small sample size and used a less reliable counting technique [337], [358]. 
Additionally, neuroimaging studies have revealed a decrease in markers of dopaminergic neuron 
terminals in PD patients receiving L-DOPA [357], [359], [360], possibly suggesting increased 
degeneration of these terminals from L-DOPA treatment. However, other explanations are also 
possible for these decreases in biomarker signal, including L-DOPA-induced changes in the 
metabolism or membrane transport of dopamine and L-DOPA [336], [337]. Thus, the question of 
L-DOPA toxicity in PD remains an unresolved and much debated topic. 
1.4 Study Rationale 
  
 This dissertation investigates the mechanism by which L-DOPA decreases parkin protein 
levels in vitro. Several points made in the preceding sections motivated us to pursue the studies 
presented here.  
 Foremost, parkin activity promotes neuronal health. This is evident from the fact that 
homozygous loss of parkin leads to early-onset PD and heterozygous loss of parkin may increase 
the risk of PD development. Additionally, there is a multitude of evidence from in vitro and in 
vivo work that parkin has broad neuroprotective activity.  
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 In light of parkin's neuroprotective capacity, it has been increasingly recognized that 
strategies to increase parkin levels and activity hold therapeutic promise for PD. This is 
especially true given the finding that parkin appears to be post-translationally inactivated in 
sporadic PD, which may contribute to neurodegeneration in the latter. However, before we can 
effectively manipulate parkin therapeutically, it is critical to first understand the regulatory 
mechanisms that normally control levels of active parkin in the cell. Although some progress has 
been made in understanding the regulation of total parkin levels, many gaps in our knowledge 
remain, particularly with respect to possible differences in the regulation of activated parkin and 
parkin in its native autoinhibited state. 
 Various stressors have been shown to decrease parkin levels in cell culture and animal 
models, providing a useful paradigm in which to investigate the regulatory mechanisms that 
control parkin levels. Although stress-induced parkin loss appears to be a common occurrence, 
the mechanisms involved in this phenomenon are largely unclear, as well as whether it truly 
represents a unified phenomenon or whether parkin loss from different stressors occurs via 
different pathways.  
 Our study aimed to shed light on the mechanism(s) by which stress can decrease parkin 
levels, with the ultimate goal that these insights may prove useful for the development of 
therapeutic strategies based on parkin upregulation. We chose L-DOPA as a cellular stressor 
because it's well-established as an in vitro stress model and because of its clinical relevance. To 
our knowledge, the effect of L-DOPA on parkin has only been examined on in one study, in 
which macaques were exposed chronically to a combined regimen of MPTP and L-DOPA [361]. 
Parkin levels in striatal homogenates were unchanged following this treatment. However, as 
discussed in Section 1.2.6, striatal homogenates are not a reliable proxy of SNpc neurons, and, 
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more importantly for our purposes, the lack of striatal parkin loss in vivo did not preclude the 
possibility that L-DOPA could be a useful model for studying parkin regulation in vitro. Indeed, 
we had reason to suspect that L-DOPA would decrease parkin levels in vitro given that it has 
been shown to cause oxidative stress in in vitro systems and oxidative stressors have been found 
to decrease parkin levels. 
 In the following chapters, we show that L-DOPA decreases parkin protein levels in 
several different cell types. Using differentiated PC12 cells, we then characterize the 
mechanisms by which L-DOPA decreases parkin, showing that this process is independent of 
cell death and L-DOPA's conversion to dopamine and finding that at least two distinct pathways 
are at play in L-DOPA-induced parkin degradation. We implicate oxidative stress, PINK1 
phosphorylation of ubiquitin, and the proteasome in one of these pathways. Additionally, we 
provide evidence against the involvement of several pathways/proteins in L-DOPA-induced 
parkin loss, including Trib3, NADPH oxidases, lysosomal degradation, and mitophagy. Finally, 
we provide preliminary evidence that parkin knockdown does not exacerbate L-DOPA-induced 
toxicity in PC12 cells, though it may increase the initial rate of this toxicity. 
 Our data provide new insights into mechanisms of parkin regulation, most notably with 
our finding that a parkin activator, phosphorylated ubiquitin, plays a role in parkin degradation. 
Future studies are warranted to further elucidate the mechanism by which this takes place and to 
investigate whether it may be possible to uncouple parkin's activation by phosphorylated 
ubiquitin and its degradation as a therapeutic strategy for PD. 
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Chapter 2 Exposure of cells to L-DOPA leads to increased parkin degradation  
2.1 Introduction 
 Although various stressors have been reported to decrease parkin levels in cells, the 
mechanisms by which parkin is lost in these models is largely unclear. In addition, it remains 
unknown to what extent the mechanisms of parkin loss following different stressors are shared. 
Given that L-DOPA has been shown to induce cellular stress in vitro, we investigated whether L-
DOPA is also capable of decreasing parkin levels in cultured cells and how this process happens. 
As previously discussed, the fact that PD patients are given L-DOPA increases the possibility 
that our results could be clinically relevant. 
2.2 Results 
2.2.1 L-DOPA decreases parkin protein in various cell types 
 We began our interrogation of L-DOPA's effects on parkin levels in PC12 cells, which 
are catecholaminergic cells derived from a rat pheochromocytoma [362]. PC12 cells can be 
induced to stop dividing and assume a neuron-like phenotype when exposed to nerve growth 
factor (NGF) [362]. This characteristic makes them a convenient and homogeneous model of 
catecholaminergic neurons. Indeed, many studies have made use of differentiated PC12 cells to 
model neuronal catecholamine handling as well as PD-related dysfunction [363]. Additionally, 
PC12 cells have levels of parkin that can be readily detected by Western immunoblotting (WB), 
making them a fitting model in which to evaluate L-DOPA's effect on parkin. 
 To determine the effects of a range of L-DOPA concentrations on parkin, differentiated 
PC12 cells were treated with several doses of L-DOPA ranging from 0 to 400 µM for 24 hours 
and cell lysates were probed for parkin by WB. The results show a dose-dependent loss of 
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parkin, with ~40% parkin loss at the highest dose of L-DOPA used (Fig. 2.1 A). Going forward, 
we chose the 200 µM dose because it yielded a robust loss of parkin with relatively mild cell 
Figure 2.1. L-DOPA decreases parkin protein in various cell types 
A,B. Dose-response and time-course experiments with L-DOPA in PC12 cells. Differentiated PC12 cells 
were treated with the indicated concentrations of L-DOPA (LD) for 24 hours (A) or 200 µM L-DOPA for 
up to 51 hours (B).  C. L-DOPA decreases parkin in primary rat cortical neurons. Neurons were treated 
with 200 µM L-DOPA for 24 hours (left) or 500 µM L-DOPA for 15-18 hours (right).  D. 200 µM L-
DOPA decreases parkin in SH-SY5Y cells (left) and MEFs (right) after 24 hours.  A-D. After treatment, 
total cell lysates were harvested for Western blotting in lysis buffer containing 2% LDS and protein levels 
were quantified relative to ERK1 & 2. Error bars show SEM; * p ≤ 0.05, ** p ≤ 0.01 relative to 0 µM L-
DOPA (A,C,D) or the corresponding 0 µM L-DOPA value at each time point (B) by paired t-test (A-D) 
with Holm correction for multiple comparisons (A, B). 
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death at 24 hours compared with higher doses (data not shown). 
 To examine the kinetics of parkin loss, a time course was performed with 200 µM L-
DOPA in PC12 cells. Cell lysates were harvested at various time points up to 50 hours after L-
DOPA addition and probed for parkin by WB. This experiment revealed a relatively slow loss of 
parkin beginning around 6 hours post-treatment and nearly finished by 24 hours post-treatment 
(Fig. 2.1 B). Given that parkin loss was robust (~45%) and almost complete after 24 hours of L-
DOPA treatment, this was the time point chosen for most subsequent experiments in PC12 cells. 
 To see whether L-DOPA has a similar effect on parkin in bona fide neurons, we 
investigated L-DOPA's effect in primary rat cortical neurons. After a 24-hour incubation with 
200 µM L-DOPA, we observed a statistically significant but very modest loss of parkin, ~15% (p 
= 0.048). Treatment of neurons with a higher dose of L-DOPA, 500 µM, for 15-18 hours 
revealed a slight increase in parkin loss, to about 20% (p = 0.001) (Fig. 2.1 C).  
 Finally, we investigated L-DOPA's effect on parkin in two other cell types: 
undifferentiated SH-SY5Y cells and immortalized mouse embryonic fibroblasts (MEFs). SH-
SY5Y cells are catecholaminergic cells derived from a human neuroblastoma [364]. In both cell 
types, parkin was relatively difficult to detect by Western blotting, suggesting that parkin levels 
are lower in these cell types than in differentiated PC12 cells and cortical neurons. In fact, one 
study has claimed that parkin levels are undetectable in MEFs [199], though other studies 
contradict this claim [283], [285]. In our hands, 24 hours of exposure to L-DOPA led to a loss of 
parkin of about 30% in both cell types (Fig. 2.1 D). 
 We chose to use differentiated PC12 cells for most of our subsequent experiments 
because of the robust L-DOPA-induced parkin loss in this model as well as the ease of PC12 cell 
parkin detection by WB. 
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2.2.2 L-DOPA-induced parkin loss occurs independently of cell death 
2.2.2.1 Timecourse of cell death from L-DOPA 
 Given that L-DOPA has been demonstrated to cause death in PC12 cells at the 
concentrations used here [339], [340], we investigated the degree of cell death caused by L-
DOPA in PC12 cell cultures. To do this, we treated PC12 cells with 200 µM L-DOPA for up to 
48 hours and counted the number of viable nuclei remaining after 24 and 48 hours of treatment. 
Because we used differentiated PC12 cells, which are not expected to divide, the results reflect 
only differences in survival. We observed a small degree of cell death (~20%) after 24 hours of 
L-DOPA treatment, which increased to ~40% after 48 hours of treatment (Fig. 2.2 A). These 
results indicate that, in line with previous studies, 200 µM L-DOPA is toxic to PC12 cells. In 
addition, they show that the toxicity is gradual, not immediate. 
2.2.2.2 Subtoxic doses of L-DOPA decrease parkin levels 
 To determine whether loss of parkin due to L-DOPA treatment can occur independently 
of cell death, we designed an experiment to assess whether subtoxic doses of L-DOPA can still 
decrease parkin. To maximize the chances that we would see an effect on parkin with relatively 
low doses of L-DOPA as well as to ensure that sufficient time would elapse after the first 
treatment to detect any cell death from L-DOPA, we used a multiple-treatment design (Fig. 2.2 
B). Cells were treated with 25-100 µM L-DOPA a total of three times, with two days between 
treatments. Lysates were harvested for Western blotting two days after the final L-DOPA 
treatment (six days after the first exposure to L-DOPA), and cells were harvested for survival 
assessment three days after the final L-DOPA treatment (seven days after the first exposure to L-
DOPA). In these experiments, all doses of L-DOPA were non-toxic (Fig. 2.2 C), but a dose-
dependent loss of parkin was observed, reaching significance with 100 µM L-DOPA (Fig. 2.2 
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D). Although we had aimed to increase the degree of parkin loss by multiple treatments with L-
DOPA, comparison of the levels of parkin loss in these experiments with those in our single-
treatment timecourse (Fig. 2.1 A) don't reveal a notable difference in parkin loss (~25% loss with 
single 100 µM L-DOPA treatment vs. ~35% loss with triple 100 µM treatment). Nevertheless, 
these results demonstrate that parkin loss occurs independently of cell death from L-DOPA. 
 
Figure 2.3. L-DOPA-induced parkin loss occurs independently of cell death 
A. Timecourse of L-DOPA toxicity in PC12 cells. Cells were treated with 200 µM L-DOPA and 
harvested for assessment of survival after 24 and 48 hours.  B. Treatment paradigm used to assess 
whether non-toxic doses of L-DOPA lead to parkin loss.  C. Quantification of cell survival after exposure 
to L-DOPA following the paradigm in (B).  D. Non-toxic concentrations of L-DOPA still induce parkin 
loss. Representative Western blot and quantification of parkin protein after exposure to L-DOPA 
following the paradigm in (B). Error bars show SEM; * p ≤ 0.05, ** p ≤ 0.01 by paired t-test with Holm 
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2.2.3 L-DOPA increases the rate of parkin degradation 
2.2.3.1 L-DOPA does not alter parkin mRNA levels 
 Having established that L-DOPA-induced parkin loss occurs in multiple cell types and is 
independent of cell death, we next set out to determine whether this loss is driven by decreased 
parkin production, increased parkin degradation, or a combination of both processes. To address 
these questions, we conducted several experiments in PC12 cells. First, we assessed parkin 
mRNA levels at various time points up to 27 hours after L-DOPA treatment. There was no 
significant change in parkin mRNA levels after L-DOPA at any of the time points tested (3 hr: p 
= 1; 6 hr: p = 1; 11 hr: p = 0.42; 27 hr: p = 1) (Fig 2.3), indicating that decreased mRNA levels 
are not responsible for parkin protein loss due to L-DOPA. 
 
Figure 2.5. L-DOPA does not alter parkin mRNA levels 
Cells were treated with 200 µM L-DOPA and harvested for qPCR analysis at the indicated time points. 
The parkin mRNA level was normalized to 18S RNA. Error bars show range from two independent 
experiments. Significance was assessed at each time point by paired t-test followed by Holm correction 
for multiple comparisons. 
  60 
2.2.3.2 L-DOPA decreases parkin in the presence of cycloheximide 
 To determine whether L-DOPA increases the rate of degradation of parkin protein, we 
treated PC12 cells with L-DOPA and cycloheximide, an inhibitor of translation. Blocking 
translation is a way to examine only the role that protein degradation plays in the expression 
level of a protein. If L-DOPA increases the rate of degradation of parkin, we would expect to see 
increased parkin loss over time compared to cycloheximide treatment alone. Indeed, we observed 
a progressive loss of parkin over 48 hours with cycloheximide that was enhanced by L-DOPA 
treatment (Fig. 2.4 A). Of note, the start of this loss appears to be delayed in both conditions, 
beginning around 12 hours after the start of treatment. Whether this observed delay is a robust 
phenomenon bears further investigation, because the three individual replicates comprising this 
experiment were variable in this regard. 
 To make sure that cycloheximide was effective at blocking translation, we performed a 
puromycin-incorporation assay. At low concentrations, puromycin is non-toxic but is 
incorporated into newly formed proteins by virtue of its similarity to aminoacyl tRNAs [365]. 
Assessing puromycin levels in the proteome after a short period of incubation can therefore be 
used as a readout of new protein translation. When we treated cells with cycloheximide, proteins 
containing puromycin were decreased by ~90% as assessed by WB (Fig. 2.4 B), indicating an 
effective blockade of translation.  
 The prolonged treatment of cells with cycloheximide in this experiment resulted in 
obvious cell death by 48 hours (data not shown), indicating that parkin loss in the presence of 
cycloheximide both with and without L-DOPA likely reflects both parkin degradation and cell 
death. This raises the concern that the increased loss of parkin protein with L-DOPA and 
cycloheximide could be due to enhanced cell death in the latter condition compared to 
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cycloheximide alone. To address this concern, we probed for ERK1 protein on the same Western 
blots we used for parkin and performed the same analysis (Fig. 2.4 C). The rationale was that, if 
enhanced parkin loss with L-DOPA and cycloheximide reflected fewer surviving cells, we would 
 
Figure 2.6. L-DOPA decreases parkin in the presence of cycloheximide 
A-C. PC12 cells were treated with 2 µg/mL cycloheximide (CHX) in the presence or absence of 200 µM 
L-DOPA and harvested for Western blotting at the indicated time points.  A. Representative Western blot 
and quantification of parkin levels not normalized to a loading control.  B. CHX effectively blocked 
translation. Cells were exposed to 2.5 µg/mL puromycin for two hours after 15 hours of CHX treatment 
with or without L-DOPA before harvest for WB. Blot was probed with an antibody against puromycin 
(left) or stained with Ponceau to visualize total protein levels (right).  C. L-DOPA doesn't decrease ERK1 
in the presence of CHX. ERK1 levels were analyzed in the same way that parkin was analyzed in (A). 
Error bars show SEM from 3 independent experiments. * p ≤ 0.05, ** p ≤ 0.01 relative to no L-DOPA at 
that time point by repeated measures 2-way ANOVA of data from the 12-48 hour  time points with 
Sidak's multiple comparisons test. 
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see a similar enhancement of ERK1 loss with L-DOPA and cycloheximide.  However, we did 
not observe an enhanced loss of ERK1 with L-DOPA and cycloheximide compared to 
cycloheximide alone, indicating that enhanced parkin loss in the former condition is unlikely to 
be a result of enhanced cell death in that condition. 
 We next determined parkin's half-life with and without L-DOPA. Because parkin loss 
only begins after 12 hours of cycloheximide treatment, we fitted linear regressions to the log-
transformed parkin values with and without L-DOPA starting from 12 hours of cycloheximide 
treatment. From these regressions, the calculated parkin half-lives were 41.9 hours with 
cycloheximide alone and 27.2 hours with cycloheximide and L-DOPA. Because we started our 
regressions after 12 hours of treatment had already elapsed, the "true" parkin half-lives were 53.9 
hours with cycloheximide alone and 39.2 hours with cycloheximide and L-DOPA. However, 
these half-lives must be interpreted with caution because they probably don't just reflect parkin 
degradation. This is because, as noted above, cell death from cycloheximide likely contributed to 
lowering overall protein levels. Despite this limitation in half-life determination, the clear 
increase in parkin loss with L-DOPA in the presence of cycloheximide suggests that L-DOPA 
increases the rate of parkin degradation. 
2.2.4 L-DOPA decreases overexpressed parkin 
2.2.4.1 L-DOPA does not consistently or specifically decrease highly overexpressed parkin 
  63 




Figure 2.7 L-DOPA does not consistently or specifically decrease highly overexpressed parkin 
A-C. Differentiated PC12 cells were transduced with a lentiviral vector carrying overexpressed parkin 
with bicistronically expressed GFP (Parkin OE) or an empty control vector. 5 days (A) or 16 hours (B,C) 
after transduction, cells were treated with 200 µM L-DOPA and harvested for WB 48 hours later. Parkin 
signal is shown using a high exposure and a low exposure. Parkin levels (A-C) and GFP levels (B,C) 
were quantified relative to ERK1 and Ponceau. Error bars in B and C show the range of the two 
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we examined whether overexpressed parkin decreases after L-DOPA treatment. For this, we 
initially transduced PC12 cells with a lentiviral vector carrying the cDNA for rat parkin under 
the EF-1α promoter. This lentiviral vector was previously generated in the lab as described in 
[266]. The promoter and UTR regions of the cDNA in this vector aren't the same as  
those of endogenous rat parkin, so an L-DOPA-induced decrease in overexpressed parkin would 
indicate that this effect is mediated at the protein level. 
 In the first experiment conducted with overexpressed parkin, L-DOPA was added 5 days 
after viral transduction, and cells were harvested for WB after 48 hours of L-DOPA treatment. 
We did not observe a decrease in overexpressed parkin with L-DOPA, though endogenous 
Figure 2.8. L-DOPA decreases "moderately" overexpressed parkin 
A. Vector map of our more moderately overexpressed parkin construct. N-terminally HA- and FLAG-tagged rat 
parkin is expressed from the minimal human parkin promoter. GFP is expressed bicistronically with parkin 
using and IRES sequence.  B. Differentiated PC12 cells were transduced with a lentiviral vector carrying 
"moderately" overexpressed parkin (OE vector). 3 days after transduction, cells were treated with 200 µM L-
DOPA for 24 hours and harvested for WB. Overexpressed parkin levels were detected using antibodies against 
parkin and HA. Quantification of overexpressed parkin and GFP levels with and without L-DOPA from three 
independent experiments is shown. Proteins were normalized to ERK1 and 2. Error bars showing  SEM are too 
small to be seen. *** p ≤ 0.001 by paired t-test. 
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parkin did decrease in cells transduced with a control vector (Fig. 2.5 A). In this experiment, 
levels of overexpressed parkin reached ~30X that of endogenous parkin. Given such a robust 
overexpression, we reasoned that perhaps we didn't see an effect because the high levels of 
parkin overwhelmed the degradation pathway.  
 In an effort to address this possibility, we added L-DOPA to transduced cells earlier, 16 
hours after transduction, when overexpressed parkin was just beginning to be expressed. This 
experiment was conducted twice, with slightly different results (Fig. 2.5 B,C). In the first 
replicate, overexpressed parkin decreased after 48 hours of L-DOPA, but this effect was not 
specific (Fig. 2.5 B). This is because GFP, which is bicistronically expressed with parkin in the 
lentiviral construct, also decreased with L-DOPA to the same degree as parkin. In the second 
replicate, parkin did not decrease with L-DOPA at all (Fig. 2.5 C).  
 We reasoned that perhaps, even with an earlier start to the L-DOPA treatment, parkin 
levels were still accumulating to such high levels after 48 hours of treatment that any L-DOPA-
induced parkin loss might be imperceptible. To address this possibility, we developed a more 
moderately overexpressed parkin construct. 
2.2.4.2 L-DOPA decreases more moderately overexpressed parkin 
 Given that the high degree of expression of our existing parkin construct was likely the 
result of the potent EF-1α promoter, we decided to substitute a weaker promoter in its place. To 
make overexpressed parkin levels as similar as possible to endogenous parkin levels, we took -
advantage of a commercially-available construct containing luciferase under the minimal 
endogenous human parkin promoter (SwitchGear Genomics). We replaced the EF-1α promoter 
in our overexpression construct with the parkin promoter from this construct (Fig. 2.6 A). Since 
this new construct would, ideally, express exogenous parkin at levels similar to endogenous 
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parkin, we attached HA and FLAG tags to the N-terminus of parkin to be able to differentiate it 
from endogenous parkin (Fig. 2.6 A).  
 Our promoter-replacement strategy to decrease exogenous parkin levels was successful. 
The new construct yielded levels of exogenous parkin that were on the order of 8X more than 
endogenous parkin (Fig. 2.6 B), down from ~30X with the EF-1α promoter. 
 We next determined the effect of L-DOPA on our new, "moderately"-overexpressed 
parkin construct. Cells were treated with L-DOPA 3 days after transduction with the construct 
and parkin levels were evaluated after 24 hours of treatment. The results show that exogenous 
parkin (detected by probing for HA) did indeed decrease after L-DOPA treatment to the same 
degree that endogenous parkin decreases after 24 hours of L-DOPA treatment (~40%) (Fig. 2.6 
B). To check for the specificity of the effect, we examined L-DOPA's effect on GFP, which is 
expressed bicistronically with parkin in this vector (Fig. 2.6 A). We did not observe any effect of 
L-DOPA treatment on GFP levels (Fig. 2.6 B), suggesting that L-DOPA's effect on parkin is 
specific. 
2.3 Discussion 
 The experiments in this chapter aimed to characterize the nature of parkin loss from L-
DOPA exposure. We found that L-DOPA increases the rate of parkin degradation independently 
of cell death. 
2.3.1 Observation of L-DOPA-induced parkin loss 
 We observed that, like various other stressors, L-DOPA decreases parkin in multiple cell 
types, both neuronal and non-neuronal. Parkin loss occurred in primary cortical neurons, 
indicating that this effect is relevant to bona fide neurons. Since the motor symptoms of PD 
result from the degeneration of dopaminergic neurons of the substantia nigra, a natural question 
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is why we didn't investigate parkin loss in these cells. The reason we used cortical neurons and 
not dopaminergic neurons is that primary ventral midbrain dopaminergic neurons are grown in 
mixed cultures with other neurons and glia, making Western blotting infeasible. Furthermore, PD 
affects non-catecholaminergic neurons in addition to dopaminergic neurons of the substantia 
nigra, so cortical neurons may well be a relevant model for the disease. 
 Although we observed some parkin loss in cortical neurons after L-DOPA, the most 
robust parkin loss occurred in differentiated PC12 cells. This observation, coupled with the fact 
that parkin was much easier to detect in PC12 cells than in SH-SY5Y cells or immortalized 
MEFs, led us to choose PC12 cells as our primary model to investigate L-DOPA's effect on 
parkin. The fact that these cells can be induced to adopt a neuron-like phenotype makes them a 
useful and much-employed model of catecholaminergic neurons. Additionally, we had 
previously confirmed the identity of the parkin band from PC12 cell lysates via knockdown 
(shown in Ch. 6), while we didn't have such validation for SH-SY5Y cells or MEFs. The lack of 
parkin band validation for SH-SY5Y cells and MEFs raises the possibility that we incorrectly 
identified a nonspecific band as parkin, which decreases the level of confidence we can have in 
results with these cell types. This is of particular concern for MEFs because parkin has been 
reported to be undetectable in these cells [199]. However, given that other studies have reported 
parkin presence and activity in MEFs [283], [285], it's possible that an insufficient volume of 
lysate was loaded to detect parkin in the former study.  
  Our dose-response experiment indicated that relatively high concentrations of L-DOPA 
(≥100 µM) are necessary to see a significant effect on parkin levels. These concentrations are 
significantly higher than L-DOPA levels reached in the cerebro-spinal fluid (CSF) of PD patients 
receiving L-DOPA, around 0.5-1 µM [344], [345]. This raises the question of how relevant our 
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observed effect on parkin is to PD patients (especially the SNpc neurons). Although it's clear that 
patients are not acutely exposed to such high doses of L-DOPA as we use in vitro, they are 
exposed chronically to low doses of L-DOPA over the course of years. It's feasible that, over 
time, a low L-DOPA concentration could have the same effect on parkin that a high dose of L-
DOPA has acutely. Furthermore, by the time patients receive L-DOPA, they are already in the 
midst of PD, so their neurons are under elevated stress. The dose of L-DOPA needed to elicit an 
effect on parkin in neurons already under stress could be lower than that for healthy neurons. 
Such a lowering of the threshold for a parkin effect in stressed cells would be analogous to a 
recent finding in which L-DOPA administration led to death of dopaminergic neurons in mice 
lacking the PD gene DJ-1 but not in wild-type mice [352]. The implication in this study was that 
DJ-1 knockout mice have increased baseline oxidative stress and that this made them more 
vulnerable to negative effects of L-DOPA.  
 If L-DOPA-induced parkin loss does indeed decrease parkin levels in patients, this could 
have deleterious effects on neuronal health, particularly because parkin has been shown to be 
inactivated by phosphorylation in PD (discussed in Section 1.2.5). 
2.3.2 L-DOPA increases parkin degradation 
 Our lab previously found that the toxins 6-OHDA and MPP+, both of which inhibit 
mitochondrial complex I and increase oxidative stress [366], [367], decrease parkin levels in 
PC12 cells [265], [266]. The time course of parkin loss with 6-OHDA is faster than with MPP+, 
with robust loss 4 hours after treatment, as opposed to 24 hours with MPP+. The kinetics of 
parkin loss from L-DOPA are more similar to those of the MPP+ model, with robust loss after 24 
hours. However, parkin loss appears to begin earlier with L-DOPA than with MPP+. It's possible 
that the similarity in time-course between the L-DOPA and MPP+ models reflects a similarity in 
  69 
the mechanism of parkin loss. Conversely, the fact that 6-OHDA causes a faster decrease in 
parkin than L-DOPA could imply a mechanistic difference between the models. However, 6-
OHDA autoxidizes much more rapidly than L-DOPA [338], and we present evidence in chapter 
4 that autoxidation of L-DOPA is involved in parkin loss. Given this, it's likely that at least part 
of the difference in kinetics between the L-DOPA and 6-OHDA models is the result of differing 
rates of autoxidation. 
 In investigating the mechanism driving parkin loss, we first looked at levels of parkin 
mRNA after L-DOPA treatment. Though there was a trend toward lower parkin mRNA starting 
11 hours after treatment, this effect was not significant and would not be nearly large enough to 
explain the degree of parkin loss we observe. It was surprising that we didn't see an increase in 
parkin mRNA following L-DOPA exposure because multiple studies, including from our lab, 
have found that varied cellular stressors increase parkin mRNA [249], [266]. In our work, it was 
6-OHDA that increased parkin mRNA levels in PC12 cells. The discrepancy between our results 
with L-DOPA and previous work suggests either that L-DOPA has a different effect on cells 
than other toxins or that our study was underpowered to see an effect that is truly there. 
 The lack of a decrease in parkin mRNA after L-DOPA treatment led us to suspect that 
increased parkin degradation was driving parkin loss. Indeed, our experiments with 
cycloheximide support this conclusion. L-DOPA significantly increased parkin loss in the 
presence of cycloheximide, decreasing the calculated half-life from 53.9 to 39.2 hours (or 41.9 
hours to 27.2 hours if considering only the time points when parkin loss from cycloheximide 
treatment has begun). As previously noted, these half-lives reflect not only parkin degradation 
but also cell death, implying that the real half-lives may actually be longer. Our findings are in 
line with previous studies that found parkin to be quite a stable protein [111], [288]–[291], 
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though, as discussed in Section 1.2.4.2.1 of the Introduction, there is disagreement about this 
[292]–[295]. Given the stability we observe, it's not surprising that increased degradation plays a 
role in parkin loss from L-DOPA. Had L-DOPA only decreased parkin production, we would not 
expect to see a 45% loss of parkin protein after 24 hours. 
 There appears to be a 12-hour delay in parkin loss with cycloheximide in the presence or 
absence of L-DOPA, which deviates from the expected pattern of exponential decay. This 
suggests that there could be a stabilizing factor that prevents parkin degradation during the first 
12 hours of treatment that subsequently disappears. Such a delay in parkin disappearance can 
also be observed in two prior studies that examined parkin stability [111], [288]. However, this 
delay did not occur in other studies [292]–[295]. Interestingly, the studies that observed a delay 
in parkin loss also reported a long parkin half-life, while the ones that did not observe a delay 
reported rapid parkin turnover. This suggests that rapid parkin loss is prevented in some model 
systems (including ours) by specific factor(s) that oppose its degradation. The fact that parkin 
loss from L-DOPA in the absence of cycloheximide is evident as early as 6 hours after treatment 
(Fig 2.1 B) suggests that, in the absence of cycloheximide, the degradation-opposing factor is 
unable to interfere with L-DOPA-mediated degradation. 
 Of note, the observed decrease in parkin half-life with L-DOPA and cycloheximide 
compared to cycloheximide alone is not sufficient to explain the degree of parkin loss that we 
observe after 24 hours of L-DOPA. The 14.7-hour difference in half-lives would result in a 
maximal parkin loss of ~20% after 24 hours of L-DOPA if not accounting for the delay in parkin 
degradation observed under cycloheximide or parkin loss of ~10% when incorporating this 
delay. Both of these estimates are much lower than the 45% parkin loss that we actually observe 
at 24 hours. This result suggests that L-DOPA increases parkin degradation through both a 
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mechanism that is independent of protein translation and one that requires protein translation and 
gets inhibited by cycloheximide. Such an interpretation is consistent with results that we present 
in chapter 4, in which we show that PINK1 is partially responsible for parkin loss from L-DOPA. 
PINK1 is continuously produced and rapidly degraded, and cycloheximide has been shown to 
prevent PINK1 accumulation in the cell under conditions that would normally stabilize it [108]. 
Therefore, cycloheximide likely prevents PINK1 stabilization from L-DOPA and thereby 
inhibits PINK1-dependent parkin loss. 
2.3.3 L-DOPA decreases "moderately" overexpressed parkin 
 L-DOPA decreased "moderately" overexpressed parkin to the same degree as 
endogenous parkin, indicating that the cellular mechanisms behind L-DOPA-induced parkin loss 
are not saturated by endogenous parkin and can degrade a supra-physiological amount of parkin. 
The fact that we did not observe a specific decrease in highly overexpressed parkin with L-
DOPA treatment underscores the importance of examining the behavior of endogenous parkin 
when investigating new questions about parkin biology. This point is relevant for the parkin field 
because many studies use highly overexpressed parkin to examine the dynamics of the PINK1-
parkin-mitophagy pathway [192], [242]. 
 The "moderately" overexpressed parkin construct we designed includes N-terminal HA 
and FLAG tags, which allows us to distinguish it from endogenous parkin. One disadvantage of 
this design is the possibility that the tag alters the response of parkin to L-DOPA. There is 
evidence that even small N-terminal tags interfere with parkin's autoinhibited conformation 
[368]. The possibility that our tagged parkin construct doesn't behave exactly like endogenous 
parkin must be kept in mind, but the fact that L-DOPA decreases both to the same extent makes 
this possibility less likely. 
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 The endogenous human parkin promoter in the "moderately"-overexpressed parkin 
construct also contains the 5’UTR sequence from human parkin, which is about twice the length 
of the 5’UTR from rat parkin (Fig. 2.7). The human and rat parkin 5’UTRs contain several 
identical stretches of sequence, the longest consisting of 9 bp (Fig. 2.7). This commonality raises 
the possibility that L-DOPA-induced loss of “moderately”-overexpressed and endogenous parkin 
could occur in part through a negative effect on parkin translation. While this possibility cannot 
be definitively ruled out, it appears unlikely. This is because, as discussed above, cycloheximide 
would have been expected to inhibit the PINK1-dependent pathway of parkin degradation that 
we define in Chapter 4. Since we still observe an increased rate of parkin disappearance from L-
DOPA treatment in the presence of cycloheximide, it suggests that the non-PINK1 dependent 
pathway of L-DOPA-induced parkin loss also causes parkin degradation rather than interfering 
with parkin translation. 
2.3.4 L-DOPA-induced parkin loss is independent of cell death 
 Given that L-DOPA has been shown to cause toxicity in vitro at concentrations used 
here, we investigated whether L-DOPA's effect on parkin is dependent on cell death. In line with 
previous studies, we observed cellular toxicity from 200 µM L-DOPA, and the degree of toxicity 
Figure 2.10 Sequence alignment between human and rat parkin 5' UTRs. 
The cDNA of human parkin is the top sequence; the cDNA of rat parkin is the bottom sequence. The purple 
highlighting in the human sequence indicates sequence that is included in the promoter of the "moderately"-
overexpressed parkin construct. The blue highlighting in the rat sequence shows the first exon of parkin; the 
light purple shows the second exon, and the dark purple shows  the third exon. Note that the 5' UTR of rat 
parkin is about half the length of the 5' UTR of human parkin. 
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increased from 24 to 48 hours of treatment. Parkin loss from 200 µM L-DOPA is nearly 
complete by 24 hours of treatment (Fig. 2.1 B), indicating that parkin loss tends to precede 
robust cell death. To determine whether this loss can still occur in cells that don't die, we treated 
cells with sub-toxic concentrations of L-DOPA and observed a dose-dependent decrease in 
parkin levels, indicating that parkin loss occurs independently of cell death. However, this 
finding does not rule out the possibility that parkin loss could be contributing to cell death from 
L-DOPA. Parkin loss by itself may not be sufficient for death, but, in conjunction with other 
factors, it could play a part or even be necessary for cell death. Indeed, given parkin's well-
documented pro-survival role against numerous toxins and our lab's data implicating parkin loss 
as a contributing factor in cell death from 6-OHDA and MPP+ [265], [266], the possibility that 
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Chapter 3 Trib3 activity is not necessary L-DOPA-induced parkin loss 
3.1 Introduction 
 Trib3 is a stress-induced pseudokinase that appears to act as a scaffold for other proteins 
in several pathways [265]. As discussed in Section 1.2.4.2.3 of the Introduction, our lab has 
previously shown that Trib3 is capable of decreasing parkin protein levels when overexpressed 
and contributes to parkin loss from 6-OHDA exposure [265]. Furthermore, it appears that Trib3-
mediated parkin loss contributes to PC12 cell death from 6-OHDA. Given that both 6-OHDA 
and L-DOPA would be expected to induce cellular oxidative stress, we asked whether Trib3 
might play a similar role in parkin loss from L-DOPA as it does in parkin loss from 6-OHDA.  
3.2 Results 
3.2.1 L-DOPA appears to increase Trib3 protein levels 
 6-OHDA significantly increases Trib3 protein levels in differentiated PC12 cells, so we 
first determined whether L-DOPA has a similar effect on Trib3 expression. Indeed, there is a 
trend toward a time-dependent increase in Trib3 levels after exposure of differentiated PC12 
cells to 200 µM L-DOPA for 11-51 hours (Figure 3.1), though this didn't reach significance 
when adjusting for multiple comparisons (likely because of the substantial variation in Trib3 
induction). The trend toward Trib3 induction was first apparent and strongest after 11 hours of L-
DOPA treatment (1.82 ± 0.23 with L-DOPA vs. 1.04 ± 0.04 without L-DOPA, adjusted p value 
0.25). This degree of maximal induction is comparable to that observed with 6-OHDA, which 
roughly doubled Trib3 levels starting 8 hours post-treatment [265]. It's difficult to compare the 
temporal kinetics of Trib3 upregulation by L-DOPA and 6-OHDA because different time points 
  75 
were examined here and in our previous study. In both cases, Trib3 expression appears to persist 




Figure 3.1 L-DOPA increases Trib3 protein levels. 
Differentiated PC12 cells were treated with 200 µM L-DOPA for the indicated times before cell lysates 
were harvested for Western blotting. A representative Western blot from 3 independent experiments is 
shown (top) * indicates a non-specific band. Levels of Trib3 protein were normalized to levels of ERK1 and 
ponceau. Trib3 levels were compared at each time point using paired t-test, and p values were adjusted using 
the Holm correction for multiple comparisons.  
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3.2.2 Trib3 knockdown does not affect L-DOPA-induced parkin loss 
 Given that L-DOPA does appear to increase Trib3 expression, we next asked whether 
Trib3 contributes to parkin loss from L-DOPA. To do this, we knocked down Trib3 using an 
shRNA created and validated in an earlier study from our lab [369] and then treated with L-
DOPA. This shRNA decreased Trib3 protein levels by about 30% in untreated cells and 
maintained Trib3 protein at roughly these levels in L-DOPA-treated cells (Figure 3.2), which is 
comparable to the degree of knockdown in our more recent paper [265]. Surprisingly, Trib3 
Figure 3.2 Trib3 knockdown does not affect L-DOPA-induced parkin loss. 
PC12 cells were transduced with lentivirus carrying an shRNA against Trib3 or a control shRNA on day 
2-4 of differentiation. 4-5 days later, cells were treated with 200 µM L-DOPA for 24 hours (A) or 48 
hours (B) before harvest for Western blotting. A representative Western blot of 2 experiments (A) or 1 
experiment (B) is shown, along with quantification of parkin and Trib3 protein levels. Proteins for 
normalized to ERK1 and 2 levels for (A) and to ERK1 and ponceau levels for (B). Error bars in (A) show 
range. 
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knockdown did not diminish L-DOPA-induced parkin loss at all in the three experiments we 
performed, though parkin loss was robust (50% or more loss) (Figure 3.2).  
3.3 Discussion 
 The results presented here suggest that, although L-DOPA upregulates Trib3 levels, 
Trib3 does not play a critical role in parkin loss from L-DOPA exposure. These findings are in 
contrast to our lab's previous data indicating that Trib3 is involved in 6-OHDA-induced parkin 
loss. Given that L-DOPA appears to enhance Trib3 expression to a similar extent as 6-OHDA 
and we previously showed that Trib3 overexpression is sufficient to decrease parkin levels as 
early as one day after viral transduction [265], it's surprising that Trib3 does not appear to be 
involved in L-DOPA-mediated parkin loss. 
 There are several possible explanations for why we observed Trib3 involvement in 6-
OHDA-induced parkin loss but not in L-DOPA-induced parkin loss. The most obvious 
explanation is that 6-OHDA and L-DOPA are not identical stressors. Though they have similar 
structures and have both been shown to induce cellular oxidative stress, parkin loss occurs much 
more quickly from 6-OHDA treatment than L-DOPA treatment, which correlates with 6-
OHDA's faster autoxidation kinetics, as discussed in Chapter 2. As such, perhaps the timing or 
the nature of the ROS produced by 6-OHDA triggers signaling cascades that aren't identical to 
those induced by L-DOPA. For example, it's feasible that the signaling triggered by 6-OHDA 
induces another factor needed for Trib3-mediated parkin loss and that this factor isn't induced by 
L-DOPA. 
 Another possible explanation for the differing effect of Trib3 knockdown in the L-DOPA 
and the 6-OHDA models has to do with the timing of cell lysis for Western blotting. In the case 
of 6-OHDA, parkin levels were assessed after 8 hours of treatment, whereas we analyzed parkin 
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levels after 24 or 48 hours of L-DOPA exposure. It's possible that, in both models, Trib3 plays a 
role only in the early rate of parkin loss, but not in parkin loss that happens with extended 
treatment. In this case, we might see parkin protection upon Trib3 knockdown at an earlier time 
point in the L-DOPA model, and we may not observe protection at a later time point in the 6-
OHDA model. This explanation would require that, by 24 hours of treatment, other factors 
involved in parkin loss from L-DOPA/6-OHDA have "caught up" the parkin loss that was 
prevented at early time points by Trib3 knockdown.  
 To conclude, the results in this chapter indicate that there are multiple mechanisms of 
stress-induced parkin loss. Different stressors may evoke parkin loss through different pathways, 
or there may be multiple time-dependent mechanisms of parkin loss that are commonly induced 
by several different stressors. In either case, we find that Trib3 is not a critical factor for the 
ultimate loss of parkin from L-DOPA treatment. 
  
  79 
Chapter 4 L-DOPA-induced oxidative stress leads to phospho-Ub-dependent parkin  
  loss independently of its activity 
4.1 Introduction 
 In Chapters 2 and 3, we established that L-DOPA increases parkin degradation in 
cultured cells and that Trib3 activity is not necessary for L-DOPA-induced parkin loss. In this 
chapter, we further elucidate the mechanism of L-DOPA-mediated parkin loss. We show that L-
DOPA leads to parkin loss through at least two distinct pathways, that one of these pathways is 
induced by oxidative stress, and that parkin interaction with PINK1-phoshorylated ubiquitin 
(phospho-Ub) is critical for proteasomal parkin degradation downstream of oxidative stress. 
Finally, we find that, surprisingly, parkin does not exhibit canonical mitochondrial poly-
ubiquitination activity after binding to L-DOPA-induced phospho-Ub. 
4.2 Results 
4.2.1 Oxidative stress plays a role in L-DOPA's effect on parkin independently of its 
conversion to dopamine 
 Given that L-DOPA has been reported to cause oxidative stress in cultured cells [339], 
[340], we examined whether L-DOPA-induced oxidative stress is responsible for parkin loss. To 
do this, we treated neuronal PC12 cells with the antioxidant glutathione in the presence of L-
DOPA. Glutathione (GSH) significantly attenuated parkin loss from L-DOPA, but, surprisingly, 
this rescue was not complete (43.3 ± 3.9% loss with L-DOPA alone vs. 18.9 ± 6.5% loss with L-
DOPA and GSH) (Fig. 4.1 A). Higher doses of glutathione, up to 10 mM, do not appear to 
increase parkin protection from L-DOPA (Fig. 4.1 B), and neither does pretreatment with 
glutathione before L-DOPA addition (Fig. 4.1 C). These results indicate that oxidative stress is at 
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least partially responsible for L-DOPA-induced parkin loss, but that a non-oxidative mechanism 
may also decrease parkin downstream of L-DOPA. 
Figure 4.1. Glutathione partially prevents L-DOPA-induced parkin loss 
A,B. Differentiated PC12 cells were co-treated with 200 µM L-DOPA and 200 µM glutathione (GSH) (A) 
or the indicated GSH concentrations (B) for 24 hours before lysates were harvested for Western blotting. 
Representative Western blots and quantification of parkin levels from 3 (A) or 2 (B) independent 
experiments are shown.  C. PC12 cells were treated as in (A,B) or pretreated with GSH for 4 hours prior 
to addition of L-DOPA ("GSH pre"). The experiment was performed once, and points in quantification of 
parkin levels represent biological replicates. Error bars show SEM in (A) and range in (B,C). * p ≤ 0.05 
by paired t-test with Holm correction for multiple comparisons. 
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 L-DOPA can generate reactive oxygen species (ROS) via non-enzymatic autoxidation 
and by conversion to dopamine, with subsequent autoxidation and oxidative metabolism of the 
latter [88], [89], [370]. To test whether conversion of L-DOPA to dopamine is required for its 
effect on parkin, we used carbidopa to block the activity of aromatic L-amino acid decarboxylase 
(AADC), the enzyme responsible for this conversion. As expected, L-DOPA significantly 
increased intracellular dopamine levels (to 3.0 ± 0.4 fold over control levels) (Fig. 4.2 A). Co-
treatment with carbidopa robustly diminished this effect (to 1.1 ± 0.3) but did not impact the loss 
of parkin from L-DOPA treatment (Fig. 4.2 A). These results suggest that autoxidation of L-
DOPA is the source of the oxidative stress that leads to parkin loss following L-DOPA treatment, 
Figure 4.2. L-DOPA autoxidation leads to parkin loss 
A. Treatment with carbidopa doesn't prevent parkin loss from L-DOPA. Cells were pretreated with 50 µM 
carbidopa (carbi) for 2 hours, then co-treated with 200 µM L-DOPA. 16-24 hours after L-DOPA addition, 
cells were harvested for analysis of intracellular dopamine (DA) levels by HPLC (left panel). 24 hours 
after L-DOPA addition, lysates were harvested for Western blotting. A representative Western blot (top) 
and quantification of parkin levels from 4 independent experiments are shown (right panel).  B. L-DOPA 
autoxidizes in cell culture medium. 200 µM L-DOPA was added to DMEM or RPMI culture medium and 
incubated for 24 hours at 37°C under 7.5% CO2 in the absence of cells. Evidence of L-DOPA-derived 
quinones can be seen in the "browning" of the medium.  C. Hydrogen peroxide induces parkin loss. Cells 
were treated with 200 µM hydrogen peroxide for 24 hours before lysates were harvested for Western 
blotting. Quantification of parkin levels in 3 independent experiments is shown. Error bars show SEM; * 
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 by paired t-test (A,C) with Holm correction for multiple comparisons 
(A). 
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not dopamine-derived ROS. In line with this possibility, we observed "browning" of the cell 
culture medium after 24 hours of exposure to L-DOPA, even in the absence of cells (Fig. 4.2 B), 
which has been shown to be a result of quinone formation from L-DOPA autoxidation [340], 
[371], [372]. 
 To confirm that oxidative stress is capable of inducing parkin loss, we treated cells with 
200 µM of the oxidizer hydrogen peroxide and observed a reduction of parkin protein analogous 
to that from L-DOPA (39.4 ± 3.8%) (Fig. 4.2 C). Altogether, these results indicate that oxidative 
stress from L-DOPA autoxidation plays a role in parkin loss from L-DOPA. 
4.2.2 PINK1 may play a role in L-DOPA-induced parkin loss in MEFs 
 PINK1 has been reported to be necessary for parkin loss from hydrogen peroxide [201]. 
Given that we implicated oxidative stress in L-DOPA-induced parkin loss, we next examined 
whether PINK1 plays a role in this loss. 
 To do this, we first made use of immortalized PINK1 knockout MEFs, which are 
advantageous over PINK1 knockdown in that the latter is completely eliminated. In Chapter 2, 
we showed that L-DOPA decreases parkin in wild-type (WT) immortalized MEFs. To examine 
whether PINK1 is necessary for this loss, we assessed the effect of L-DOPA on parkin levels in 
PINK1 knockout MEFs.  
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 We noticed that PINK1 knockout MEFs have a longer doubling time than WT MEFs 
Figure 4.3. PINK1 may play a role in L-DOPA-induced parkin loss in MEFs 
A,B. WT or PINK1 KO immortalized MEFs were treated with 200 µM L-DOPA for 24 hours before 
harvest for WB and assessment of parkin levels. For each experiment, parkin levels with L-DOPA 
treatment were normalized to parkin levels without L-DOPA in that genotype. A. Cells were grown and 
treated according to "protocol 1": cells were plated at a density of 0.8-1.25E5 cells/mL in growth medium 
containing 10% FBS and allowed to grow for 24 hours before addition of L-DOPA. An outlier in the "WT 
L-DOPA" condition was identified and removed using the outlier analysis modality of Prism 6.  B. Cells 
were grown and treated according to "protocol 2": cells were plated at a density of 5-10E5 cells/mL in 
growth medium containing 0.1% FBS and treated with L-DOPA 3 hours later. Error bars represent SEM 
or range (B, WT L-DOPA) from independent experiments. * p ≤ 0.05, *** p ≤ 0.001 by paired t-test with 
Holm correction for multiple comparisons.  
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(data not shown), so, in addition to treating PINK1 knockout MEFs with L-DOPA according to 
the protocol we previously used for WT MEFs, we also devised a new treatment paradigm that 
aimed to minimize the effects of the different growth rates of the two cell lines. In the previously 
used protocol (hereafter called protocol 1), cells were plated at a relatively low density, allowed 
Figure 4.4. PINK1 plays a role in L-DOPA-induced parkin loss in PC12 cells 
A,B,E. Knockdown of PINK1 partially prevents parkin loss from L-DOPA and CCCP. Cells were 
transduced with shRNA against PINK1 for 4 days before being harvested for qPCR analysis (A) or 
treated with 200 µM L-DOPA (B) or 10 µM CCCP (E). Cell lysates were harvested for WB after 24 hours 
of L-DOPA (B) and 12 hours CCCP (E). Representative Western blots and quantification of parkin levels 
from at least 4 independent experiments are shown.  C,D. Representative Western blot (C) and 
quantification (D) of the timecourse of CCCP-induced parkin loss. Cells were treated with 10 µM CCCP 
for up to 25 hours before being harvested for Western blotting. (D) shows results of 3 independent 
experiments. Error bars show SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 by paired (A,B,E) or unpaired 
(D) t-test, with Holm (B,E) or Holm-Sidak (D) correction for multiple comparisons. For (D), significance 
was queried between untreated and CCCP groups at each time point. 
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to grow for 24 hours, and then treated with L-DOPA for 24 hours. The new protocol (protocol 2) 
aimed to minimize the rate and the total number of cell divisions; as such, cells were plated at a 
higher density in low-serum medium and treated with L-DOPA 3 hours after plating.  
 The results using these two treatment protocols are slightly different and suggest that 
PINK1 may be involved in L-DOPA-induced parkin loss in MEFs under certain circumstances 
(Fig. 4.3 A,B). Upon removal of an outlier flagged by an outlier detection algorithm, PINK1 
knockout MEFs showed significantly less parkin loss from L-DOPA than WT MEFs using 
protocol 1 (WT: 42.4 ± 2.7% loss; PINK1 KO: 13.4 ± 4.0%; p = 0.001) (Fig. 4.3 A). This 
suggests that PINK1 may play a role in L-DOPA-induced parkin loss under the conditions of 
protocol 1. However, the 13% parkin loss in L-DOPA-treated PINK1 knockout cells was also 
significant (p = 0.027 vs. untreated PINK1 KO cells), indicating that L-DOPA also induces 
parkin loss through a PINK1-independent pathway under these conditions.  
 In contrast to the results obtained using protocol 1, L-DOPA-induced parkin loss in wild-
type MEFs appears very mild (~11%), if present at all, under the conditions of protocol 2 (Fig. 
4.3 B). Note that the data using protocol 2 are more preliminary, only representing 2-3 
experiments, so there are no statistically significant differences within this dataset. In contrast to 
the apparently large difference in parkin loss in WT MEFs between protocols 1 and 2, the degree 
of parkin loss in PINK1 KO MEFs appears similar between the two protocols (~13% in #1 and 
~23% in #2), and similar to the apparent degree of parkin loss in WT MEFs using protocol 2 
(~11%). This suggests, preliminarily, that the conditions of protocol 2 may preclude PINK1-
dependent parkin loss from L-DOPA while not interfering with the PINK1-independent pathway 
also observed using protocol 1. All together, these experiments suggest that, under full-serum 
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growth conditions and when L-DOPA treatment is delayed until 24 hours post-plating, PINK1 
may play a role in L-DOPA-induced parkin loss in MEFs. 
4.2.3 PINK1 plays a role in L-DOPA-induced parkin loss in PC12 cells 
 Our data using PINK1 knockout MEFs suggested that PINK1 may be involved in L-
DOPA-induced parkin loss under certain circumstances. Therefore, we were encouraged to 
examine whether PINK1 plays a role in our more well-characterized model of L-DOPA-induced 
parkin loss in differentiated PC12 cells. To do this, we knocked down PINK1 using a previously-
characterized shRNA [217] in these cells and assessed how this affected L-DOPA-induced 
parkin loss. PINK1 knockdown was very effective at the mRNA level, reducing PINK1 
transcript levels to 14.1 ± 3.5% of control levels after 4 days (Fig. 4.4 A); we were not able to 
assess PINK1 protein levels due to lack of a reliable antibody.  
 Knockdown of PINK1 attenuated L-DOPA-induced parkin loss by about half (36.7 ± 
2.8% parkin loss with sh-ctrl vs. 17.7 ± 6.3% loss with sh-PINK1) (Fig. 4.4 B), indicating that 
PINK1 is involved in this process.  
 Given that PINK1 knockdown appears to only partly attenuate L-DOPA-induced parkin 
loss, we asked whether the remaining parkin loss in the sh-PINK1 condition was due to a 
PINK1-independent mechanism of loss (similarly to the MEF results) or due to the activity of 
residual PINK1. To address this question, we turned to CCCP as a positive control for PINK1-
dependent parkin loss [231]. As expected, CCCP led to a significant loss of parkin protein (52.4 
± 4.3% remaining after 25 hours), which was nearly complete by 10 hours of treatment (Fig. 4.4 
C,D). Surprisingly, knockdown of PINK1 also only led to a partial prevention of parkin loss 
from CCCP (49.1 ± 7.0% parkin loss with sh-ctrl vs. 27.9 ± 4.8% loss with sh-PINK1) (Fig. 4.4 
E).  
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 To better understand why PINK1 knockdown only partially protected parkin levels from 
L-DOPA and CCCP, we sought to determine whether PINK1 knockdown fully abolished PINK1 
activity. For this, we turned to phosphorylated ubiquitin (phospho-Ub) as a readout of PINK1 
activity. At baseline, ubiquitin phosphorylated at Ser65 is present at very low or undetectable 
levels in cells [261], [373]. PINK1 stabilization and activation following mitochondrial 
depolarization leads it to phosphorylate ubiquitin and results in an accumulation of phospho-
Figure 4.5. L-DOPA induces PINK1-dependent phospho-poly-Ub formation 
A,B. L-DOPA and CCCP induce phospho-poly-Ub formation. Cells were treated with 200 µM L-DOPA for 24 
hours and 10 µM CCCP for 10 hours before being harvested for Western blotting. Representative Western blot 
(A) and quantification (B) of phospho-poly-Ub (p-Ub) levels with L-DOPA and CCCP from 3-4 independent 
experiments are shown.  C, D. PINK1 knockdown attenuates phospho-poly-Ub induction from L-DOPA and 
CCCP. Lysates from the experiments shown in Fig. 4.4 B and Fig. 4.4 E were probed for phospho-Ub by WB. 
Dots represent individual experiments. Error bars show SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 by paired 
(C,D) or unpaired (B) t-test, with Holm correction for multiple comparisons (C). 
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poly-Ub chains (as well as mono-phospho-Ub) detectable by Western blotting [261], [373]. As -
expected, we observed little phospho-poly-Ub in untreated cells (Fig. 4.5 A). However, treatment 
with L-DOPA or CCCP induced the appearance of high molecular weight phospho-Ub ladders, 
consistent with formation of phospho-poly-Ub chains (Fig. 4.5 A). The strength of this phospho-
Ub signal was significantly higher (by ~10-fold) with CCCP than with L-DOPA (Fig. 4.5 B), 
suggesting greater PINK1 activation by CCCP. CCCP also induced appearance of a band with a 
molecular weight consistent with that of mono-phospho-Ub (Fig. 4.5 A). We did not observe this 
band upon L-DOPA treatment, possibly due to limits in the threshold for signal detection. 
 To determine whether our PINK1 knockdown was effective at fully abolishing PINK1 
activity, we assessed L-DOPA- and CCCP-induced phospho-Ub levels after PINK1 knockdown. 
We found that knockdown of PINK1 attenuates the phospho-poly-Ub signal from both L-DOPA 
and CCCP exposure (to 40.5 ± 16.3% of sh-ctrl for L-DOPA and to 27.5 ± 5.1% of sh-ctrl for 
CCCP), indicating that PINK1 is indeed involved in generating this signal (Fig. 4.5 C,D). In the 
case of CCCP, there remained a residual phospho-poly-Ub signal with PINK1 knockdown above 
the level of phospho-poly-Ub in untreated cells (27.5 ± 5.1% vs. 1.4 ± 3.5% in untreated sh-ctrl) 
(Fig. 4.5 C), suggesting that knockdown did not fully abolish PINK1 activity. In the case of L-
DOPA, PINK1 knockdown brought the phospho-poly-Ub signal back to the baseline level 
observed in one preliminary experiment (40.5 ± 16.3% vs. 58.3% in untreated sh-ctrl) (Fig. 4.5 
D), suggesting that our PINK1 knockdown may have been sufficient to fully eliminate L-DOPA-
induced PINK1 activity. 
 Preliminarily, the phospho-Ub results above suggest that PINK1 knockdown did not 
completely prevent CCCP-induced parkin loss because of residual PINK1 activity. By contrast, 
these data suggest that PINK1 knockdown did not completely prevent L-DOPA-induced parkin 
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loss because of a concurrent PINK1-independent mechanism of parkin loss. Regardless of its 
relative contribution to parkin loss, these data clearly show that PINK1 plays a role in parkin loss 
from L-DOPA treatment in PC12 cells. 
4.2.4 Parkin's interaction with phospho-Ub contributes to its loss from L-DOPA 
 Having implicated PINK1 in L-DOPA-induced parkin loss in PC12 cells, we next sought 
to uncover the mechanism by which PINK1 contributes to this loss. PINK1 phosphorylates Ser65 
on both parkin and on ubiquitin [155], [157], [162]–[169]; the latter then binds non-covalently to 
parkin. We reasoned that one or both of these events underlies PINK1-mediated parkin loss. To 
determine the relative contributions of these events to parkin loss from L-DOPA treatment, we 
generated several point mutants in the "moderately" overexpressed parkin construct described in 
Section 2.2.3.4. To test the importance of parkin phosphorylation, we generated a S65A parkin 
mutant; to test the importance of parkin binding to phospho-Ub, we utilized the parkin mutants 


























Figure 4.6. Expression levels of parkin mutants are similar 
Differentiated PC12 cells were transduced with lentiviral vectors carrying the indicated parkin 
mutants and bicistronically expressed GFP for 3 to 6 days before cells were harvested for Western 
blotting. Representative blots are shown. To compare relative expression levels of the different parkin 
mutants, parkin levels for each construct were normalized first to ERK1 and 2 to control for loading 
differences and then to GFP to control for variability in viral titer. The results of this quantification 
are shown on the right. Error bars show SEM; * p ≤ 0.05 relative to WT by paired t-test with Holm 
correction for multiple comparisons. 
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parkin and phospho-Ub, though K151E has been demonstrated to be more effective in this regard 
[170]. We delivered the parkin mutants to PC12 cells via lentiviral transduction. Although the 
viral titers between constructs varied slightly due to inherent variability in the viral production 
process, we found that all parkin mutants used in this study were expressed at similar levels (i.e. 
~8-fold higher than endogenous parkin) in cells when controlling for titer (Fig. 4.6). 
 We first investigated the effect of CCCP on mutant parkin because it is a canonical model 
of PINK1 activation. CCCP led to a significant loss of wild-type overexpressed parkin after both 
6 and 12 hours of treatment (33.5 ± 2.7% and 62.8 ± 1.7% parkin loss after 6 and 12 hours, 
respectively) (Fig. 4.7 A,B). By contrast, both H302A and K151E were fully protected from 
CCCP-induced loss at the 6-hour time point (Fig. 4.7 A). By 12 hours, K151E remained fully 
protected, but H302A showed a loss of 26.2 ± 4.4% (Fig. 4.7 B). A likely explanation for the 
discrepancy between K151E and H302A at 12 hours is the fact that H302A has been shown to 
have greater residual phospho-Ub binding than K151E. These results indicate that binding to 
phospho-Ub is crucial for parkin loss from CCCP.  
 Surprisingly, the S65A parkin mutant was not at all protected from CCCP compared to 
wild-type parkin (65.9 ± 1.5% S65A vs. 66.5 ± 2.7% WT remaining at 6 hours; 36.9 ± 3.2% 
S65A vs. 37.2 ± 1.7% WT remaining at 12 hours) (Fig. 4.7 A,B), indicating that parkin 
phosphorylation, per se, is not important for its loss. We tested whether a protective effect of 
S65A might be revealed in the context of a parkin mutant that's deficient in binding to phospho-
Ub, but we did not observe any protection of a H302A/S65A double mutant over the H302A 
single mutant after 12 hours of CCCP (73.8 ± 4.4% H302A vs. 77.0 ± 0.4% H302A/S65A 
remaining) (Fig. 4.7 B). Altogether, these data show that parkin's interaction with phospho-Ub 
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leads to its degradation following CCCP treatment and suggest that parkin phosphorylation does 
not influence this process. 
 To confirm that parkin phosphorylation isn't involved in its loss from CCCP, we sought 
to make sure that parkin phosphorylation still plays a role in activating parkin after CCCP 
treatment, as expected. This was particularly important to do as all of our mutants have an N-
Figure 4.7. Parkin's interaction with phospho-Ub leads to its loss from CCCP 
A,B. Differentiated PC12 cells were transduced with lentiviral vectors carrying the indicated parkin 
mutants. Three to five days after infection, cells were treated with 10 µM CCCP for 6 (A) or 12 hours (B) 
before harvest for WB and assessment of parkin levels. Representative blots and quantifications of parkin 
levels from at least 3 independent experiments are shown. The level of each parkin mutant after CCCP 
treatment was normalized to the level of the same mutant after control treatment. The respective control 
for each mutant is represented by the gray bar in the quantifications. Error bars show SEM; *** p ≤ 0.001, 
**** p ≤ 0.0001 relative to WT by one-way ANOVA of CCCP-treated mutants with Holm-Sidak's 
multiple comparisons test. 
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terminal tag to differentiate them from endogenous parkin, and such tags have been found to 
disrupt parkin's autoinhibited conformation by opening the Ubl domain [368]. Given that parkin 
phosphorylation has also been suggested to open the Ubl domain [157], [158], [172]–[175], it 
was important to ensure that parkin phosphorylation was not made functionally redundant by the 
presence of the tag. To investigate this, we compared the levels of CCCP-induced phospho-poly-
Ub in cells transduced with S65A parkin compared to wild-type parkin. Since parkin 
phosphorylation contributes to its activation and parkin activity leads to phospho-poly-Ub 
formation in the CCCP model, we would expect to see decreased levels of phospho-poly-Ub in 
cells expressing S65A parkin if parkin phosphorylation still has a functional effect. Indeed, cells 
Figure 4.8. Parkin phosphorylation has a functional effect in the CCCP model 
Differentiated PC12 cells were transduced with mutant parkin constructs and treated with CCCP for 6 
hours as described in Fig. 4.7. Relative levels of phospho-poly-Ub for each mutant were quantified by 
normalizing the p-Ub signal first to ERK1&2 and then to the corresponding mutant parkin level in 
untreated cells (to control for infection efficiency). C431S is catalytically inactive parkin. Note that 
endogenous parkin was present in all conditions. Quantification from 5 independent experiments is 
shown. Error bars show SEM. * p ≤ 0.05, ** p ≤ 0.01 by paired t-test with Holm correction for multiple 
comparisons. 
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transduced with S65A had significantly decreased levels of phospho-poly-Ub compared with 
those expressing wild-type parkin (WT: 2.12 ± 0.18; S65A: 1.72 ± 0.23; p = 0.04); similarly, 
cells expressing the H302A/S65A double mutant had significantly decreased levels of phospho-
poly-Ub compared to those expressing the H302A single mutant (H302A: 1.73 ± 0.13; 
H302A/S65A: 1.19 ± 0.04; p = 0.007) (Fig. 4.8). These results demonstrate that parkin 
phosphorylation plays a functional role in the CCCP model and is not made redundant by the 
presence of a tag. In light of this, our observation that the S65A parkin mutant is lost to same 
degree as wild-type parkin upon CCCP exposure indicates that parkin phosphorylation status 
does not impact this loss. Instead, PINK1-mediated ubiquitin phosphorylation is critical for 
parkin loss. 
 Next, we examined whether the parkin mutants would show a similar pattern of 
protection from L-DOPA-induced loss. Indeed, the mutants deficient in binding phospho-Ub 
were significantly protected from loss compared to wild-type parkin (WT: 38.0 ± 2.9% loss; 
H302A: 22.9 ± 2.1% loss; K151E: 20.7 ± 4.3% loss), whereas S65A and H302A/S65A were no 
different than wild-type and H302A alone, respectively (Fig. 4.9). This indicates that parkin 
binding to phospho-Ub also underlies the PINK1-mediated parkin degradation in the L-DOPA 
model. 
4.2.5 Parkin's interaction with phospho-Ub is necessary for its loss downstream of oxidative 
stress 
 One crucial difference between the responses of the parkin mutants to CCCP and L-
DOPA is the degree of protection we observed with H302A and K151E. As noted above, these 
mutants were fully protected from loss at 6 hours of CCCP, with K151E retaining full protection 
at 12 hours (Fig. 4.7). By contrast, H302A and K151E were only protected by ~50% from L-
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DOPA-induced loss (Fig. 4.9). This result suggests that L-DOPA causes parkin loss in part 
through a mechanism independent of phospho-Ub (and therefore likely independent of PINK1 
activity). This is consistent with our observation that PINK1 knockdown only prevented L-
DOPA-induced parkin loss by ~50% (Fig. 4.4 B). It's also consistent with our observation that 
glutathione only prevented L-DOPA-induced loss by about half (Fig. 4.1 A). All of these 
findings suggest that L-DOPA causes parkin loss through at least two different pathways.  
Figure 4.9. Parkin's interaction with phospho-Ub contributes to its loss from L-DOPA 
Differentiated PC12 cells were transduced with lentiviral vectors carrying the indicated parkin mutants. 
Three to five days after transduction, cells were treated with 200 µM L-DOPA for 24 hours before harvest 
for WB and assessment of parkin levels. Representative blots and quantifications of parkin levels from at 
least 3 independent experiments are shown. The level of each parkin mutant after L-DOPA treatment was 
normalized to the level of the same mutant after control treatment. The respective control for each mutant 
is represented by the gray bar in the quantifications. Error bars show SEM; ** p ≤ 0.01 relative to WT by 
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 To determine whether the glutathione-sensitive and the phospho-Ub-dependent 
mechanisms of parkin loss are in the same pathway, we next investigated whether glutathione 
can abrogate the phospho-poly-Ub induced by L-DOPA. Indeed, we found that glutathione 
reduced the ~3.5-fold increase in phospho-poly-Ub from L-DOPA treatment to ~1.3-fold of 
Figure 4.10. Parkin's interaction with phospho-Ub is necessary for its loss downstream of oxidative stress 
A. Glutathione almost completely abrogates the L-DOPA-induced phospho-poly-Ub signal. 
Differentiated PC12 cells were co-treated with 200 µM L-DOPA and 200 µM glutathione (GSH) for 24 
hours before lysates were harvested for Western blotting. A representative blot and quantification of 
phospho-poly-Ub levels from 5 independent experiments are shown.  B. Parkin mutants deficient in 
binding phospho-Ub are protected from hydrogen peroxide-induced loss. Differentiated PC12 cells were 
treated with 200 µM hydrogen peroxide for 24 hours 3-5 days after transduction with the indicated parkin 
mutants. Representative blots and quantification of parkin levels from 5 independent experiments are 
shown. The level of each parkin mutant after peroxide treatment was normalized to the level of the same 
mutant after control treatment. The respective control for each mutant is represented by the gray bar in the 
quantification. Error bars show SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 by paired t-test with Holm 
correction for multiple comparisons (A) or relative to WT by one-way ANOVA of peroxide-treated 
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control levels (Fig. 4.10 A). This indicates that phospho-Ub formation is downstream of 
oxidative stress from L-DOPA autoxidation. 
 In support of this conclusion, we found that 200 µM hydrogen peroxide induced a 
phospho-poly-Ub signal (Fig. 4.10 B). Furthermore, while wild-type parkin levels decreased by 
half upon peroxide treatment, the levels of the H302A and K151E parkin mutants were not 
significantly different with and without peroxide (WT: parkin levels 50.9 ± 4.3% with peroxide 
relative to no treatment, p = 0.001; K151E: 96.2 ± 8.0% relative to no treatment, p = 0.97; 
H302A: 86.4 ± 5.4% relative to no treatment, p = 0.2) (Fig. 4.10 B). As with the CCCP and L-
DOPA models, we did not observe any protection from peroxide-induced loss with the S65A 
mutant (Fig. 4.10 B).  
 We have shown that glutathione only partially prevents L-DOPA-induced parkin loss but 
nearly fully prevents L-DOPA-induced phospho-poly-Ub formation. Additionally, we found that 
parkin mutants that fail to bind phospho-Ub are only partially protected from L-DOPA-induced 
loss but completely protected from peroxide-induced loss. These observations lead to the 
conclusion that L-DOPA decreases parkin both via an oxidative stress-dependent mechanism and 
an oxidative stress-independent mechanism and that the oxidative stress-dependent mechanism 
depends on parkin's association with phospho-Ub.  
4.2.6 L-DOPA-induced phospho-Ub is present in both cytosolic and mitochondrial fractions 
and leads to mitochondrial parkin translocation 
 Given the importance of phospho-Ub for parkin loss from L-DOPA treatment, we next 
queried where in the cell L-DOPA-induced phospho-poly-Ub is found. Previous work has shown 
that phospho-poly-Ub is present in both the cytosol and on mitochondria following PINK1 
activation by mitochondrial depolarization [261]. The involvement of PINK1 in generating  
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Figure 4.11. L-DOPA-induced phospho-Ub is present in both cytosolic and mitochondrial fractions and 
leads to mitochondrial parkin translocation 
A-F. PC12 cells were treated with 200 µM L-DOPA for 14-17 hours (A,C,E) or 10 µM CCCP for 6 hours 
(B,D,F) before being harvested for sub-cellular fractionation. 15% of the resulting cytosolic fractions and 
100% of the mitochondria-enriched fractions were loaded on gels for Western blotting.  A,B. 
Representative Western blots showing the distribution of phospho-ubiquitin, parkin, GAPDH, UQCRC1, 
and Tom20 between cytosolic and mitochondrial fractions. A-D. Phospho-poly-Ubiquitin is present both 
in the cytosol and on mitochondria after L-DOPA (A,C) and CCCP (B,D) treatment. The phospho-poly-
Ubiquitin signal in the cytosolic and mitochondrial fractions was normalized to the percentage of the 
fraction that was loaded to estimate the total level of phospho-poly-Ubiquitin in each fraction. The same 
quantification was carried out for mitochondrial (Tom20, UQCRC1) and cytosolic (parkin, GAPDH) 
proteins from untreated cells to confirm that fractionation was successful.  A,B,E,F. Parkin translocates to 
mitochondria after L-DOPA (A,E) and CCCP (B,F) treatment. Parkin levels in the mitochondrial fraction 
with drug or control treatment were normalized to levels of UQCRC1 and plotted in E and F.  Error bars 
show SEM from at least 4 independent experiments; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 
0.0001 by paired t-test. 
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phospho-Ub downstream of L-DOPA suggested that phospho-Ub would similarly be both 
mitochondrial and cytosolic following L-DOPA treatment. Indeed, crude sub-cellular 
fractionation revealed that similar amounts of phospho-poly-Ub were present in the 
mitochondrial and cytosolic fractions after L-DOPA and CCCP treatment (L-DOPA: 1.76 ± 0.49 
mitochondrial vs. cytosolic phospho-Ub, p = 0.22; CCCP: 0.81 ± 0.12 mitochondrial vs. 
cytosolic p-Ub, p = 0.23) (Fig. 4.11 A-D).  
 Given the substantial presence on phospho-poly-Ub in the mitochondrial fraction after L-
DOPA treatment and the affinity of parkin for phospho-Ub, we predicted that we would observe 
mitochondrial parkin translocation following L-DOPA. Indeed, we saw a modest but significant 
increase of parkin in the mitochondrial fraction after 14-17 hours of L-DOPA treatment (1.31 ± 
0.08 with L-DOPA vs. without, p = 0.01) (Fig. 4.11 A,E), a time before L-DOPA-induced parkin 
loss is complete (Fig. 2.1 B). As a positive control, we examined mitochondrial translocation of 
parkin following CCCP. To mirror the time point that we chose for monitoring L-DOPA-induced 
translocation, we fractionated cells after 6 hours of CCCP, a time point at which parkin loss is 
underway but not complete (Fig. 4.4 C,D). The results reveal an increase of parkin in the 
mitochondrial fraction after CCCP on the same order as that which we saw with L-DOPA (1.55 
± 0.08 with CCCP vs. without, p = 0.007) (Fig. 4.11 B,F). 
 Altogether, these results suggest that parkin associates with phospho-poly-Ub both in the 
cytosol and on mitochondria following L-DOPA treatment. 
4.2.7 Phospho-Ub-induced parkin degradation is proteasomal 
 We next sought to investigate the more distal mechanism of parkin degradation in the 
oxidative stress/phospho-Ub-dependent pathway of L-DOPA-induced parkin loss.  
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 Two previous studies from the same group found parkin degradation to be proteasomal 
after mitochondrial depolarization [201], [231], suggesting that the proteasome may mediate the 
phospho-Ub-dependent parkin loss in our models. Indeed, the proteasomal inhibitor epoxomicin 
fully abrogated CCCP-induced parkin loss, as expected, (CCCP: 63.5 ± 7.6%; CCCP + 
epoxomicin: 94.5 ± 7.6% of untreated) (Fig. 4.12 A), and it partially abrogated L-DOPA-induced 
parkin loss (L-DOPA: 61.1 ± 3.0%; L-DOPA + epoxomicin: 80.5 ± 3.3% of untreated) (Fig. 4.12 
B). These results suggest that parkin is partially degraded via the proteasome after L-DOPA 
Figure 4.12 Phospho-Ub-induced parkin degradation is proteasomal 
A,B. Differentiated PC12 cells were co-treated with either 10 µM CCCP (A) or 200 µM L-DOPA (B) and 
100 nM epoxomicin for 12 (A) or 24 (B) hours before being harvested for Western blotting. 
Representative Western blots and quantification of parkin levels from at least 5 independent experiments 
are shown. * in blots marks a known non-specific band. Error bars show SEM; * p ≤ 0.05, *** p ≤ 0.001, 
by paired t-test with Holm correction for multiple comparisons. 
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treatment. 
 Proteasomal inhibition prevented L-DOPA-induced parkin loss to the same degree as 
glutathione treatment and the mutation of K151, by about ~50%. This observation, coupled with 
the fact that CCCP-induced parkin loss was fully prevented by both proteasomal inhibition and 
mutation of K151, places proteasomal parkin degradation in the same pathway as parkin loss 
from L-DOPA-induced oxidative stress and PINK1 activation. It also implies that the oxidative 
stress-independent mechanism of parkin loss is non-proteasomal. 
 Parkin autoubiquitination has been reported following mitochondrial depolarization, 
reflected by the formation of higher-molecular weight parkin bands by WB [199], [206], [231], 
[232], [236], and it was previously suggested that this autoubiquitination is what targets parkin 
for proteasomal degradation following mitochondrial depolarization [231]. In the above studies, 
the ubiquitinated parkin signal was generally strongest for the band corresponding to mono-
ubiquitinated parkin and diminished with intensity for multiply-ubiquitinated parkin species. In 
contrast with these reports, we did not observe evidence of higher-molecular weight parkin bands 
after L-DOPA or CCCP treatment, even in the presence of epoxomicin (Fig. 4.12 A,B) (although 
it must be noted that the presence of non-specific bands makes this assessment more difficult). 
This lack of detectable ubiquitination may be due to de-ubiquitination of parkin by 
deubiquitinating enzymes like USP8 [232], which could be more rapid in our system than in the 
studies above because all but one examined overexpressed parkin. 
 Taken together, these data indicate that parkin is degraded proteasomally following its 
association with L-DOPA-induced phospho-Ub, without evidence of autoubiquitination. 
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4.2.8 Parkin loss from L-DOPA treatment does not appear to depend on its mitochondrial 
activity 
 As described in Section 1.2.3.1.2.2, PINK1 and parkin participate in a positive feedback 
loop wherein parkin poly-ubiquitination activity on mitochondria provides PINK1 with ubiquitin 
substrates for phosphorylation. Thus, we predicted that parkin activity was responsible for 
generating the phospho-poly-Ub that we observe after L-DOPA treatment and therefore that L-
DOPA-induced parkin loss would depend on this activity. 
 To examine this possibility, we assessed the levels of stress-induced phospho-poly-Ub in 
PC12 cells transduced with our "moderately overexpressed" parkin, a catalytically inactive 
parkin mutant (C431S), or an empty control vector. In CCCP-treated cells, expression of wild-
type parkin increased the phospho-poly-Ub signal by about 3-fold over that of cells expressing 
empty vector, as expected (Fig. 4.13 A,B). This increased phospho-poly-Ub signal can be 
overwhelmingly attributed to parkin activity because catalytically inactive parkin failed to 
robustly increase the phospho-poly-Ub signal (1.31 ± 0.07 relative to empty vector) (Fig. 4.13 
A,B). Unexpectedly, the L-DOPA-induced phospho-poly-Ub signal was not increased in cells 
expressing wild-type parkin compared to empty vector or C431S (WT: 0.83 ± 0.02; C431S: 1.25 
± 0.12 relative to empty vector) (Fig. 4.13 D,E). A similar result was observed in the hydrogen 
peroxide model (WT: 1.19 ± 0.17; C431S: 0.92 ± 0.13 relative to empty vector) (Fig. 4.13 G,H). 
This result suggests that, in the L-DOPA model, parkin does not build the poly-ubiquitin chains 
that become phosphorylated by PINK1, in contrast to the positive feedback loop observed with 
CCCP.  
 The lack of evidence for parkin-dependent phospho-poly-Ub formation following L-
DOPA treatment suggested that mitochondrial parkin activity is not necessary for its loss from L- 
  102 
  
Figure 4.13. L-DOPA-induced phospho-poly-Ub formation appears to be independent of parkin activity 
A-I. Differentiated PC12 cells were transduced with lentiviral vectors carrying wild-type or C431S 
parkin. Three to five days after transduction, cells were treated with 10 µM CCCP for 6 hours (A-C) or 12 
hours (C), 200 µM L-DOPA for 24 hours (D-F), or 200 µM hydrogen peroxide for 24 hours before being 
harvested for Western blotting. Representative Western blots and quantifications of phospho-poly-
Ubiquitin (B,E,H) and parkin (C,F,I) levels are shown. Individual points in quantifications represent 
individual experiments. Error bars show SEM; * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001 by paired t-test 
with Holm correction for multiple comparisons (B,E,H) or relative to WT by one-way ANOVA of drug-
treated mutants with Holm-Sidak's multiple comparisons test (C,F,I). 
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Figure 4.14. Parkin does not poly-ubiquitinate Mfn2 following L-DOPA treatment 
Differentiated PC12 cells were treated with 10 µM CCCP or 200 µM L-DOPA for the indicated time 
periods before harvest for WB. Representative Western blots and quantification of unmodified Mfn2 
levels relative to ERK1 and 2 are shown. Error bars show SEM from three independent experiments. * p 
≤ 0.05 by unpaired t-test, Holm-Sidak correction for multiple comparisons. Significance was queried 
between untreated and drug-treated groups at each time point. 
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DOPA, in contrast to our initial hypothesis. Indeed, L-DOPA exposure decreased catalytically 
inactive C431S parkin to the same extent as wild-type parkin (WT: 38.0 ± 2.9% loss; C431S: 
44.2 ± 2.5% loss) (Fig. 4.13 D,F). By contrast. C431S was protected from CCCP-induced loss by 
~50% after both 6 and 12 hours (6hr: WT: 33.5 ± 2.7% loss; C431S: 16.9 ± 1.8% loss; 12hr: 
WT: 62.8 ± 1.7% loss; C431S: 31.7 ± 3.0% loss) (Fig. 4.13 A,C), consistent with the diminished 
phospho-poly-Ub observed in C431S-expressing cells relative to cells expressing exogenous 
wild-type parkin. In the case of hydrogen peroxide, C431S was modestly protected from 
peroxide-induced loss (WT: 49.1 ± 4.3% loss; C431S: 34.6 ± 3.2% loss), but this effect was less 
 robust than that seen with CCCP. These results indicate that the loss of overexpressed parkin 
from CCCP, but not from L-DOPA, depends on its activity.  
 Of note, the finding that C431S parkin was not protected from L-DOPA-induced loss 
indicates that this loss is not due to autoubiquitination. This is because parkin has been shown to 
only autoubiquitinate in cis [298]. 
 The lack of evidence for phospho-poly-Ub formation by exogenous parkin following L-
DOPA treatment suggests that endogenous parkin similarly does not contribute to the formation 
of these chains. To examine this possibility for mitochondrial phospho-poly-Ub, we assessed 
ubiquitination of the mitochondrial GTPase Mfn2 following L-DOPA treatment. A recent study 
showed that Mfn2 is a preferred mitochondrial parkin substrate in the mitophagy pathway and 
provided evidence that Mfn2 poly-ubiquitination by parkin precedes and may be required for 
parkin to efficiently ubiquitinate other mitochondrial substrates [219]. This primacy of Mfn2 
ubiquitination, coupled with the fact that poly-ubiquitin chains on mitochondrial proteins are the 
substrates for mitochondrial phospho-poly-Ub, suggests that Mfn2 ubiquitination can be a useful 
proxy for the contribution of endogenous parkin to mitochondrial phospho-poly-Ub formation. 
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 Assessment of Mfn2 ubiquitination following CCCP treatment revealed rapid poly-
ubiquitination and ultimate loss of the former (32.4 ± 4.5% loss after 25 hours relative to time 
zero) (Figure 4.14 A,B), consistent with our observation that overexpressed parkin enhanced 
phospho-poly-Ub formation in the CCCP model. By contrast, we did not observe any 
ubiquitination or loss of Mfn2 from up to 48 hours of L-DOPA treatment despite robust (~50%) 
parkin loss (Fig. 4.14 C,D; Fig. 4.15 A). This result is in line with our findings using 
overexpressed parkin and suggests that L-DOPA-induced loss of endogenous parkin likewise 
does not depend on its mitochondrial poly-ubiquitination activity. 
4.2.9 L-DOPA and CCCP do not induce changes in mitochondrial protein levels consistent 
with robust mitophagy 
 The lack of ubiquitination and loss of Mfn2 upon L-DOPA treatment suggests that L-
DOPA does not induce parkin-mediated mitophagy. To assess whether this is indeed the case, we 
looked at the levels of other mitochondrial proteins after L-DOPA treatment. Mitophagy leads to 
a gradual decrease in mitochondrial proteins of all compartments, as detected by WB [221], 
[222], [232]. On the contrary, we did not observe ubiquitination or a significant loss of any of the 
mitochondrial proteins we looked at, including VDAC, Tom20, Tim23, and UQCRC1, through 
48 hours of L-DOPA treatment (Fig. 4.15 A). These proteins are present in different 
mitochondrial compartments (VDAC, Tom20: OMM; Tim23: IMM; UQCRC1: IMM/matrix), 
making it unlikely that we did not detect mitophagy because of an obfuscating mechanism 
affecting only one mitochondrial compartment. To confirm the efficacy of L-DOPA treatment in 
these experiments, we assessed parkin levels and observed the expected decrease (54.1 ± 2.2% 
loss after 48 hours relative to time zero) (Fig. 4.15 A). In addition, we observed a decrease in the 
long isoform of OPA1 after L-DOPA (45.0 ± 0.6% decrease after 48 hours relative to time zero)  
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(Fig. 4.15 A). OPA1 is a mitochondrial GTPase that is cleaved in response to mitochondrial 
stress, so L-DOPA-induced loss of the long OPA1 isoform is consistent with mitochondrial 
stress in this model. The lack of robust mitophagy with L-DOPA is consistent with the lack of 
mitochondrial poly-ubiquitination by parkin described in the previous section. 
 Given that parkin was clearly active after CCCP treatment (Fig. 4.13 A,B; Fig. 4.14 A,B), 
we sought to determine whether this activity led to mitophagy in the CCCP model, as would be 
canonically expected. Examining the same proteins as we did for L-DOPA, we did not observe 
ubiquitination or loss consistent with mitophagy (Fig. 4.15 B). Levels of Tim23 did decrease 
with CCCP (23.2 ± 10.8% decrease after 25 hours relative to time zero), but those of VDAC, 
Tom20, and UQCRC1 remained unchanged (Fig. 4.15 B). As with L-DOPA, parkin loss was still 
robust in these experiments (47.6 ± 4.3% loss) (Fig. 4.4 C,D), and levels of the long isoform of 
OPA1 dropped precipitously in response to membrane potential loss (83.5 ± 7.1% decrease after 
25 hours relative to time zero) (Fig. 4.15 B). These results indicate that even when parkin is 
clearly active and Mfn2 has been poly-ubiquitinated, mitophagy may not take place.  
 Altogether, we have found that, downstream of L-DOPA autoxidation, parkin's 
association with phospho-Ub leads to its proteasomal degradation independently of parkin 
autoubiquitination, mitochondrial poly-ubiquitination, and mitophagy. 
4.2.10 L-DOPA does not appear to decrease parkin solubility 
 Having shed light on the oxidative stress-dependent mechanism of L-DOPA-induced 
parkin loss, we next sought to determine how parkin is lost in the oxidative stress-independent 
pathway. 
 Multiple kinds of stress have been reported to disrupt parkin structure and decrease its 
solubility (discussed in Section 1.2.4.2). To determine whether L-DOPA leads parkin to become  
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Figure 4.15. L-DOPA and CCCP do not induce changes in mitochondrial protein levels consistent with 
robust mitophagy 
A,B. Differentiated PC12 cells were treated with 200 µM L-DOPA (A) or 10 µM CCCP (B) for the indicated 
times before harvest for WB. Representative blots and quantifications of the indicated proteins from 3 
independent experiments are shown. A. L-DOPA does not significantly decrease levels of UQCRC1, VDAC, 
Tim23, or Tom20, while it does induce loss of parkin and Opa1-long.  B. CCCP does not significantly 
decrease levels of UQCRC1, VDAC, or Tom20, while it does induce loss of Tim23 and Opa1-long. * p ≤ 
0.05 by unpaired t-test, with Holm-Sidak correction for multiple comparisons. Significance was queried 
between untreated and drug-treated groups at each time point. 
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insoluble in our usual cell lysis buffer and possibly fail to enter the gel during SDS-PAGE, we 
harvested PC12 cells in a buffer containing 8 M urea in addition to the usual 2% LDS after L-
DOPA treatment. Such a buffer should be more effective at solubilizing aggregated proteins 
[374]. We did not observe a significant difference in parkin loss between samples harvested in 
our usual lysis buffer compared to those harvested in urea-containing buffer (30.7 ± 4.7% loss in 
usual buffer vs. 20.1 ± 4.8% in urea buffer, p = 0.32) (Fig. 4.16 A). This suggests that L-DOPA 
does not cause parkin to become insoluble in our usual lysis buffer. 
4.2.11 Parkin is not degraded lysosomally or via caspase cleavage in PC12 cells following L-
DOPA treatment 
 Parkin has also been reported to be degraded lysosomally and to be cleaved by caspases. 
Therefore, we tested whether inhibitors of these pathways would abrogate parkin loss from L-
DOPA.  
 Treatment with lysosomal inhibitor bafilomycin A1 did not attenuate parkin loss from L-
DOPA in PC12 cells (L-DOPA: 41.1 ± 3.5% loss; L-DOPA + bafilomycin: 36.6 ± 1.7% loss) 
(Fig. 4.16 B); in fact, bafilomycin A1 significantly decreased parkin levels by itself (14.8 ± 0.8% 
loss, p = 0.011). This indicates that parkin is not lost via lysosomal degradation in the oxidative 
stress-independent pathway. 
 Likewise, pan-caspase inhibition using Z-VAD-FMK (carbobenzoxy-valyl-alanyl- 
aspartyl-[O-methyl]-fluoromethylketone) did not diminish L-DOPA-induced parkin loss in PC12 
cells (L-DOPA: 41.0 ± 5.7% loss; L-DOPA + Z-VAD-FMK: 40.8 ± 4.0% loss) or, preliminarily, 
in primary cortical neurons (L-DOPA: 18.8 ± 2.9% loss; L-DOPA + Z-VAD-FMK: 22.4 ± 5.9% 
loss) (Fig. 4.17 A,B), indicating that caspase cleavage does not contribute to L-DOPA-induced 
parkin loss in these cell types. However, Z-VAD-FMK did attenuate L-DOPA-induced loss in  
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  Figure 4.16. L-DOPA-induce parkin loss is unchanged in cells lysed in 8M urea or treated with 
bafilomycin A1 
A. Parkin is lost to the same extent after L-DOPA whether cells are harvested in buffer containing Triton 
X-100 and 2% LDS or 8M urea and 2% LDS. Differentiated (n = 3) or undifferentiated (n = 2) PC12 cells 
were treated with 200 (n = 4) or 250 µM (n = 1) L-DOPA for 24 hours before being harvested in buffer 
containing Triton X or 8M urea, sonicated, supplemented with LDS and DTT, and used for Western 
blotting. Parkin levels in L-DOPA-treated samples for each buffer were normalized to parkin levels in 
control samples in that buffer; the gray bar in the quantification represents parkin levels in the control 
samples for each buffer.  B. Inhibition of lysosomal degradation doesn't prevent parkin loss from L-
DOPA. Differentiated PC12 cells were co-treated with 200 µM L-DOPA and 50 nM bafilomycin A1 
(BafA1) for 24 hours before cells were harvested for Western blotting (n = 3 independent experiments). 
Increased LC3B II signal was a positive control for the effectiveness of bafilomycin A1. Error bars show 
SEM; * p ≤ 0.05 by paired t-test with Holm correction for multiple comparisons. 
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Figure 4.17. Caspase inhibition does not attenuate L-DOPA-induced parkin loss in PC12 cells or primary 
cortical neurons 
A-C. Differentiated PC12 cells (A), primary rat cortical neurons (B) or SH-SY5Y cells (C) were co-
treated with 200 µM (A,C) or 500 µM (B) L-DOPA and 100 µM Z-VAD-FMK (Z-VAD) for 24 hours 
before cells were harvested for Western blotting. Prevention of the formation of cleaved caspase 3 was a 
positive control for the effectiveness of Z-VAD-FMK. Representative Western blots and quantifications 
of parkin levels from at least 3 independent experiments are shown. Error bars show SEM; * p ≤ 0.05 by 
paired t-test with Holm correction for multiple comparisons. 
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SH-SY5Y cells (L-DOPA: 35.0 ± 4.0% loss; L-DOPA + Z-VAD-FMK: 19.5 ± 4.6% loss, p = 
0.005) (Fig. 4.17 C). This indicates that caspases may play a role in L-DOPA-induced parkin 
loss in SH-SY5Y cells and highlights the fact that this loss can occur via different mechanisms in 
different cell types. The fact that parkin loss in both cortical neurons and differentiated PC12 
cells was unaffected by Z-VAD-FMK was encouraging with regard to the neuronal fidelity of the 
latter. 
4.2.12 HtrA2/Omi may play a role in the oxidative stress-independent pathway of L-DOPA-
induced parkin loss 
  Given that lysosomal and caspase inhibition did not attenuate L-DOPA-induced parkin 
loss in PC12 cells, we next used a commercially-available panel of protease inhibitors (Sigma) to 
cast a "wider net" for proteases that could be involved in parkin degradation. This panel included 
inhibitors with activity toward serine, cysteine, acid, and metallo- proteases (Table 4.1). We 
subsequently realized that only a subset of these inhibitors have been reported to be cell 
permeable (indicated in bold and underlined typeface in Table 4.1) [375]–[383], and, of these, 
only E-64, N-ethylmaleamide, and phosphoramidon appear to be unequivocally cell permeable 
[384], [385]. Assessment of the effects of these inhibitors on L-DOPA-induced parkin loss in 
PC12 cells in a preliminary, single-replicate experiment revealed a possible protective effect on 
parkin loss only with the serine protease inhibitor AEBSF (4-(2-Aminoethyl) benzenesulfonyl 
fluoride) (L-DOPA: 40.3% loss; L-DOPA + AEBSF: 21.7% loss) (Fig. 4.18). Subsequent 
experiments with a higher dose of AEBSF revealed that the latter could fully prevent L-DOPA-
induced parkin loss (L-DOPA: 50.6 ± 2.5% parkin remaining; L-DOPA + AEBSF: 104.8 ± 5.2% 
parkin remaining) (Fig. 4.19 A).  
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Inhibitor Protease Class 
AEBSF  serine 
6-Aminohexanoic acid (EACA) various 
Antipain serine/cysteine 
Aprotinin serine 







Pepstatin A acid 
Phosphoramidon metalloproteases 
Trypsin inhibitor (SBTI) trypsin 
 
Table 4.1. Protease inhibitors in the Sigma protease inhibitor panel 
Names of inhibitors as well as the protease class that they inhibit are indicated. Inhibitors in bold and 
underlined typeface have been reported to be cell-permeable. 
  113 
  
Figure 4.18. Effects of protease inhibitors on parkin loss from L-DOPA 
Differentiated PC12 cells were treated with the indicated protease inhibitors concurrently with 200 µM L-
DOPA for 24 hours before cell lysis for WB. Parkin levels were quantified relative to ERK1. Each 
inhibitor was used in one experiment. Individual graphs correspond to individual Western blots, except 
for the last two graphs (with SBTI and Pepstatin A), which came from the same blot. The Pepstatin A 
data were segregated because the control conditions for Pepstatin A contained acetic acid and ethanol 
(used to solubilize the latter). Concentrations of inhibitors used: AEBSF 400 µM, EACA 5 mg/ml (38.1 
mM), Antipain 100 µM, Aprotinin 120 µM, Benzamidine 1 mM, Bestatin 40 µM, Chymostatin 100 µM, 
E-64 50 µM, EDTA 1 mM, N-Ethylmaleimide 20 µM, Leupeptin 100 µM, Pepstatin A 10 µM, 
Phosphoramidon 25 µM, SBTI 30 µM. 
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 The complete prevention of parkin loss with AEBSF raised several questions. First, given 
that we have identified two pathways of L-DOPA-induced parkin loss, we inferred that AEBSF 
must interfere with both, and we sought to determine how this happens. The explanation for 
AEBSF's interference with the oxidative stress-dependent pathway became clear when we 
incubated it with L-DOPA in DMEM culture medium (in which L-DOPA quinone formation is 
more apparent than in the PC12 culture medium, RPMI (Fig. 4.2 B)). AEBSF completely 
Figure 4.19. AEBSF fully prevents L-DOPA-induced parkin loss 
A. Differentiated PC12 cells were co-treated with 200 µM L-DOPA and 800 µM AEBSF for 24 hours 
before cell lysis and assessment of parkin levels by WB. Parkin was normalized to ERK2. Error bars 
show SEM from 3 independent experiments. ** p ≤ 0.05 by paired t-test with Holm correction for 
multiple comparisons.  B. AEBSF interferes with L-DOPA autoxidation. 200 µM L-DOPA and 800 µM 
AEBSF were added to DMEM alone or in combination and incubated for 24 hours at 37°C under 7.5% 
CO2 in the absence of cells.  
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prevented the appearance of L-DOPA-quinones (Figure 4.19 B). The most likely explanation for 
this effect is that AEBSF prevents L-DOPA autoxidation, which would account for its inhibition 
of the oxidative stress-dependent pathway of parkin loss. 
  We next asked how AEBSF prevents parkin loss via the oxidative stress-independent 
pathway. In addition to being a serine protease inhibitor, AEBSF is also an inhibitor of NADPH 
oxidases, membrane enzymes that generate ROS. We examined whether AEBSF prevents parkin 
loss by inhibition of NADPH oxidases and concluded that it doesn't; these data are presented in 
Chapter 5. Barring other off-target effects, this suggests that AEBSF-mediated serine protease 
inhibition could play a role in parkin loss via the oxidative stress-independent pathway. A 
possible AEBSF target in this regard is the serine protease HtrA2/Omi, which has been reported 
to cleave parkin between the RING1 and IBR domains [309]. HtrA2 is a mitochondrial protease 
Figure 4.20. HtrA2/Omi may play a role in L-DOPA-induced parkin loss 
A. Differentiated PC12 cells were co-treated with 200 µM L-DOPA and the indicated concentrations of 
UCF-101 for 24 hours before cell lysis and assessment of parkin levels by WB. Quantification of two 
independent experiments is shown. Error bars show range.  B. Parkin cleavage products are not observed 
following L-DOPA treatment. Differentiated PC12 cells were treated with 200 µM L-DOPA for 24 hours 
before cell harvest for WB. 
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that can translocate to the cytosol upon cellular stress [386].  
 To examine whether HtrA2 may be involved in L-DOPA-induced parkin loss, we 
performed two preliminary experiments assessing the effect of the HtrA2 inhibitor UCF-101 on 
parkin loss from L-DOPA treatment. In these experiments, ≥20 µM UCF-101 attenuated parkin 
loss from L-DOPA (L-DOPA: 28.6 ± 9.7% loss; L-DOPA + 20 µM UCF-101: 7.7 ± 10.0% loss) 
(Fig. 4.20 A), suggesting preliminarily that HtrA2 may contribute to L-DOPA-induced parkin 
loss. We do not observe parkin cleavage fragments with L-DOPA (although both of our parkin 
antibodies would be expected to detect the ~16 kDa cleavage fragment generated by HtrA2) (Fig. 
4.20 B), suggesting that, if HtrA2 does play a role in parkin loss from L-DOPA, it isn't via direct 
parkin proteolysis.  
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Figure 4.21. Model of L-DOPA-induced parkin loss 
L-DOPA decreases parkin via two pathways: oxidative stress-dependent and -independent. The latter may 
involve the serine protease HtrA2/Omi. The former pathway is a result of L-DOPA autoxidation, which 
induces PINK1 stabilization and phosphorylation of poly-ubiquitin chains in both the cytosol and on 
mitochondria. Parkin associates with these phospho-poly-Ub chains, but does not itself build ubiquitin 
chains on mitochondrial proteins. Following its association with phospho-poly-Ub, parkin is degraded via 
the proteasome. 
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4.3 Discussion 
 In this chapter, we show that L-DOPA decreases parkin via two pathways in PC12 cells: 
an oxidative stress-dependent pathway driven by L-DOPA autoxidation and an oxidative stress-
independent pathway (Fig. 4.21). The former leads to PINK1-mediated phosphorylation of poly-
ubiquitin chains, and parkin's association with this phospho-poly-Ubiquitin leads to its non-
autoubiquitination-dependent degradation via the proteasome. Surprisingly, we did not detect 
evidence of mitochondrial poly-ubiquitination by parkin, indicating that its loss does not appear 
to be precipitated by its own mitochondrial activity. The nature of the oxidative stress-
independent pathway of parkin loss from L-DOPA remains poorly defined, but may involve the 
action of serine proteases, in particular the serine protease HtrA2/Omi. Our findings are 
discussed in detail below. 
4.3.1 Two pathways of parkin loss 
 Intriguingly, our data suggest that L-DOPA exposure causes parkin loss through two 
distinct mechanisms: oxidative stress-dependent and -independent, with each pathway 
accounting for about half of total parkin loss. Several pieces of evidence support this conclusion. 
First, parkin binding to phospho-Ub was only partially responsible for its loss after L-DOPA but 
fully responsible for its loss after the oxidant hydrogen peroxide. Second, treatment with the 
antioxidant glutathione only partially prevented parkin loss after L-DOPA, even at very high 
doses. The same concentration of glutathione almost totally prevented the appearance of 
phospho-poly-Ub after L-DOPA, suggesting that lack of antioxidant potency was not a problem 
with the drug. Finally, several interventions (PINK1 knockdown, mutation of H302 & K151, and 
proteasomal inhibition) targeting parkin loss downstream of oxidative stress all rescued parkin 
loss by the same ~50% observed with glutathione. The most parsimonious explanation of all 
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these results is that glutathione fully abrogates L-DOPA-induced oxidative stress and the 
phospho-Ub-dependent loss that occurs downstream of this oxidative stress. This implies that L-
DOPA also decreases parkin in an oxidative stress-independent manner. 
 L-DOPA can lead to oxidative stress via autoxidation and by ROS formation downstream 
of conversion to dopamine. The former appears to be responsible for parkin loss in our model 
because preventing L-DOPA's conversion to dopamine had no effect on parkin loss. In line with 
this possibility, we observed a browning of the cell culture medium consistent with quinone 
formation following L-DOPA treatment.  
 The mechanism of the oxidative stress-independent pathway of parkin loss in our model 
remains unclear. Dopamine has been reported to directly modify parkin and cause it to become 
insoluble [320], but a similar modification of parkin by L-DOPA would be an oxidative process 
that should be prevented by glutathione treatment [387], indicating that this mechanism is 
unlikely to underlie oxidative stress-independent parkin loss. Instead, there are several other 
possibilities to explain how L-DOPA can affect parkin in a non-oxidative manner.  
 There is precedent to suggest that L-DOPA can have cellular effects independent of its 
autoxidation or conversion to dopamine. For example, L-DOPA can be metabolized by the 
enzyme catechol-O-methyltransferase (COMT) to 3-O-methyldopa, which can have deleterious 
effects via elevation of homocysteine levels [388]. PC12 cells have COMT [362], so it's feasible 
that parkin loss may take place downstream of L-DOPA's conversion to 3-O-methyldopa in our 
model. Additionally, L-DOPA has been reported to be a ligand of the G-protein-coupled receptor 
OA1 [389] and to depress blood pressure and heart rate of rats in an OA1-dependent manner 
when injected into the solitary nucleus of the brainstem [390]. It remains unknown whether 
PC12 cells express OA1, but this question merits further investigation given our results. Finally, 
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L-DOPA has been found to incorporate into poly-peptide chains during protein synthesis by 
virtue of its similarity to tyrosine [343], [391]. However, it's unlikely that such direct 
incorporation underlies the oxidative stress-independent mechanism of parkin loss because we 
showed in Ch. 2 that L-DOPA can still decrease parkin levels even during translational inhibition 
by cycloheximide (which would abrogate the PINK1-dependent pathway of parkin loss). More 
work will be required to determine which, if any, of these mechanisms underlie L-DOPA's non-
oxidative effect on parkin levels.   
4.3.2 Mechanisms of parkin degradation 
 Our finding in Chapter 2 that L-DOPA increases parkin degradation suggests that both 
the oxidative stress-dependent and -independent pathway of parkin loss increase parkin 
degradation. This is because L-DOPA treatment still induced parkin loss even in the presence of 
cycloheximide, which would have been expected to interfere with the oxidative stress- and 
PINK1-dependent pathway of parkin loss, as discussed in Chapter 2. This result suggests that the 
oxidative stress-independent pathway is responsible for L-DOPA-induced parkin degradation in 
the presence of cycloheximide. 
4.3.2.1 Oxidative stress-dependent degradation 
 In the case of the oxidative stress-dependent pathway, our results suggest that parkin 
degradation is mediated by the proteasome and that this degradation is a consequence of parkin 
binding to phospho-Ub. This finding is in line with previous work from our group that suggested 
that parkin loss from the oxidative stressor 6-OHDA is at least partly proteasomal [266]. It also 
confirms prior work that showed proteasomal parkin degradation following mitochondrial 
depolarization [201], [231] or PINK1 overexpression [296]. Finally, it supports the findings of 
other studies that parkin can be degraded proteasomally [302], [305], [306], [392].  
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 Many of the above studies and others [110], [249], [298]–[301] suggested that 
proteasomal parkin degradation is mediated by autoubiquitination, but they didn't test this 
possibility directly. Our work indicates that, downstream of L-DOPA-induced phospho-Ub 
binding, parkin's proteasomal degradation is not due to autoubiquitination. This is because 
catalytically inactive exogenous parkin was not at all protected from L-DOPA-induced loss, and 
parkin has been shown to only autoubiquitinate in cis [298]. Additionally, we did not detect 
evidence of parkin ubiquitination, even in the presence of proteasomal inhibition. If the 
mechanism of proteasomal parkin degradation downstream of binding to phospho-Ub is the same 
following CCCP and L-DOPA, which seems likely, it would imply that parkin degradation from 
mitochondrial depolarization is also not mediated by autoubiquitination. This is contrary to the 
model proposed by Rakovic et al. to explain depolarization-induced parkin loss [231]. Instead, 
our results are consistent with the finding by Durcan et al. that parkin autoubiquitination actually 
appears to protect it from degradation [232].  
 How does parkin get targeted for proteasomal degradation downstream of its association 
with phospho-Ub if not through auto-ubiquitination? There are several possible mechanisms, 
discussed in Section 1.2.4.2 of Chapter 1. First, another E3 ubiquitin ligase may target parkin for 
degradation. The ubiquitin ligase Nrdp1 is a prime candidate in this regard, having been reported 
to induce parkin degradation [305]. In fact, there is evidence that loss of a positive upstream 
regulator of Nrdp1 can elevate parkin levels and blunt parkin loss from mitochondrial 
depolarization [235]. Alternatively, direct parkin interaction with the proteasome via its Ubl 
domain [178], [179] could lead to its proteasomal degradation downstream of its interaction with 
phospho-Ub. 
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4.3.2.2 Oxidative stress-independent degradation 
 With regard to the mechanism of oxidative stress-independent parkin degradation, further 
investigation will be needed to elucidate this process. Our data indicate that this degradation isn't 
proteasomal because epoxomicin prevented parkin loss to roughly the same extent (~50%) as 
other inhibitors of the oxidative stress/phospho-Ub pathway (glutathione and the H302A and 
K151E parkin mutants), not more. Our data also indicate that parkin is not lost due to lysosomal 
degradation or caspase cleavage in PC12 cells, both of which have been reported to degrade 
parkin [288], [310], [311]. In fact, the lysosomal inhibitor bafilomycin A1 led to parkin loss by 
itself. This may be due to the fact that bafilomycin has been shown to decrease mitochondrial 
membrane potential [393], [394], which would induce PINK1 stabilization, ubiquitin 
phosphorylation, and therefore parkin loss.  
 Multiple stressors have been reported to shift parkin from the Triton X-soluble fraction to 
the 2% SDS-soluble fraction. However, our usual lysis buffer already contains 2% lithium 
dodecyl sulfate, and we didn't observe a protection of parkin levels when harvesting cells in 8M 
urea in addition to 2% LDS. This suggests that lack of parkin solubility following L-DOPA 
treatment does not represent the oxidative stress-independent mechanism of parkin loss. 
However, future work should address the possibility that parkin forms an aggregate resistant to 8 
M urea/2% LDS. 
 Our results with the serine inhibitor AEBSF and the HtrA2 inhibitor UCF-101 provide 
preliminary evidence that the serine protease HtrA2/Omi may be involved in parkin loss from L-
DOPA. However, given that AEBSF has other cellular effects and that off-target effects of UCF-
101 have been reported [395], it will be important to follow up these findings with a targeted 
approach to assess the contribution of HtrA2 to parkin loss. Though HtrA2 has been reported to 
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cleave parkin directly, we don't observe parkin cleavage fragments after L-DOPA, suggesting 
that, if HtrA2 indeed plays a role in parkin loss from L-DOPA, it may do so upstream of parkin 
proteolysis. 
4.3.3 PINK1-dependence of parkin loss from oxidative stress 
  Our data show that, upstream of proteasomal degradation, oxidative stress from L-DOPA 
leads to parkin loss through the action of PINK1. This finding is in line with that of Rakovic and 
colleagues, who showed that PINK1 is necessary for parkin loss from hydrogen peroxide [201].  
 An outstanding question is how L-DOPA-mediated oxidative stress leads to PINK1 
stabilization. To date, PINK1 stabilization has only been observed following loss of 
mitochondrial membrane potential or buildup of misfolded protein in the mitochondrial matrix 
[95], [396]. It follows that oxidative stress from L-DOPA induces one or both of these processes. 
There's evidence that L-DOPA can inhibit mitochondrial complexes I and IV, possibly without 
conversion to dopamine [355], [397], and that complex I and IV inhibition can lead to loss of 
mitochondrial membrane potential [315], [398], [399]. This could be a mechanism by which L-
DOPA leads to PINK1 stabilization in our model. We also observe phospho-Ub induction with 
hydrogen peroxide, which has been shown to be capable of decreasing mitochondrial membrane 
potential [316], [317], though one study did not observe this effect [201]. This suggests that 
mitochondrial depolarization may be a general consequence of oxidative stress, although it's 
possible that different oxidants decrease membrane potential via different mechanisms. 
4.3.4 Critical role of phospho-Ub in parkin loss from oxidative stress 
 Our experiments with parkin point mutants reveal for the first time which action of 
PINK1 leads to parkin loss downstream of cellular stress. We found that parkin binding to 
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phospho-Ub is critical for its loss, while parkin phosphorylation, per se, appears to be 
dispensable.  
 This finding explains why we still observed parkin loss even with PINK1 knockdown 
upon CCCP treatment; while PINK1 knockdown significantly abrogated phospho-poly-Ub 
induction, there remained residual phospho-Ub, which would be expected to lead to parkin loss. 
The fact that PINK1 knockdown didn't fully abrogate phospho-poly-Ub induction after CCCP 
indicates that either the knockdown was not sufficient to fully prevent PINK1 activity or that 
another kinase phosphorylates ubiquitin in our system. Other ubiquitin kinases are expected to 
exist, though PINK1 is the only one that has been identified to date [182]. In the case of L-
DOPA, it appears likely that PINK1 is entirely responsible for ubiquitin phosphorylation 
following L-DOPA treatment. This is because knockdown of PINK1 dropped phospho-poly-Ub 
levels back to baseline in a preliminary experiment and led to a similar level of parkin protection 
(~50%) as other inhibitors of the oxidative stress/phospho-Ub-dependent degradation pathway, 
namely glutathione, the H302A & K151E parkin mutants, and epoxomicin. 
 We were surprised to find that the S65A parkin mutant was not at all protected from loss 
induced by any of the stressors we used. This result was unexpected for several reasons. First, 
phosphorylated parkin has been shown to have a higher affinity for phospho-Ub than 
unphosphorylated parkin [155], [157], [158], [170]. Given the importance of binding phospho-
Ub for parkin loss, we would have expected S65A to have a decreased propensity to bind 
phospho-Ub and therefore to exhibit greater protection from loss. A possible explanation for this 
discrepancy could be that the time points we chose to monitor parkin loss were too late to see a 
protective effect of the S65A mutation; perhaps, by the time we looked at parkin levels, even the 
more weakly-binding S65A mutants had bound phospho-Ub and were degraded. In the case of 
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the L-DOPA model, it's also unclear whether PINK1 actually phosphorylates parkin or not. If 
not, the S65A mutant would clearly not be expected to behave any differently than wild-type.  
 The second reason we were surprised not to observe any protection with the S65A mutant 
is specific to the CCCP model. Parkin phosphorylation is necessary for full parkin activation 
[155], [162], [163], [165], [167], [172], and, as expected [155], [261], parkin activity contributed 
to the formation of phospho-poly-Ub chains after CCCP treatment in our hands. We observed a 
decreased phospho-poly-Ub signal in cells expressing the S65A mutant compared to those 
expressing wild-type parkin, consistent with impaired activation of the S65A mutant. It's 
surprising that this decrease in phospho-poly-Ub did not translate into enhanced protection of 
S65A parkin. It's possible that that the decrease in phospho-Ub was too small (~20%) to have a 
significant effect on parkin levels. This decrease would likely be significantly greater in a system 
without the background of phospho-poly-Ub generated by endogenous parkin. In summary, it's 
likely that parkin phosphorylation can, in fact, contribute to its degradation, but it would 
probably do this insofar as it would increase parkin's association with phospho-Ub. 
4.3.5 Subcellular distribution of phospho-poly-Ub 
 Given the importance of phospho-Ub binding to parkin loss, we investigated the relative 
distribution of phospho-poly-Ub between cytosol and mitochondria after L-DOPA and CCCP 
treatment and found a substantial amount of the former in each fraction.  
 Our data are in line with previous work that detected phospho-poly-Ub both on 
mitochondria and in the cytosol [261], [400]. Because we found PINK1 to be responsible for a 
large proportion of ubiquitin phosphorylation following L-DOPA and CCCP, this result suggests 
a mechanism by which cytosolic parkin could be activated by PINK1. One outstanding question 
is which, if any [182], protein(s) are conjugated with phospho-poly-Ub following L-DOPA 
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treatment, and, relatedly, whether the cytosolic pool of phospho-poly-Ub is attached to a 
cytosolic protein or to an errant mitochondrial protein. 
 In line with the fact that parkin associates with mitochondria by virtue of binding to 
mitochondrial phospho-Ub [163], [214], [401], our data reveal parkin translocation to 
mitochondria after both L-DOPA and CCCP. The increase in mitochondrial parkin was very 
modest (~1.3-1.5X control) in both cases, which at face value could suggest that this 
phenomenon is not important. However, the fact that we observed the expected robust 
ubiquitination of the mitochondrial parkin substrate Mfn2 with CCCP demonstrates that our 
observed degree of parkin translocation is capable of having a strong mitochondrial effect. A 
possible reason for why we don't observe a larger translocation effect could be that ongoing 
parkin degradation counteracts this effect.  
4.3.6 Mechanism of phospho-Ub-induced parkin loss 
 An exciting question that our work raises is how parkin binding to phospho-Ub following 
cellular stress leads to its loss. One important aspect of this question is whether parkin binding to 
phospho-Ub is sufficient for its loss, or whether other factors induced by oxidative stress and 
whole-cell mitochondrial depolarization (other than PINK1) are required. Evidence from the 
literature supports the former possibility. First, a study by Shiba-Fukushima et al. [401] observed 
that overexpression of ubiquitin together with parkin led to a decrease in parkin protein levels 
compared to overexpression of parkin alone. However, overexpression of S65A or S65E 
ubiquitin, which can't be phosphorylated, did not have this effect on parkin. This observation 
suggests that ubiquitin phosphorylation may be sufficient to decrease parkin levels in the absence 
of a cell-wide stressor. Consistent with our findings, Shiba-Fukushima et al. also observed that 
the S65A parkin mutant was lost to the same extent as wild-type parkin from ubiquitin 
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overexpression, implying that parkin phosphorylation did not play a role in this loss. A second 
piece of evidence that parkin loss from phospho-Ub binding doesn't require stress-induced 
factors other than PINK1 is the finding that PINK1 overexpression is sufficient to decrease 
overexpressed parkin levels [296]. 
 With regard to the specific function of phospho-Ub in inducing parkin loss, there are 
several possibilities. One of these is that the conformational change in parkin that occurs upon 
binding to phospho-Ub [157], [158], [170]–[172] exposes a surface that makes it vulnerable to 
degradation. If this is the case, the conformational change must be specific to phospho-Ub 
binding and not be induced by parkin phosphorylation, because we show that only the former is 
important for parkin loss. Both events have been proposed to release parkin's Ubl domain from 
its interaction with the RING1 domain [157], [158], [170], [172], [400], though recent studies 
have challenged this claim [171], [173]. Both events have also been shown to facilitate the 
access of E2 ubiquitin-conjugating enzymes to parkin's E2 binding site [157], [162]. 
Accordingly, neither of these effects is likely to be the crucial conformational change. 
Significant movement of the IBR domain has so far only been attributed to phospho-Ub binding 
[170], [171], raising the possibility that this conformational change is what leads to parkin loss.  
 Alternatively, instead of leading to a conformational change, perhaps binding to phospho-
Ub is important for parkin loss because it brings parkin into proximity with other proteins that 
promote its loss. Given the fact that phospho-Ub is generated proximal to mitochondria by 
PINK1, it's possible that parkin encounters degradative factors upon translocation to 
mitochondria. Both HtrA2 and Nrdp1 are intriguing candidates in this regard; HtrA2, because it 
usually resides in the mitochondria [386]; Nrdp1, because there is evidence that it may influence 
mitophagy and therefore may also be proximal to mitochondria [235]. 
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 An important implication of our finding that phospho-Ub is involved in parkin loss is that 
a parkin activation signal appears to be intimately linked with parkin's degradation. We observed 
this phenomenon across different models of cellular stress, suggesting that it is broadly 
generalizable. Given that parkin dephosphorylation and dissociation from phospho-Ub has not 
been reported and that Pao et al. observed parkin degradation in an activated state following 
mitochondrial depolarization [162], it's possible that parkin degradation is the mechanism by 
which cells decrease parkin activity once it's no longer needed. Much work has been focused on 
understanding parkin activation and activity and on elevating this activity as a therapeutic 
strategy [59], [223], [234], [249], [278], but if parkin is degraded promptly after it's activated, 
efforts to increase its activation may have limited utility. Our work raises the importance of 
finding ways to activate parkin without sacrificing it in the process.  
 A very recent study has found that phospho-Ub levels are elevated in the substantia nigra 
of patients with Lewy body disease, a category that includes PD [183]. This suggests that there 
may be an increased need for parkin activity in these patients, likely in response to elevated 
mitochondrial stress. Given our findings, it may also indicate that parkin levels are lowered in 
these patients. This could lead to a pathological outcome if the need for parkin outstrips the 
supply of parkin. As such, finding a way to uncouple parkin's association with phospho-Ub from 
its degradation is an attractive therapeutic option because it could prolong the natural stress 
response (in the form of parkin activation) already mounted in PD patients. 
4.3.7 Independence of parkin degradation from its mitochondrial activity 
 An important and surprising finding presented here is that, in the L-DOPA model, 
contrary to the CCCP model, parkin degradation does not appear to depend on its mitochondrial 
activity. Three pieces of evidence support this conclusion: 1. Exogenous catalytically inactive 
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parkin is degraded to the same extent as wild-type parkin; 2. Exogenous parkin does not 
contribute to the formation of phospho-poly-Ub chains following L-DOPA; and 3. Parkin doesn't 
poly-ubiquitinate Mfn2 after L-DOPA.  
 A caveat for interpreting the data with exogenous parkin is the concurrent presence of 
endogenous parkin in cells expressing the former. The concern is that endogenous parkin could 
be, in fact, building the ubiquitin chains destined for phosphorylation, but we don't observe an 
increase in phospho-poly-Ub with exogenous parkin or protection of C431S parkin because 
there's an upper limit on the number of phospho-poly-Ub chains that L-DOPA induces and 
endogenous parkin is sufficient to fulfill the need for poly-ubiquitination. However, this seems 
unlikely given the evidence that parkin-mediated formation of phospho-poly-Ub chains is part of 
a positive feedback loop [208]; thus, more parkin would be expected to result in more chains.  
Additionally, the fact that we did not observe Mfn2 ubiquitination or loss after L-DOPA 
treatment provides further evidence that parkin degradation doesn't depend on its mitochondrial 
activity. As discussed in the results section, Mfn2 is a preferred parkin poly-ubiquitination 
substrate, and parkin-mediated Mfn2 ubiquitination and loss has been proposed to be a key first 
step before parkin can ubiquitinate most of its other mitochondrial substrates [219]. Given this, 
the lack of Mfn2 ubiquitination after L-DOPA treatment suggests that parkin activity does not 
contribute to mitochondrial phospho-poly-Ub chains in this model. Taken together with our 
results using exogenous parkin, it suggests that, after L-DOPA, parkin activity doesn't contribute 
to phospho-poly-Ub-building, mitochondrial or cytosolic, at all. 
 It's novel that parkin doesn't appear to contribute to phospho-poly-Ub formation in the L-
DOPA model. This is because, to our knowledge, no one has reported parkin binding to 
phosphorylated poly-Ub chains built by another ligase, as appears to happen following L-DOPA 
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treatment. This is certainly plausible, however, as several other ubiquitin ligases have been 
reported to poly-ubiquitinate proteins on the mitochondrial surface [402]–[404], and there are 
hundreds eukaryotic ubiquitin ligases [405]. One or several of these may build the phospho-poly-
Ub chains that we observe on mitochondria and in the cytosol following L-DOPA. 
4.3.8 Lack of dominant negative C431S activity in the CCCP model 
 A surprising observation that deserves brief mention is that catalytically inactive parkin 
did not exert a dominant negative effect on phospho-poly-Ub formation by endogenous parkin in 
the CCCP model. We had predicted to see such an effect because parkin activity contributes to 
phospho-poly-Ub formation after CCCP treatment and C431S would be expected to compete 
with endogenous parkin for activation by PINK1. Instead, phospho-poly-Ub was increased by 
about 30% in cells expressing C431S parkin relative to empty vector. While puzzling at first, this 
observation can be rationalized by the recent proposal by Kumar et al. that efficient activity by a 
parkin molecule necessitates the binding of E2-conjugated ubiquitin to a different activated 
parkin molecule in a novel ubiquitin binding patch (described in Ch.1) [171]. Given that C431S 
parkin can still adopt an activated confirmation via its phosphorylation or binding to phospho-
Ub, it would be able to assist in the activity of endogenous parkin by priming an E2-conjugated 
ubiquitin for use by the latter. Since C431S is overexpressed ~8-fold over endogenous parkin, 
the slight increase in phospho-poly-Ub we observe with C431S over empty vector may be 
explained by excess C431S parkin enhancing the activity of endogenous parkin.  
4.3.9 Lack of mitophagy following L-DOPA and CCCP treatment 
 We did not observe loss of mitochondrial proteins consistent with a robust induction of 
mitophagy after CCCP or L-DOPA. It's important to note that analysis of mitochondrial proteins 
by Western blotting is a relatively insensitive way to detect mitophagy compared with 
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microscopic analysis. Therefore, it's possible that we missed a mild induction of mitophagy by 
L-DOPA and CCCP. Nevertheless, induction of robust mitophagy should be readily detectable 
by examining the levels of mitochondrial proteins [95], [221], [222], [231]–[233], so we can 
firmly conclude that such a strong phenotype does not occur in our models.  
 Given the lack of Mfn2 ubiquitination and parkin-dependent phospho-poly-Ub formation 
in the L-DOPA model, the lack of robust mitophagy in this model is not surprising. By contrast, 
in the CCCP model, the discrepancy between the robust ubiquitination and degradation of Mfn2 
and the mild or non-existent effect of CCCP on most other mitochondrial proteins was puzzling 
at first, though not without precedent [231].  
 However, a recent study by Durcan et al. provides a possible explanation for this 
observation [219]. The authors found the mitofusins to be the primary and preferred 
mitochondrial substrates of parkin. Furthermore, they provided evidence that extraction of Mfn2 
from the mitochondrial membrane by the AAA-ATPase p97 and its subsequent degradation is a 
key step for allowing parkin to ubiquitinate other mitochondrial proteins and for mitophagy to 
proceed. Given that we observe robust ubiquitination of Mfn2, but not other mitochondrial 
proteins, after CCCP, it's possible that p97 is not active in this context in our model. Consistent 
with this possibility, we do not observe a decrease in the degree of Mfn2 ubiquitination after 5 
hours of CCCP, suggesting that it does not get extracted from the mitochondrial outer membrane. 
By contrast, Durcan et al. found a notable decrease in Mfn2 ubiquitination by 4 hours of CCCP, 
which was abrogated by a p97 inhibitor.  
 More work will be needed to understand why mitophagy can take place under certain 
circumstances but not under others. 
  132 
4.3.10 Question regarding parkin activity 
 A significant outstanding question of our work is whether or not parkin carries out any 
ubiquitination following L-DOPA treatment. As discussed, we do not observe classic readouts of 
mitochondrial parkin activity after L-DOPA, namely Mfn2 ubiquitination, contribution to 
phospho-poly-Ub chain building, and mitophagy. However, especially given the large number of 
reported parkin substrates [59], this does not guarantee that parkin is inactive.  
 There's evidence that progressively greater mitochondrial damage leads to a progressively 
more extreme cellular response, with mitophagy representing the most extreme of these [233], 
[244], [406]. Milder mitochondrial damage, including oxidative stress, has been shown to evoke 
mitochondrially-derived vesicles (MDVs), the formation of some of which has been shown to 
depend on parkin activity [233], [245], [246]. Parkin has also been found to repress formation of 
a different species of MDV [64]. If CCCP is a more severe mitochondrial stressor than L-DOPA, 
which seems likely given the greater degree of Opa1-long cleavage we observed with the former, 
perhaps L-DOPA-mediated oxidative stress elicits a milder mitochondrial response, such as 
MDV formation. In line with this idea, oxidative stress, generated inside the mitochondria by 
antimycin A or outside the mitochondria by glucose oxidase, which produces hydrogen peroxide, 
was found to elicit significant formation of MDVs, whereas CCCP elicited substantially fewer 
[233].  
 Induction of distinct mitochondrial pathways by L-DOPA and CCCP could explain why 
we observe ubiquitination of Mfn2 and parkin-dependent phospho-poly-Ub after CCCP but not 
L-DOPA. The wide range of reported parkin activities at the mitochondria implies that there 
must exist some kind of modulation of parkin's mitochondrial actions to differentiate between 
these different pathways. Ubiquitination of Mfn2 and parkin-dependent phospho-poly-Ub 
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formation could be specific to the initiation of mitophagy and not, for example, MDV formation. 
Such a scenario would be logical in the case of Mfn2 because its ubiquitination has been shown 
to be a critical first step for dissociation of mitochondria from the endoplasmic reticulum [219], a 
process likely more important for engulfment of the whole organelle than for the budding off of 
vesicles.  
 One piece of evidence against the possibility that L-DOPA elicits parkin-dependent 
MDVs is that parkin was not found to localize with MDVs generated by cytosolic oxidative 
stress [233]. However, this observation was not quantified, and parkin colocalization with these 
vesicles may not have been observed because this association could be very transient. Another 
piece of evidence that could be raised against a model in which L-DOPA elicits parkin-
dependent MDVs is that parkin loss was not observed during parkin-dependent MDV formation 
[233]. However, the experiment in question used highly-overexpressed parkin. Our finding that 
highly-overexpressed parkin did not respond to L-DOPA in the same way as endogenous parkin 
did, coupled with a similar finding by others [231], highlights the importance of analyzing parkin 
regulation and activity using endogenous parkin. If, in the above study [233], overexpressed 
parkin did not increase the phospho-Ub level by building phospho-poly-Ub chains, it's entirely 
feasible that the parkin degradation machinery was saturated and that this is why the authors did 
not detect parkin loss.   
 Although it's possible that parkin ubiquitinates non-mitophagy substrates after L-DOPA 
treatment, it's also possible that parkin fails to be activated after L-DOPA despite associating 
with phospho-Ub. In line with this possibility, Kondapalli et al. did not find evidence of parkin 
phosphorylation after 6-OHDA treatment, though it's possible that phospho-parkin was below 
their detection threshold [168]. Given that phosphorylation of parkin is necessary for its full 
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activation, a lack of phosphorylation following L-DOPA treatment would translate to lower 
parkin activity.  
 Another mechanism that could keep parkin inactive after L-DOPA treatment is oxidative 
modification of its cysteine residues by L-DOPA or a ROS resulting from its oxidation. Parkin 
has been shown to be vulnerable to modification by various oxidizers, including dopamine, nitric 
oxide, and hydrogen peroxide, which leads to its inactivation [302], [318]–[321], [324]–[326]. 
 More work will be needed to determine whether or not parkin is active toward non-
mitophagy-related substrates following L-DOPA treatment. 
4.4 Conclusion 
 In conclusion, the work presented in this chapter defines two distinct pathways of parkin 
loss from L-DOPA and shows that one of them, the oxidative stress-dependent pathway, 
overlaps with a previously established mechanism of parkin activation, namely parkin binding to 
phospho-Ub. Unexpectedly, we did not observe evidence of mitochondrial parkin activity 
downstream of this binding, indicating that phospho-Ub-dependent parkin loss can be uncoupled 
from this activity. 
 Our results expand on previous work that showed that mitochondrial depolarization 
induces parkin loss [162], [201], [231]–[234] and suggest a way to bridge the at times 
contradictory conclusions (see Section 1.2.3.1.3) of previous studies into a cohesive model of 
parkin degradation due to PINK1 activity. In this model, parkin binding to phospho-Ub is the 
key determinant of its loss. Such loss can occur during the process of mitophagy [232], [233], or 
it can occur from parkin association with phospho-Ub during conditions that preclude mitophagy 
(e.g. cellular reliance on oxidative phosphorylation) [231]. Additionally, phospho-Ub-dependent 
parkin loss can be linked to parkin's own ubiquitination activity or occur independently of this 
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activity. Our model also posits that phospho-Ub-induced parkin loss is proteasomal, but it doesn't 
result from parkin autoubiquitination. 
 Given the fact that dissociation of parkin from phospho-Ub has not been reported, we 
speculate that degradation of parkin following its activation by phospho-Ub may be the 
mechanism by which cells "turn off" parkin once its function has been fulfilled. More work will 
be required to test this hypothesis. 
 Finally, our finding that phospho-Ub plays a critical role in parkin loss may have clinical 
implications because elevated levels of phospho-Ub have been found in patients with Lewy body 
disease. 
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Chapter 5 NADPH oxidase activity is not necessary for L-DOPA-induced parkin loss 
5.1 Introduction 
  In chapter 4, I described our observation that the serine protease inhibitor AEBSF 
prevents parkin loss from L-DOPA. In addition to inhibiting serine proteases, AEBSF is also 
known to inhibit NADPH oxidase activity [407], [408]. Given this second function, we 
investigated the possibility that NADPH oxidase activity may play a role in parkin loss from L-
DOPA. 
 NADPH oxidases are multi-subunit enzyme complexes found in the plasma membrane 
and organellar membranes of many cell types [409]. These complexes oxidize molecular oxygen 
to either superoxide radical or hydrogen peroxide on the outer surface of the membrane that 
Figure 5.1. Schematic of active NADPH oxidase complexes.  
The catalytic subunit of an NADPH oxidase is called NOX or DUOX. There are 5 NOX isoforms and two 
DUOX isoforms. The cofactors needed by different NOX/DUOX isoforms for activation vary. From K. 
Bedard and K.-H. Krause, “The NOX Family of ROS-Generating NADPH Oxidases: Physiology and 
Pathophysiology,” Physiol. Rev., vol. 87, no. 1, pp. 245–313, 2007. 
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contains them [410]. NADPH oxidases are defined by their catalytic subunit, called either NOX 
or DUOX; there are 5 different NOX isoforms and 2 different DUOX isoforms. The composition 
of the enzyme complex formed by each NOX/DUOX isoform is distinct, although some proteins 
are shared between complexes (Fig. 5.1) [408], [410]. The integral membrane protein p22phox is 
required for the activity of NOX1-4 [410]. Whereas NOX1-3 and 5 generate superoxide, NOX4 
and the DUOXes generate hydrogen peroxide [408]. 
 The first characterized function of NADPH oxidases was to generate the microbicidal 
ROS used by phagocytes during phagocytosis [411]. However, NADPH oxidases are present in 
various cell types throughout the body and have been found to impact many processes including 
cellular signaling, gene expression, and cell growth/senescence [409], [412]. In the brain, 
different NOX isoforms have been detected in neurons, astrocytes, and microglia [409]. In 
normal physiological circumstances, brain NADPH oxidases appear to be involved in 
phagocytosis by microglia, intracellular signaling in astrocytes and neurons, and the process of 
long-term potentiation [412].  
 However, there is also accumulating evidence that NADPH oxidase activity contributes 
to neurodegeneration [409], [412]. In particular, NOX2-derived ROS from activated microglia 
contribute to neurotoxic inflammation and oxidative stress [409], [412]. There is also evidence 
that intra-neuronal NADPH oxidases may contribute to neuronal death in cis [409], [413], [414]. 
 Several PD-relevant stressors have been shown to upregulate or activate NOX1 and 
NOX2 in vitro and in vivo. Paraquat was found to upregulate NOX1 expression in N27 cells and 
immortalized human dopaminergic neurons and to induce nigral degeneration in vivo in a 
NOX1-dependent manner [415], [416]. MPP+ increased NOX2 protein levels in PC12 cells and 
in N27 cells [417], [418]. Finally, 6-OHDA has been reported to elevate NOX2 mRNA and 
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activity in the substantia nigra of rats [419] and to increase NOX1 protein in cultured 
dopaminergic neurons and NOX1 mRNA in the rat substantia nigra [413]. The increases in 
NOX1 were implicated in 6-OHDA-induced ROS formation in vitro and nigral degeneration in 
vivo [413]. 
 Given the above evidence that NADPH oxidases can be activated by cellular stress and 
our finding that AEBSF prevents parkin loss from L-DOPA in PC12 cells, we hypothesized that 
L-DOPA increases NADPH oxidase activity and that this activity contributes to parkin loss. 
PC12 cells have been found to express NOX1, 2, and 4 mRNA [420], [421], so this mechanism 
is theoretically feasible. To test the possible involvement of NADPH oxidases in parkin loss, we 
assessed parkin protection using another NADPH oxidase inhibitor, analyzed mRNA levels of 
the two NOX isoforms reported to be upregulated by stress, performed an assay to assess 
NADPH oxidase activity, and knocked down various NADPH complex components in 
conjunction with L-DOPA treatment. Our results do not support the conclusion that NADPH 
oxidases play a role in L-DOPA-mediated parkin loss. 
5.2 Results 
5.2.1 VAS3947 prevents L-DOPA- and hydrogen peroxide-induced parkin loss 
 Given that AEBSF inhibits serine proteases in addition to NADPH oxidases, appears to 
interfere with L-DOPA autoxidation, and has questionable cell permeability, we sought an 
alternative approach to test whether AEBSF prevents L-DOPA-induced parkin loss via NADPH 
oxidase inhibition. For this, we used VAS3947, a cell-permeable NADPH oxidase inhibitor 
without known off-target effects (though a closely-related compound, VAS2870, can thioalkylate 
cysteine residues in proteins) [408]. Like AEBSF, VAS3947 appears capable of inhibiting 
various NOX isoforms [422].  
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 We observed complete prevention of parkin loss from L-DOPA in differentiated PC12 
cells co-treated with 50 µM VAS3947 (relative parkin level 0.70 ± 0.02 with L-DOPA vs. 0.96 ± 
0.06 with L-DOPA and VAS3947, p = 0.02) (Fig. 5.2 A). Similarly, VAS3947 appears to fully 
prevent parkin loss from hydrogen peroxide treatment, though this experiment was only 
performed twice and hence the parkin protection from VAS3947 did not reach statistical 
significance (Fig. 5.2 B). To make sure that VAS3947 does not interfere with L-DOPA 
autoxidation like AEBSF seems to, we incubated 50 µM VAS3947 with 200 µM L-DOPA in cell 
culture medium for 24 hours and qualitatively examined L-DOPA quinone formation. Although 
Figure 5.2. VAS3947 completely prevents parkin loss from L-DOPA and hydrogen peroxide treatment. 
Differentiated PC12 cells were co-treated with 50 µM VAS3947 and 200 µM L-DOPA (A) or 200 µM 
hydrogen peroxide (B) for 24 hours before cell lysis for Western blotting. Representative Western blots 
(top) and quantification of normalized parkin levels (bottom) are shown. Parkin was normalized to ERK1 
and 2 for (A) and to ERK1 and 2 and ponceau for (B). ** p ≤ 0.01, * p ≤ 0.5 by paired t-test with Holm 
correction for multiple comparisons. Error bars show SEM for (A) and range for (B). 
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the cell culture medium appeared slightly less brown when L-DOPA was coincubated with 
VAS3947 compared to L-DOPA alone (reflecting less quinone formation), this difference was 
substantially less pronounced than that observed with AEBSF (Figs. 5.3, 4.X). This suggests that 
VAS3947 does not possess strong antioxidant properties and that its prevention of parkin loss is 
unlikely to be mediated by interference with L-DOPA autoxidation. The fact that VAS3947 
prevented parkin loss from L-DOPA suggested that one or more NADPH oxidases is involved in 
this process. Given the reported induction of NOX1 and 2 activity during stress and their 
contribution to neurodegeneration, these two NOXes appeared to be likely candidates for 
Figure 5.3. VAS3947 does not appear to substantially interfere with L-DOPA quinone formation. Two 
different cell culture media (DMEM and RPMI) were incubated with 50 µM VAS3947 and 200 µM L-
DOPA (without cells) for 24 hours at 37°C under 7.5% CO2. Browning of the medium with L-DOPA 
reflects quinone formation.  
  141 
mediating L-DOPA's effects on parkin. 
5.2.2 Preliminary lack of evidence for upregulation of NOX1 and 2 levels and activity after L-
DOPA exposure 
 Given that the levels and activity of NOX1 and 2 have been reported to be upregulated by 
various stressors after as little as 6 hours [413], [423], we performed two preliminary 
experiments to assess whether L-DOPA also upregulates NOX1 and 2. First, we examined 
mRNA levels of NOX1 and 2 after 8 hours of L-DOPA treatment. Comparing 3 biological 
Figure 5.4. L-DOPA does not appear to increase NOX1 and 2 mRNA levels or activity. 
A. Quantification of NOX1 and NOX2 mRNA levels from PC12 cells treated with or without 200 µM L-
DOPA for 8 hours. mRNA levels were normalized to 18S RNA. Dots represent biological replicates from 
one experiment. Error bars show SD. B. Chemiluminescent traces from a lucigenin assay using lysates from 
untreated cells. 50 µM VAS3947 or DMSO were added to lysates before the start of the assay. NADPH was 
added to lysates right before time zero. The difference between the DMSO and the VAS3947 traces at each 
time point represents the "VAS-inhibitable" signal. C. The VAS-inhibitable signal from cells treated with or 
without L-DOPA for 5 hours (top) or 10 hours (bottom) before lysis for the lucigenin assay. In B. and C., 
error bars show range of two technical replicates from one experiment. 
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replicates per condition in this one experiment, we did not observe an increase in NOX1 or 
NOX2 mRNA in L-DOPA-treated cells over untreated cells (Fig. 5.4 A). This suggests that, 
unlike other stressors, L-DOPA may not increase NOX1 and 2 expression. 
 To assess whether L-DOPA induces an increase in NOX1 and 2 activity, we used lysates 
from control and L-DOPA-treated cells in a lucigenin assay, a well-established method to 
monitor superoxide production by NADPH oxidases [424]. In this assay, NADPH is added to 
cell lysates in order to stimulate NOX activity, and the light-emitting reaction of the resultant 
superoxide with lucigenin is measured using a luminometer. As expected, we observed an 
increase in lucigenin chemiluminescence upon addition of NADPH to untreated cell lysates (Fig. 
5.4 B). This chemiluminescent signal was decreased by about half by addition of VAS3947 to 
the lysates, indicating that NADPH oxidases are indeed involved in generating the superoxide 
detected by the assay, at least partially (Fig 5.4 B). To specifically assess superoxide generated 
by NADPH oxidases, we subtracted the residual chemiluminescent signal in lysates containing 
VAS3947 from the chemiluminescent signal of cells without VAS3947. The resulting "VAS-
inhibitable" signal was considered a readout of NADPH oxidase activity. We then performed a 
preliminary experiment to assess whether L-DOPA increases this signal. The lysates of cells 
treated with L-DOPA for 5 or 10 hours did not generate more chemiluminescence than those of 
control cells, indicating that NOX1 and 2 activity was not increased at these times (Fig. 5.4 C). 
 The fact that we did not observe an increase in NOX1 and 2 mRNA or in lucigenin 
chemiluminescence upon L-DOPA treatment suggests preliminarily that L-DOPA doesn't 
increase NOX1 and NOX2 levels or activity. However, given that we only performed one of 
each experiment, more work is required before a firm conclusion on this topic can be made. 
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5.2.3 Knockdown of NOX1, NOX2, p22phox, and DUOX1/2 doesn't attenuate L-DOPA-
induced parkin loss 
 Although we did not find evidence of NOX1 and 2 upregulation after L-DOPA treatment, 
it's feasible that baseline NADPH oxidase activity could contribute to L-DOPA-induced parkin 
loss. To address this possibility and to try to narrow down which NOX isoform could be 
involved in parkin loss, we knocked down several NADPH complex components using shRNAs 
and treated with L-DOPA. 
 Given the evidence linking NOX1 and 2 to neurodegeneration, we first knocked down 
these two isoforms, alone or in combination. The shRNAs used were previously described [425], 
[426]. Transducing cells with shNOX1 or shNOX2 alone decreased NOX1 mRNA levels by 
~70% and NOX2 mRNA levels by ~88%, respectively, whereas co-transducing cells with 
shNOX1 and shNOX2 decreased NOX1 mRNA levels by ~40% and NOX2 mRNA levels by 
~83% (Fig. 5.5 A). We did not observe any effect on L-DOPA-induced parkin loss in cells 
transduced with shNOX1 or shNOX2, alone or in combination (Fig. 5.5 B). This suggested that 
NOX1 and 2 are not involved in parkin loss from L-DOPA. However, these results did not prove 
that NADPH oxidases are not involved in L-DOPA-mediated parkin loss because PC12 cells had 
been previously reported to express NOX4. It was possible that NOX4 activity was responsible 
for parkin loss or that it compensated for the lack of NOX1 and 2. 
 To more conclusively determine whether NADPH oxidases play a role in L-DOPA-
mediated parkin loss, we devised a strategy to inhibit all of the NOX isoforms together. NOX5 is 
absent from the rodent genome [427], so we only needed to inhibit NOX1-4 and DUOX1/2. To  
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target NOX1-4 simultaneously, we knocked down the membrane protein p22phox, which is 
necessary for the activity of NOX1-4. We used two previously-described shRNAs to knockdown 
p22phox [428], [429], which decreased p22phox mRNA by ~45% and ~90%, respectively (Fig. 
5.5 A). Surprisingly, knockdown of p22phox did not attenuate parkin loss from L-DOPA, 
suggesting that NOX1-4 do not contribute to L-DOPA-induced parkin loss (Fig. 5.5 C). 
 To knock down DUOX1 and 2, we designed three shRNAs that would target both 
isoforms, though it's unclear whether these isoforms are present in PC12 cells. Indeed, we could 
not detect DUOX1 or 2 mRNA in PC12 cells using three different primer sets for each isoform, 
although two of the primer sets for DUOX1 and all of the primer sets for DUOX2 had been 
previously published [430]–[432]. This suggests that DUOX1 and 2 are unlikely to play a role in 
L-DOPA-mediated parkin loss. Nevertheless, we examined whether L-DOPA-mediated parkin 
loss was affected in cells transduced with shDUOX1/2. As expected, there was no prevention of 
parkin loss in cells transduced with any of the three shDUOX1/2 constructs (Fig. 5.5 D). 
5.3 Discussion 
 The data presented in this chapter indicate that NADPH oxidase activity is unlikely to be 
involved in parkin loss from L-DOPA. Although we observed full prevention of L-DOPA-
induced parkin loss using the inhibitors AEBSF and VAS3947, interference with the activity of 
all known NADPH oxidases via shRNA knockdown did not attenuate L-DOPA-induced parkin 
(Previous page) Figure 5.5. Knockdown of NADPH complex components doesn't attenuate parkin loss 
from L-DOPA. A-D. Differentiated PC12 cells were transduced with lentiviral vectors carrying shRNAs for 
3 days (shNOX1 and shNOX2) or 4-5 days (shp22phox and shDUOX) before cells were harvested for 
qPCR (A) or treated with 200 µM L-DOPA for 24 hours (B-D). B-D. Representative Western blots (left) 
and quantification of parkin levels (right) are shown. Parkin was normalized to ERK1 and 2 and ponceau in 
(B) and to ERK1 and 2 in (C) and (D). In (A-D), dots represent averages of at least 2 biological replicates 
from independent experiments. **** p ≤ 0.0001, *** p ≤ 0.001, ** ≤ 0.01, * ≤ 0.05 by paired t-test with 
Holm correction for multiple comparisons. Error bars represent SEM.  
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loss. In support of the knockdown results, we did not observe evidence of upregulation of NOX1 
and 2 levels or activity after L-DOPA treatment in preliminary experiments. 
 One weakness of our knockdown experiments is that we only assessed knockdown at the 
mRNA level, not the protein level. However, knockdown of NOX1, 2, and p22phox was 
previously shown to result in a decrease in protein levels by 72 hours or earlier [433]–[437], 
making it unlikely that knockdown was not reflected at the protein level in our system.  
 The fact that knockdown of NADPH complex components did not corroborate our 
findings with AEBSF and VAS3947 suggests that these inhibitors prevent L-DOPA-induced 
parkin loss through mechanisms other than NADPH oxidase inhibition. As discussed in Chapter 
4, AEBSF-mediated inhibition of L-DOPA autoxidation is likely partly responsible for its 
protective effect on L-DOPA-induced parkin loss. However, VAS3947 does not appear to 
substantially interfere with L-DOPA autoxidation, indicating that it probably prevents parkin loss 
from L-DOPA treatment through a distinct mechanism. Importantly, the fact that VAS3947 fully 
prevents L-DOPA-induced parkin loss indicates that it acts upstream of both the oxidative stress-
dependent and the oxidative stress-independent mechanism of parkin loss from L-DOPA. Given 
that VAS3947 does not have any reported off-target effects, it's difficult to speculate on exactly 
how VAS3947 may prevent parkin loss upstream of these two pathways. However, a close 
structural analog of VAS3947, VAS2870, has been found to react with cysteine residues in the 
skeletal muscle ryanodine receptor/Ca2+ -release channel [438]. If VAS3947 has similar 
reactivity to VAS2870, it's possible that its preventative effect on parkin loss involves its 
reaction with thiol groups in proteins, perhaps even in parkin itself. 
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Chapter 6 Parkin knockdown does not exacerbate cell death from L-DOPA or   
  hydrogen peroxide 
6.1 Introduction 
 As discussed in Section 1.2.3.4, the ability of parkin to promote cell survival is very well-
documented. One piece of evidence for this is that multiple studies have found that parkin 
knockdown increases cell death from various stressors, usually by ~20% [250], [262], [263], 
[266], [270], [274], [439], [440]. Results from our own lab have been slightly contradictory on 
this topic, with one study finding an increase in 6-OHDA-induced death of ~15% with parkin 
knockdown and another study not finding a sensitizing effect of parkin knockdown on 6-OHDA-
induced death [265], [266]. However, the dose of 6-OHDA and the degree of 6-OHDA-induced 
cell death between these two studies was different, with significantly more toxicity reported in 
the second study. 
 Given our finding in Chapter 4 that L-DOPA and hydrogen peroxide induce formation of 
the parkin activator phospho-Ub and that a substantial fraction of parkin interacts with this 
phospho-Ub, we hypothesized that parkin activation by L-DOPA and hydrogen peroxide may 
protect against death induced by these stressors. This model would be in line with the above 
studies that found sensitization to stress-induced death upon parkin knockdown. To test this 
hypothesis, we performed several preliminary experiments in which we knocked down parkin in 
the presence of L-DOPA or hydrogen peroxide and assessed cell survival. The results of these 
experiments suggest that parkin knockdown doesn't exacerbate cell death from L-DOPA or 
hydrogen peroxide, but they don't rule out the possibility that parkin knockdown increases the 
initial rate of cell death from these stressors. 
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6.2 Results 
6.2.1 Parkin knockdown does not appear to enhance ultimate cell death from L-DOPA or 
hydrogen peroxide 
 We sought to determine whether parkin knockdown increases the final "death toll" from 
L-DOPA and hydrogen peroxide. To do this, we performed several preliminary experiments 
examining the stress-induced death of differentiated PC12 cells with and without parkin 
knockdown at relatively late time points: after 48 hours of hydrogen peroxide treatment and 7 
days after exposure to L-DOPA.  
 To knock down parkin, we used a lentiviral vector carrying an shRNA that was created 
and validated in a previous study from our lab [265]. The knockdown efficiency of this shRNA 
was ~50% after 5 days (Fig. 6.1 A). The typical lentiviral transduction efficiency of PC12 cells 
we observe is ~70-80% (Fig. 6.1 B), indicating that the actual level of parkin knockdown in a 
given transduced cell was greater than 50%. 
 Knockdown of parkin did not exacerbate cell death from 100-180 µM hydrogen peroxide 
after 48 hours in three experiments (Fig. 6.2 A). We did not perform a time-course experiment to 
examine the kinetics of cell death from hydrogen peroxide, so it's feasible that a sensitizing effect 
of parkin knockdown could become apparent at a different time point. Indeed, a previous study 
reported that parkin knockdown sensitized PC12 cells to hydrogen peroxide-induced death after 
24 hours [263].  
 Next, we carried out two preliminary experiments to assess whether parkin loss sensitizes 
PC12 cells to death induced by L-DOPA. To ensure that cell death from L-DOPA was complete, 
we waited 7 days after treatment before assessing cell death, replacing half the cell culture 
medium twice during this time (per normal PC12 cell culture protocol). Cell division was not a 
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concern as we used differentiated PC12 cells, which don't divide. Parkin knockdown did not 
sensitize cells to L-DOPA-induced death in the two experiments that we performed (Fig. 6.2 B).  
Figure 6.1. Parkin knockdown in PC12 cells using a lentivirally-delivered shRNA. 
A,B. Differentiated PC12 cells were transduced with a lentiviral vectors carrying an shRNA against 
parkin or a control shRNA. A. Cells were harvested for Western blotting 5-6 days after transduction to 
assess parkin knockdown. A representative Western blot (top) and quantification of parkin knockdown 
from 4 experiments (bottom) is shown. ** p ≤ 0.01 by paired t-test. Error bars show SEM. B. Cells 
transduced with lentivirus co-expressing sh-parkin and GFP were fixed for immunostaining 5 days after 
transduction. Fixed cells were stained with Hoechst to visualize nuclei (top) and with an antibody against 
GFP to identify transduced cells (bottom). 
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6.2.2 Preliminary evidence that parkin knockdown may enhance the initial rate of cell death 
from L-DOPA 
Figure 6.2. Parkin knockdown does not sensitize cells to ultimate death from hydrogen peroxide and L-
DOPA.  
A,B. Quantification of remaining viable nuclei after exposure to hydrogen peroxide (A) or L-DOPA (B). 
Data were normalized to the 0 µM H2O2 sh-ctrl condition in (A) and to the respective 0 µM condition of 
each virus in (B). Differentiated PC12 cells were transduced with lentiviral vectors carrying an shRNA 
against parkin or a control shRNA for 5 to 6 days before treatment with the indicated concentrations of 
hydrogen peroxide for 48 hours (A) or L-DOPA for 7 days (with 2 medium changes) (B.) Data from all 
concentrations of hydrogen peroxide (A) or L-DOPA (B) were combined to generate the rightmost 
graphs. Dots represent the average of three biological replicates from independent experiments. ** p ≤ 
0.01, * p ≤ 0.05 by paired t-test with Holm correction for multiple comparisons. Error bars show SEM in 
(A) and range (left) or SD (right) in (B). 
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 Although our data suggest that parkin knockdown does not ultimately sensitize cells to 
death from hydrogen peroxide and L-DOPA, it's possible that parkin knockdown may increase 
the initial rate of cell death from hydrogen peroxide and L-DOPA. Indeed, it appears that all the 
studies reporting a sensitization of parkin-deficient cells to stressors assessed cell death at 
relatively early time points. With this in mind, we performed a preliminary experiment 
examining L-DOPA-induced cell death with and without parkin knockdown at an earlier time 
point, after 48 hours of L-DOPA treatment. In this experiment, parkin knockdown did sensitize 
cells to death from L-DOPA by ~10%, on average (Fig. 6.3). Though more experiments are 
needed to confirm this effect, this result suggests that parkin knockdown may accelerate cell 
death from L-DOPA. 
Figure 6.3. Parkin knockdown may sensitize cells to death after 48 hours of L-DOPA. 
Differentiated PC12 cells were transduced with lentiviral vectors carrying the indicated shRNAs for 5 
days before treatment with the indicated concentrations of L-DOPA for 48 hours. Cell death was assessed 
by quantifying the number of viable nuclei remaining after treatment. The numbers of viable nuclei with 
each L-DOPA concentration were normalized to the respective 0 µM condition of each virus. Data from 
all concentrations of L-DOPA were combined to generate the rightmost graph. Dots represent biological 
replicates of one experiment. *** p ≤ 0.001, ** p ≤ 0.01 by paired t-test with Holm correction for 
multiple comparisons Error bars show SD. 
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6.3 Discussion 
 The data presented in this chapter suggest that parkin knockdown doesn't exacerbate cell 
death from L-DOPA and hydrogen peroxide, but that it may delay this death. These results 
suggest that the reported sensitizing effects of parkin knockdown to various stressors at early 
time points may disappear with longer exposure to the stressors. 
 Parkin has a well-established pro-survival role, and it would presumably be activated by 
its binding to the phospho-Ub induced by L-DOPA and hydrogen peroxide. As such, a question 
raised by the experiments in this chapter is why we did not observe sensitization to cell death 
from L-DOPA and hydrogen peroxide upon parkin knockdown. There are several possible 
answers to this question: 
 1. The degree of parkin knockdown in our experiments was not strong enough to reveal a 
sensitizing effect from parkin loss. Although this is the most straightforward explanation, it 
seems unlikely. This is because our group has previously found that parkin knockdown with the 
same shRNA used here did not sensitize cells to death from 6-OHDA, but, in the same 
experiments, this shRNA was effective at completely abolishing the protective activity of Trib3 
knockdown [265]. These results indicate that sensitization to 6-OHDA from parkin knockdown 
was possible with the degree of knockdown achieved in the latter experiments, but that another 
factor precluded such sensitization in the condition of 6-OHDA treatment and parkin knockdown 
alone. It seems likely that an analogous mechanism precludes sensitization from parkin 
knockdown in the L-DOPA and hydrogen peroxide models. 
 2. Another possible explanation for why parkin knockdown does not appear to enhance 
ultimate cell death in our models is that parkin fails to be activated despite binding to phospho-
Ub. Given that parkin has been reported to be inactivated via oxidative modifications of its 
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cysteine residues by stressors, it's possible that L-DOPA and hydrogen peroxide functionally 
inactivate parkin by this mechanism. Alternatively, parkin may only be weakly active after 
binding to phospho-Ub if it is not phosphorylated by PINK1 in the L-DOPA and hydrogen 
peroxide models. 
 3. A third reason why parkin knockdown may not exacerbate death from L-DOPA and 
hydrogen peroxide is that parkin is degraded following its activation. This explanation 
encompasses two distinct scenarios. In the first, parkin is degraded so rapidly following its 
activation that there is no time for it to do anything protective. Given the evidence that parkin 
binding to phospho-Ub is sufficient to promote its degradation (discussed in Section 4.3.6), L-
DOPA and hydrogen peroxide would have to accelerate parkin loss downstream of its binding to 
phospho-Ub for this scenario to be plausible. Otherwise, it's unclear how parkin would ever be 
able to have any functional effect. In the second scenario, parkin degradation following its 
activation by L-DOPA and hydrogen peroxide is not immediate, such that it can have a 
functional effect before it's degraded. However, this functional effect is tightly coupled to 
ongoing parkin activation by the continuous degradation of parkin following its activation. If the 
parkin activation mechanisms dissipate while cells are still under stress, levels of activated 
parkin will also drop due to its degradation, leaving the cells vulnerable to stress. Thus, this 
second scenario depends on a decrease in phospho-Ub, parkin phosphorylation, or an as-yet 
unidentified activity-enhancing factor while cells are still under stress from L-DOPA and 
hydrogen peroxide. This second scenario fits the possibility suggested by our data that parkin 
knockdown may accelerate cell death from L-DOPA and hydrogen peroxide. In this model, 
parkin activity at early time points protects cells from death, but parkin activation mechanisms 
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decrease at later time points, causing a drop in active parkin and therefore abrogating parkin's 
ability to defend against continued stress. 
 More work will be required to determine which, if any, of these explanations account for 
the lack of ultimate cell sensitization to L-DOPA- and hydrogen peroxide-induced death by 
parkin knockdown. If parkin degradation is found to be the underlying cause of this lack of 
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Chapter 7 Conclusions and Future Directions 
 This dissertation provides new insights into the regulation of the neuroprotective 
ubiquitin ligase parkin. Although much attention has been focused on the mechanisms 
underlying parkin's neuroprotective action in preventing PD, comparatively little is known about 
how parkin levels are regulated, especially following its activation. Given the interest in 
developing therapeutic strategies for PD based on upregulation of parkin levels and activity, 
understanding how levels of total and, especially, of active parkin are controlled will be critical 
for the effective design of such strategies. The results of our investigation into L-DOPA-
mediated parkin loss may prove valuable in this regard. Furthermore, our findings may be of 
particular relevance to PD given that L-DOPA remains the most common treatment of PD motor 
symptoms. The major findings of this dissertation as well as recommended follow-up studies are 
summarized below. 
7.1 L-DOPA leads to parkin loss in vitro 
 Chapter 2 presented evidence that L-DOPA induces parkin loss in differentiated PC12 
cells, primary rat cortical neurons, SH-SY5Y cells, and MEFs. This is the first demonstration 
that L-DOPA can decrease parkin levels. In addition, we found that, at least in PC12 cells, parkin 
loss can be uncoupled from cell death and appears to be mediated by an increase in the rate of 
parkin degradation. A question raised by these findings is whether L-DOPA may have a similar 
effect in the SNpc neurons of PD patients who receive it therapeutically. To investigate this 
question, would be useful to examine whether therapeutic doses of L-DOPA have an effect on 
SNpc parkin levels in an in vivo rodent model. Ideally, the effect of L-DOPA on parkin should 
be examined both in wild type animals and in an alpha-synuclein-based animal model. The 
advantage of the former study is that L-DOPA treatment would be the only variable at play, 
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allowing greater ease of interpretation of the results. The advantage of the latter study is that an 
alpha-synuclein-based animal model would more closely approximate the state of SNpc neurons 
in PD. Additionally, it may be worthwhile to examine parkin levels in post-mortem brain tissue 
of PD patients who took different cumulative lifetime doses of L-DOPA. However, unless there 
is a clear lack of association between L-DOPA dose, parkin levels, and degree of neuronal loss, 
there may be multiple interpretations for any findings, which would preclude firm conclusions 
from being made. 
 Although we chose L-DOPA as a stressor in this study in part because of its clinical 
relevance, it's important to note that the results of our work have important implications 
regardless of whether therapeutic doses of L-DOPA have a similar effect on parkin in patients. 
Our finding that parkin is degraded following its apparent activation by oxidative stress-induced 
phospho-Ub suggests a novel regulatory mechanism for active parkin that can be manipulated 
therapeutically. Furthermore, this finding promises to be relevant for PD patients because of the 
increased phospho-Ub signal in the substantia nigra of these patients. 
7.2 Conversion of L-DOPA to dopamine is not necessary for its effect on parkin 
 In chapter 4, we showed that abrogating L-DOPA's conversion to dopamine using the 
AADC inhibitor carbidopa did not attenuate parkin loss from L-DOPA. This suggests that 
conversion to dopamine is not required for L-DOPA's effect on parkin in our system. However, 
just because dopamine is not necessary in our model doesn't mean that it wouldn't be sufficient to 
decrease parkin in other circumstances. Indeed, it's likely that elevated cytosolic dopamine would 
be capable of reducing parkin levels. This is because part of L-DOPA's effect on parkin is 
mediated by oxidative stress, and elevated cytosolic dopamine has been shown to increase 
cellular oxidative stress [441], [442]. The potential of cytosolic dopamine to decrease parkin 
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levels would be interesting to explore given the evidence that cytosolic dopamine may contribute 
to PD pathogenesis [341]. To test this directly, an attractive strategy would be to inhibit VMAT, 
the transporter responsible for dopamine sequestration from the cytosol into synaptic vesicles. 
This can be done either pharmacologically, using a VMAT inhibitor like reserpine, or via 
shRNA-mediated VMAT knockdown. If VMAT inhibition is found to decrease parkin levels, 
this result could have implications for parkin loss in PD because VMAT activity has been found 
to be decreased in synaptic vesicles from PD patients [443]. 
7.3 L-DOPA-mediated parkin loss occurs via two distinct mechanisms 
 Though our findings regarding oxidative stress-induced parkin loss following L-DOPA 
treatment may be broadly applicable to other stressors, like dopamine, that cause oxidative stress, 
we also identified an oxidative stress-independent pathway by which L-DOPA decreases parkin 
levels, the nature of which remains unclear. 
 To elucidate the oxidative stress-independent mechanism of parkin loss, several avenues 
of investigation can be pursued. The first unanswered question about this mechanism is how L-
DOPA exerts an effect on parkin levels independently of its autoxidation or its conversion to 
dopamine. As discussed in Section 4.3.1, there are several possible mechanisms by which this 
may take place, the most likely of which are L-DOPA stimulation of its reported receptor OA1 
and the metabolism of L-DOPA by COMT. To examine if OA1 is involved in parkin loss from 
L-DOPA, it would first be necessary to determine if PC12 cells express this receptor; if they do, 
knocking it down in conjunction with L-DOPA treatment should reveal whether it's involved in 
parkin loss from L-DOPA; if they don't, then L-DOPA-mediated OA1 stimulation is not 
responsible for parkin loss in PC12 cells. To examine the possible contribution of L-DOPA 
  158 
metabolism by COMT to parkin loss, a first step would be to investigate whether a COMT 
inhibitor like tolcapone attenuates L-DOPA-mediated parkin loss.  
 Further downstream in the oxidative stress-independent pathway of parkin loss, our data 
suggest that the serine protease HtrA2/Omi may play a role. To determine whether or not this is 
actually the case, it will be critical to interfere with HtrA2 using a targeted approach like 
shRNA-mediated knockdown and assess whether this attenuates L-DOPA-induced parkin loss. If 
HtrA2 is not found be involved in parkin loss after L-DOPA treatment, it may be helpful to 
perform an shRNA screen targeting known cellular proteases in the presence of L-DOPA. 
 Alternatively, parkin may not be cleaved proteolytically following L-DOPA treatment 
but may instead form a urea-insoluble aggregate that doesn't enter the gel during Western 
blotting. To test whether this is the case, lysates from cells expressing our moderately-
overexpressed, tagged parkin with and without L-DOPA can be subjected to a filter trap assay, a 
method for detecting large insoluble protein aggregates [444]. Detecting parkin aggregates using 
this assay should be performed using an antibody against the tag, such that un-transduced cells 
can serve as a negative control for signal specificity. 
7.4 Trib3 is not necessary for parkin loss from L-DOPA 
 Previous results from our lab indicate that Trib3 is involved in parkin loss from 6-OHDA. 
However, as described in Chapter 3, we did not observe a protective effect from Trib3 
knockdown on L-DOPA-induced parkin loss, despite an apparent increase in Trib3 protein after 
L-DOPA treatment. This suggests that Trib3 is not necessary for parkin loss from L-DOPA and 
therefore that 6-OHDA and L-DOPA decrease parkin levels through non-identical mechanisms. 
However, given that the effect of Trib3 knockdown on parkin loss was examined at different 
time points during 6-OHDA and L-DOPA exposure, it would be desirable to examine the effect 
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of Trib3 knockdown on L-DOPA- and 6-OHDA-induced parkin loss at the same time to more 
conclusively determine whether they decrease parkin in different ways. 
7.5 NADPH oxidase activity is not necessary for parkin loss from L-DOPA 
 Chapter 5 described our finding that NADPH oxidases do not play a role in L-DOPA-
mediated parkin loss, despite full protection from this loss by the NADPH oxidase inhibitors 
AEBSF and VAS3947. Given that the oxidative stress-independent mechanism by which L-
DOPA decreases parkin is still unclear and that these inhibitors fully prevent parkin loss, 
understanding how they do this may shed light on the latter mechanism. In the case of AEBSF, 
part of its protective effect on parkin levels likely stems from its apparent ability to interfere with 
L-DOPA autoxidation, and another part may stem from inhibition of the serine protease Htra2. In 
the case of VAS3947, prevention of parkin loss could be a result of covalent binding of 
VAS3947 to parkin, which could cause it to misfold and therefore be resistant to L-DOPA-
induced degradation mechanisms. To test the possibility that VAS3947 covalently binds it, 
parkin could be immunoprecipitated following treatment of cells with VAS3947, and its 
modification assessed using mass spectrometry. 
 Though NADPH oxidase activity isn't required for parkin loss from L-DOPA, it's 
possible that this activity could contribute to parkin loss in other circumstances. For example, 
there is evidence that microglial NOX2 activation elevates oxidative stress in several models of 
neurodegeneration [409]. Given our finding that oxidative stress leads to parkin loss, future work 
could examine whether upregulation of NOX2 activity in these models induces neuronal parkin 
loss and whether such loss contributes to neurodegeneration. 
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7.6 Oxidative stress leads to parkin loss downstream of parkin binding to phospho-Ub 
 In Chapter 4, we demonstrated that oxidative stress from L-DOPA or hydrogen peroxide 
exposure leads to an induction of phospho-poly-Ub in PC12 cells and that parkin binding to this 
phospho-Ub is necessary for its oxidative stress-dependent degradation. In addition to showing 
that parkin loss following oxidative stress is downstream of its interaction with phospho-Ub, we 
also found that this interaction is critical for parkin loss following mitochondrial depolarization 
by CCCP. To our knowledge, this is the first demonstration that oxidative stress induces 
phospho-Ub formation and that parkin binding to stress-induced phospho-Ub leads to its 
degradation.  
 Given that parkin's interaction with phospho-Ub leads to its activation, a significant 
outstanding question of our work is why there seems to be a connection between parkin 
degradation and its apparent activation. I hypothesized in Chapter 4 that parkin degradation 
downstream of its binding to phospho-Ub may represent the normal turnover mechanism for 
activated parkin, serving as a check on levels of activated parkin in the cell. If this is the case, it 
would open a new dimension of parkin biology for investigation, because parkin's fate after its 
activation is currently unknown.  
 More work will be needed to conclusively determine whether parkin degradation 
following its binding to phospho-Ub in our models requires stress-induced factors other than 
PINK1. As discussed in Chapter 4, there are two pieces of evidence in favor of the possibility 
that PINK1-mediated ubiquitin phosphorylation is sufficient for parkin loss: the finding that 
PINK1 overexpression by itself can decrease levels of overexpressed parkin [296] and the 
observation that overexpression of wild-type, but not S65A ubiquitin, decreased overexpressed 
parkin levels [401]. To further examine the sufficiency of PINK1 stabilization for parkin loss, 
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several experiments can be performed. First, the observations that PINK1 and ubiquitin 
overexpression can decrease overexpressed parkin should be confirmed with endogenous parkin. 
If they are confirmed, it should be determined whether there are increased levels of phospho-Ub 
following PINK1 or ubiquitin overexpression and whether parkin mutants that can't bind 
phospho-Ub (either generated by CRISPR or using our "moderately-overexpressed" mutants) fail 
to be degraded by PINK1 or ubiquitin overexpression. If this is the case, it would suggest that 
parkin association with phosphorylated ubiquitin is sufficient to cause its degradation and that 
other stress-induced factors resulting from L-DOPA, hydrogen peroxide, and CCCP treatment 
are not necessary for this degradation. Conversely, if phospho-ubiquitin induction by PINK1 or 
ubiquitin overexpression is not sufficient to induce parkin degradation, it would suggest that 
other stress-induced factors are critical for parkin degradation following its interaction with 
phospho-Ub. To identify such factors, future studies could examine which stress-related factors 
are commonly induced by L-DOPA, hydrogen peroxide, and CCCP, individually introduce these 
factors together with PINK1 overexpression in cells, and assess which are able to decrease 
parkin levels. 
 Another question raised by our work is how parkin's interaction with phospho-Ub leads 
to its degradation. Two possible answers, discussed in Chapter 4, are that parkin's interaction 
with phospho-Ub brings it into contact with degradative factors or that this interaction induces a 
conformational change in parkin that leads to its loss. To begin to distinguish between these 
possibilities, several experiments can be performed. First, if PINK1 overexpression proves 
sufficient to decrease parkin in a phospho-Ub-dependent manner, a PINK1 construct lacking the 
mitochondrial localization sequence can be ectopically targeted to the surface of different 
organelles, and parkin degradation can be assessed. It was previously reported that PINK1 
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targeted to peroxisomes or lysosomes using a regulated heterodimerization system could induce 
parkin translocation and ubiquitination of these organelles [445]. This implies that PINK1 can 
phosphorylate ubiquitin on or near the surface of these organelles. As such, if PINK1 targeted to 
a different organelle fails to induce parkin degradation, it would suggest that mitochondrial 
factors are important for this degradation and that phospho-Ub may serve to bring parkin in 
proximity to these factors. Conversely, if ectopically expressed PINK1 can still decrease parkin, 
it may suggest that something about phospho-Ub binding per se leads to parkin loss. 
 As described in Chapter 1, binding to phospho-Ub induces a conformational change in 
parkin in which the IBR domain moves away from the Ubl domain. It was recently reported that 
this displacement of the IBR domain reveals a novel ubiquitin binding site and that parkin 
mutations that prevent ubiquitin binding to this site inhibit parkin activity [171]. If it appears that 
parkin's interaction with phospho-Ub per se leads to its degradation, it would be interesting to 
test whether this is due to parkin's interaction with ubiquitin at this novel site uncovered by 
phospho-Ub binding. To do this, future experiments could make use of the parkin mutants 
characterized in the above study that are deficient in binding ubiquitin at the novel site. 
 Finally, as discussed in Section 1.2.4.2.3, many cellular stressors have been reported to 
decrease parkin protein levels. An outstanding question of our work is whether all or some of the 
parkin loss from these other stressors also takes place by the phospho-Ub-dependent mechanism 
identified here. Given that we found this pathway to be involved in parkin loss from three 
different stressors (L-DOPA, hydrogen peroxide, and CCCP), it seems likely that this 
mechanism plays a role in parkin loss from other stressors as well, particularly those that elicit 
oxidative and/or mitochondrial stress. 
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7.7 Parkin is degraded proteasomally downstream of binding to phospho-Ub 
 Parkin degradation following mitochondrial depolarization or PINK1 overexpression was 
previously found to be proteasomal [201], [296]. In line with these findings, Chapter 4 presented 
evidence that proteasomal degradation is responsible for parkin loss downstream of binding to 
phospho-Ub. However, contrary to the suggestion of one of the above studies and of many 
others, our data indicate that, at least following L-DOPA treatment, proteasomal parkin 
degradation is not a result of parkin autoubiquitination.  
 This finding raises the question of how parkin is targeted to the proteasome. Two 
possibilities that bear investigation are that direct binding of parkin to the proteasome via its Ubl 
domain leads to its degradation or that the ubiquitin ligase Nrdp1, which has previously been 
reported to ubiquitinate parkin, causes it to be degraded. To test the first possibility, future 
studies can knock down the proteasomal subunits Rpn13 and Rpn10, both of which have been 
reported to bind parkin's Ubl domain, and examine the effect this has on parkin degradation. In 
addition, it would be worthwhile to examine whether mutating the reported proteasome-
interacting site in parkin's Ubl domain, centered around I44, abrogates parkin loss downstream of 
its interaction with phospho-Ub. To test the involvement of Nrdp1 in parkin loss, the former can 
be knocked down. Additionally, the effects of L-DOPA on Nrdp1 levels and its possible 
interaction with parkin can be assessed. 
7.8 Canonical parkin activity on mitochondria is not required for its loss from L-DOPA 
 Parkin activation by phospho-Ub following mitochondrial depolarization has been shown 
to lead to a positive-feedback loop involving parkin-mediated poly-ubiquitination of 
mitochondrial proteins and phosphorylation of these poly-ubiquitin chains by PINK1. Therefore, 
it was surprising and novel that we didn't find evidence of parkin-mediated mitochondrial poly-
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ubiquitination following phospho-Ub induction by L-DOPA, as described in Chapter 4. This 
chapter presented two pieces of evidence for the lack of parkin-mediated mitochondrial poly-
ubiquitination following L-DOPA: lack of ubiquitination of Mfn2 and failure of overexpressed 
parkin to increase the phospho-poly-Ub signal above that in cells with only endogenous levels of 
parkin. As discussed in Chapter 4, a weakness of the latter experiment as a measure of 
mitochondrial parkin activity is the presence of endogenous parkin in all conditions. Therefore, it 
would be desirable to confirm that parkin doesn't contribute to phospho-poly-Ub chain formation 
using another method. The most straightforward way to do this would be to knock down parkin 
and determine whether this decreases phospho-poly-Ub formation following L-DOPA.  
 Given that we did not observe evidence of canonical parkin activity following L-DOPA 
treatment, an outstanding question is whether parkin is activated by L-DOPA-induced phospho-
Ub. Although the most straightforward way to assess this is to examine levels and/or 
ubiquitination of parkin substrates, this is disadvantageous for a couple of reasons. First, many 
parkin substrates have been reported, and lack of ubiquitination of one or several of them could 
simply mean that parkin activity is directed at other substrates following L-DOPA treatment. 
Conversely, the detection of ubiquitination or decreased levels of a parkin substrate could reflect 
activity of a different ubiquitin ligase, which would require parkin knockdown to rule out. 
 Fortunately, several experiments that don't rely on examination of parkin substrates can 
be performed to shed light on the question of parkin activity following L-DOPA treatment. All of 
these experiments depend on proteasomal inhibition in the presence of L-DOPA to prevent the 
degradation of parkin following its interaction with phospho-Ub. In addition, CCCP should be 
used as a positive control for activated parkin in all of these methods.  
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 The first method to examine parkin activity following L-DOPA treatment relies on 
assessment of stable oxy-ester formation between C431S parkin and ubiquitin. During the 
normal process of parkin-mediated ubiquitination, the catalytic cysteine of parkin covalently 
binds the C-terminal of ubiquitin via its thiol group before transferring the ubiquitin to a 
substrate. When this catalytic cysteine is replaced with a serine, which has an -OH group instead 
of a thiol, ubiquitin becomes "trapped" upon its transfer to this serine [446]. Parkin containing 
such trapped ubiquitin can then be detected by Western blotting because it migrates at a higher 
molecular weight than unmodified parkin. Alkaline treatment can break the bond between 
ubiquitin and S431, allowing this species to be distinguished from parkin that has been mono-
ubiquitinated on a lysine residue. Given that this technique catches parkin "in the act" of 
ubiquitination, the detection of trapped ubiquitin on parkin following L-DOPA treatment would 
suggest that parkin is indeed active following its binding to L-DOPA-induced phospho-Ub. 
 A closely related technique to detect activated parkin to that described above relies on 
novel activity probes recently described in a study by Pao et al. [162]. Pao et al. chemically 
modified ubiquitin-charged E2 enzymes to trap the catalytic cysteine of active parkin in the 
process of receiving ubiquitin from the E2, leading to a covalently-modified parkin molecule. 
Incubating cell lysates with these probes led to covalent probe addition exclusively to parkin in 
an activated conformation, as detected by a shift in the molecular weight of modified parkin 
[162].  Future studies can add these probes to lysates of cells treated with L-DOPA to determine 
whether parkin is activated. An advantage of this technique to that described above is that these 
probes can label endogenous, non-mutated parkin. 
 Finally, the last method recommended to assess parkin activity following L-DOPA 
treatment is immunoprecipitation of modestly overexpressed, tagged parkin followed by 
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stringent washing and an in vitro autoubiquitination assay. This method of assaying parkin 
activity has previously been described [447]. An important negative control for this method is 
the confirmation that identical treatment of catalytically inactive parkin does not generate an 
autoubiquitination signal. 
  If parkin is indeed found to be active following L-DOPA treatment using the above 
methods, it will be interesting to assess the purpose and targets of its activity following L-DOPA 
treatment. One possibility that should be examined is whether parkin activity leads to the 
formation of MDVs after L-DOPA treatment. 
7.9 Parkin knockdown does not exacerbate toxicity from L-DOPA or hydrogen peroxide 
 Chapter 6 presented preliminary evidence that parkin knockdown does not exacerbate 
cell death from L-DOPA or hydrogen peroxide treatment in PC12 cells, but that it may increase 
the initial rate of this death. Three possible explanations were offered to explain why we did not 
observe ultimate sensitization to these stressors upon parkin knockdown, each of which can be 
tested in future work.  
 To address the possibility that our parkin knockdown was not strong enough to reveal a 
sensitizing effect from parkin loss, it would be ideal to generate a parkin knockout cell line using 
CRISPR and assess whether these cells have an increased vulnerability to stress-induced death. 
To address the possibility that parkin isn't actually active after L-DOPA or hydrogen peroxide 
treatment because of modification or very rapid degradation following phospho-Ub binding, the 
activity assays described in the above section can be employed. Similarly, the hypothesis that 
parkin activity diminishes over the course of stress exposure can be examined by these activity 
assays. Finally, the possibility that L-DOPA directly modifies parkin can be assessed by parkin 
immunoprecipitation followed by mass spectrometry. 
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7.10 Final Remarks 
 The research presented in this dissertation has broken new ground on several fronts. First, 
we have shown for the first time that L-DOPA is capable of decreasing parkin levels in vitro. 
Second, we have demonstrated that the mechanism of L-DOPA-mediated parkin loss partially 
overlaps with the mechanism of parkin activation, raising the possibility that parkin activation 
and degradation may be normally coupled in the cell as a way to control active parkin levels. 
Finally, we have challenged the suggestion of previous studies that parkin-mediated 
autoubiquitination or mitochondrial ubiquitination is necessary for its loss downstream of PINK1 
activity. 
 The process we have studied here may be relevant for PD patients. There are several 
reasons for this. First, L-DOPA is the gold-standard treatment of PD motor symptoms, so the 
effects of L-DOPA that we observe in vitro may happen over time in patients. Second, our data 
implicates oxidative stress in parkin loss, and signs of oxidative stress are well-documented in 
the brains of PD patients. Finally, phospho-Ub, which we show to be critical for parkin loss from 
oxidative stress, has been found to be elevated in the substantia nigra of patients with Lewy body 
disease, a broad disease category that includes PD [183]. 
 In addition to being of potential relevance to the disease process in PD, our findings have 
an important implication for the development of therapeutic strategies based on parkin 
activation. Specifically, our observation that parkin is degraded following interaction with its 
activator phospho-Ub suggests that therapeutic strategies that delay parkin degradation following 
its activation may be especially promising. 
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Chapter 8 Materials & Methods 
8.1 Antibodies 
Table 8.1 Antibodies used 
Target Dilution Company Catalog Number 
Cleaved caspase 3 1:1000 Cell Signaling Technology 9661 
ERK1/2 1:5000 Santa Cruz Biotechnology SC-93 
GAPDH 1:1000 Novus Biologicals NB 300-221 
GFP 1:1000 Thermo Fisher Scientific A-11122 
GFP 
1:1000 
(IF) Thermo Fisher Scientific A10262 
HA 1:1000 Cell Signaling Technology 3724 
LC3B 1:1000 Abcam ab48394 
Mfn2 1:1000 Cell Signaling Technology 9482 
Opa1 1:1000 Cell Signaling Technology 80471 
Parkin 1:500 Cell Signaling Technology 4211 
Parkin 1:500 Cell Signaling Technology 2132 
phospho-Ub 1:1000 Cell Signaling Technology 37642 
Puromycin 1: 25000 EMD Millipore MABE343 
Tim23 1:1000 BD Biosciences 611222 
Tom20 1:1000 Cell Signaling Technology 42406 
Trib3 1:1000 Calbiochem ST1032 
UQCRC1 1:2000 Thermo Fisher Scientific 459140 
VDAC 1:1000 Cell Signaling Technology 4866 
Mouse 1:5000 LI-COR 925-68070 
Rabbit 1:5000 LI-COR 925-32211 
 
8.2 Materials & Reagents 
Western blotting: 
Cell Lysis Buffer (Cell Signaling Technologies) 
Bovine Serum Albumin (ThermoFisher Scientific) 
Tris Buffered Saline (ThermoFisher Scientific) 
Powdered milk (LabScientific) 
Tween 20 (ThermoFisher Scientific) 
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cOmplete Mini protease inhibitor tablet –EDTA (Millipore Sigma) 
Protein Assay Dye Reagent Concentrate (Bio-Rad) 




Neurobasal Medium (Thermo Fisher Scientific) 
B-27 supplement (Thermo Fisher Scientific) 
Glutamax (Thermo Fisher Scientific) 
Poly-D-lysine (P1149, Millipore Sigma) 
HBSS (Thermo Fisher Scientific) 
Rat tail collagen (Roche; Millipore Sigma) 
RPMI 1640 medium (Corning) 
Horse serum (Millipore Sigma) 
Fetal bovine serum (Gemini BioProducts) 
 
NGF (kind gift of Genentech, Gemini Bio-Products #300-174P) 
DMEM medium (Corning) 
DMEM/F12 medium (Cellgro) 
 
Miscellaneous: 
Lenti-X concentrator (Clontech, #631231) 
Halt protease & phosphatase inhibitor (Thermo Fisher Scientific #78440) 
Superblock blocking buffer (Thermo Fisher Scientific) 
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Drugs/inhibitors: 
L-DOPA (Millipore Sigma) 
Hydrogen peroxide (Wallgreens) 
CCCP (Millipore Sigma) 
Carbidopa (Tocris) 
Epoxomicin (Selleckchem.com) 
Bafilomycin A1 (gift from YoungJoo Yang from Ai Yamamoto's lab) 
Z-VAD-FMK (Selleckchem.com) 
UCF-101 (EMD Millipore) 
Glutathione (Millipore Sigma) 
Cycloheximide Millipore Sigma) 
AEBSF (Millipore Sigma) 
VAS3947 (EMD Millipore) 
Lucigenin (Cayman Chemical) 
NADPH (Cayman Chemical) 
Puromycin (Millipore Sigma) 
8.3 Cell culture 
8.3.1 PC12 cells 
Cells were grown on dishes coated with rat tail collagen. Collagen was dissolved in 5 mL 
0.2% (v/v) acetic acid and diluted 1:20 in sterile, deionized water prior to coating plates. 139 
µL/cm2 or 17.6 µL/cm2 of diluted collagen was added to multi-well plates or 10 cm dishes, 
respectively, and plates were left uncovered to dry overnight in a laminar flow hood. Cells were 
plated the following day.  
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Undifferentiated PC12 cells were maintained in RPMI 1640 supplemented with 10% 
horse serum, 5% fetal bovine serum, and 1% penicillin-streptomycin. When cells were ≥70% 
confluent, they were split or used for differentiation.  
To differentiate PC12 cells, cells from one 10 cm dish of undifferentiated PC12 cells 
were first resuspended in 4mL RPMI with 1% horse serum and 1% penicillin-streptomycin. 
Then, cells were passed through a 5-mL repeat pipettor tip to disperse them, counted using a 
hemacytometer, and plated at a density of ~3x105 cells/mL (1mL/well in a 12-well plate) in 
RPMI with 1% horse serum, 1% penicillin-streptomycin, and 50ng/mL human recombinant 
NGF. The remaining undifferentiated PC12 cells were plated on a freshly-coated 10 cm dish. 
Cells were used in experiments after 5-10 days of differentiation. In experiments with lentiviral 
transduction, cells were transduced after 3-5 days of differentiation; for shRNA constructs, cells 
were treated with drugs 4-5 days after transduction; for overexpression constructs, cells were 
treated with drugs 3-5 days after transduction. 
For both differentiated and undifferentiated cells, half of the medium was replaced every 
2-3 days with fresh medium and cells were kept in an incubator under 7.5% CO2. 
8.3.2 Primary rat cortical neurons 
Cortical neurons were grown on plates coated with poly-D-lysine. 139 µL/cm2 of 0.1 
mg/mL poly-D-lysine was added to multiwell plates, and plates were left covered in the cell 
culture incubator overnight. The following day, the poly-D-lysine solution was aspirated and the 
wells were washed at least three times with sterile deionized water. The wells were allowed to 
dry and cells were plated the same day. 
Cortices were harvested from E17-E18 rat embryonic brains in cold HBSS without 
calcium chloride, magnesium chloride, or magnesium sulfate using a dissection microscope. The 
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brains were very generous gifts from Carlo Corona (Dr. Michael Shelanski's lab) and Chandler 
Walker (Dr. Ulrich Hengst's lab). The cortices were dissociated by a 10-minute incubation in 
0.05% trypsin at 37°C and subsequent trituration in HBSS with two fire-polished pasteur pipettes 
of decreasing aperture size. Neurons were then passed through a cell strainer, counted, and plated 
at 5x105 cells/mL on poly-D-lysine-coated plates in Neurobasal medium supplemented with 2% 
B27, 500mM Glutamax, and 1% penicillin-streptomycin. 
Half of the medium was replaced with fresh medium twice a week, and cells were kept in 
an incubator under 5% CO2. Cells were used for experiments after 6-9 days in vitro. 
8.3.3 SH-SY5Y cells 
 Human neuroblastoma SH-SY5Y cells were a kind gift from Dr. Ismael Santamaria Perez 
and were grown in DMEM/F12 medium supplemented with 10% FBS, 2 mM glutamine, 1% 
penicillin-streptomycin in a under 5% CO2. 
8.3.4 Immortalized Mouse Embryonic Fibroblasts 
 Immortalized MEFs were a kind gift from Dr. Thong Ma, from Un Kang's lab. The 
isolation and immortalization of these cells were described in [296]. Cells were grown in DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin under 5% CO2. For low serum 
experiments, cells were grown in DMEM with 0.1% FBS. 
8.3.5 Human Embryonic Kidney 293T cells 
 HEK293T cells were grown in DMEM supplemented with 10% FBS and 1% penicillin-
streptomycin under 5% CO2. Cells were passaged every 3-4 days. 
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8.4 Cloning 
8.4.1 shRNA constructs 
 Annealed oligomer sequences (IDT) for shRNAs were cloned into the pLVTHM vector. 
The latter was cut using MluI and ClaI before ligation with annealed oligomer. The shRNA 
target sequences used in this study were as follows: Previously generated plasmids: Trib3: 5'-
TGCTCGATTTGTCTTCAGCAA-3'; Control shRNA (shTrib3 scrambled): 5'-
GACCCTTGAATTGACTGTT-3'; Parkin: 5'-GGACACATCAGTAGCTTTG-3'; plasmids 
generated in this study: PINK1: 5'-TCAGGAGATCCAGGCAATT-3'; NOX1: 5'-
AGATCTATTTCTACTGGAT-3'; NOX2: 5'-GTCATCACACTGTGTCTTA-3'; p22phox#1: 5'-
AAATTACTACGTCCGGGCTGT-3'; p22phox#2: 5'-AACCCAATTCCAGTGACAGAT-3'; 
DUOX1/2#1: 5'-GGAAGAAGGTGGAGATCAG-3'; DUOX1/2#2: 5'-
TCTCATTCCTGGAGCGACA-3'; DUOX1/2#3: 5'-TGACAAGGACTCAGCGGCA-3'. 
8.4.2 Tagged parkin under parkin promoter 
 Two steps were involved in generating a "moderately overexpressed" parkin construct. 
First, rat parkin cDNA was amplified from a previously generated parkin construct (described in 
[265]) using primers to attach HA- and FLAG-tags on the N-terminus. The primers used were: F: 
ctagcctcgaggtttaaacATGTACCCATACGATGTTCCAGATTACGCTGCAGCAAATGATATC
CTGGATTACAAGGATGACGACGATAAGctcccgcggacgcgtacgATAGTGTTTGTCAGG; R: 
tgcagcccgtagtttaaacctaCACGTCAAACCAGTGATC. This amplified, N-tagged cDNA was then 
inserted into a pWPI vector (Addgene) that had been linearized at the PmeI restriction site. In-
Fusion cloning (Clontech) was used for this purpose, according to the manufacturer's 
instructions. 
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 In the second step, the EF-1α promoter of the pWPI-HA-FLAG-parkin construct was cut 
out at the PpuMI and PacI sites, and the minimal human parkin promoter amplified from a 
commercially available luciferase construct (SwitchGear Genomics) was inserted in its place 
using the NEBuilder® HiFi DNA Assembly kit from New England Biolabs. 
8.5 Site-directed mutagenesis 
 Site-directed mutagenesis of  "moderately overexpressed" parkin was carried out using 
the Q5 Site-Directed Mutagenesis kit from New England Biolabs, according to the 
manufacturer's instructions. 
8.6 Lentiviral preparation 
Early passage 293T cells were plated at a density of ~14-18 x 106 cells/15cm plate. The 
next day, cells were transfected with 21 µg expression vector, 16.5 µg psPAX2, and 7.5 µg 
VSVg plasmids per plate using the calcium phosphate transfection method, as follows. Plasmids 
were combined in a 250 mM solution of calcium chloride. This solution was added directly to an 
equal volume of 2X HBSS, pH 7.0-7.2. The resulting solution was mixed briefly by pipetting 
and added right away to cells, using 2.5mL per plate. The cell medium was changed after an 
incubation period of at least 4 hours and at most overnight. Virus-containing medium was 
harvested 2 and 3 days after transfection, pooled, passed through a 0.45 µm filter, combined with 
1/3 the volume of Lenti-X concentrator, and incubated at 4°C overnight. The next day, the 
medium-Lenti-X mixture was centrifuged at 1500 x g at 4°C for 45 minutes, the supernatant was 
disposed of, and the tubes used for centrifugation were placed upside-down for several minutes 
to ensure maximal removal of supernatant. The virus-containing pellet was resuspended in sterile 
PBS at a ratio of 200µL PBS/ 36mL virus-containing medium, aliquoted, and stored at -80°C.  
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To evaluate viral titer, a range of viral solution volumes was added to differentiating 
PC12 cells, cells were fixed 3 days later, and GFP expression was evaluated by 
immunofluorescence. Viral infection efficiency was calculated by dividing the number of GFP-
positive cells by the number of nuclei in the same field (assessed by Hoechst stain) using Fiji. 
For knockdown experiments, viral solution volumes yielding ≥70% infection efficiency were 
used, with an effort to match infection efficiencies between viruses. For exogenous parkin 
experiments, viral titer was assessed by Western blot, with viral volumes for subsequent 
experiments adjusted to achieve equal expression levels between constructs. 
8.7 L-DOPA, hydrogen peroxide, and CCCP treatments 
Prior to drug treatment, half of the medium was removed from cells and the volume of 
remaining medium in each well was adjusted using conditioned medium. An equal volume of 
fresh medium containing drugs at 2X the working concentration was added to cells to initiate the 
experiment. 
For L-DOPA experiments, a 10 mM L-DOPA stock solution was prepared fresh before 
every experiment in 50 mM HCl and filter-sterilized. L-DOPA stock solution or an equal volume 
of 50 mM HCl was diluted in fresh medium before addition to cells. In experiments involving 
pretreatment of cells with an inhibitor, the inhibitor was added with fresh medium and L-DOPA 
was added directly to each well. 
3% (w/v) hydrogen peroxide was diluted with sterile distilled water 1:1000 before 
subsequent dilution in fresh medium. 
CCCP was dissolved in DMSO to yield a 10 mM stock solution, which was filter-
sterilized and added to fresh medium before addition to cells. The stock solution was stored at -
80°C and used multiple times. 
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8.8 Inhibitor & antioxidant treatments 
Inhibitors and antioxidants were dissolved in water when possible and in DMSO when 
not water-soluble. In most cases, stock solutions of the drugs were diluted in fresh medium 
before addition to cells (with the exception of cycloheximide, in which case fresh medium was 
added to cells the day before treatment and cycloheximide stock solution was added directly to 
cells). In such cases, drugs and cellular stressors (L-DOPA, H2O2, CCCP) were added to cells at 
the same time. In the cases of carbidopa and cycloheximide, the latter were added to cells before 
treatment with L-DOPA. Cells were pretreated with carbidopa for 1.5 hours and cycloheximide 
for ~15 minutes before L-DOPA addition. 
8.9 Western blotting 
Cell lysates were harvested in 1X Cell Lysis Buffer supplemented with Complete Mini 
protease inhibitor tablet –EDTA or directly in Western blot loading buffer (29% Cell Lysis 
Buffer, cOmplete Mini protease inhibitor tablet, 1X NuPage Reducing Agent, 1X NuPage LDS 
Sample Buffer, 36% water). Lysis buffers were added directly to culture plate wells.  
When harvested in Cell Lysis Buffer, lysates were kept on ice and subsequently sonicated 
with a probe sonicator at the lowest amplitude with a pattern of 1 second ON/ 1 second OFF, for 
a total of 10 seconds ON. The protein concentration in lysates was then determined using the 
Bradford assay using Protein Assay Dye Reagent Concentrate and following the manufacturer’s 
instructions for using a microplate and plate reader. Of note, the BCA assay is inappropriate for 
measuring protein concentrations of samples treated with L-DOPA because L-DOPA itself 
produces a color in the assay. Upon determining protein concentrations, samples were diluted 
with water to match the concentration of the most dilute sample and supplemented with NuPage 
Reducing Agent and NuPage LDS Sample Buffer.  
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Following addition of Reducing Agent and LDS Buffer to cell lysates, these were boiled 
for 20 minutes in a dry heat bath at 95-100°C. After boiling, sample proteins were separated by 
SDS-PAGE and detected by Western blotting. The NuPAGE electrophoresis system was used, 
with precast Bis-Tris gels, MOPS SDS running buffer (or MES SDS running buffer for low 
molecular weight proteins), and NuPAGE transfer buffer. Generally, 4-12% gels were used and 
~20 µg of protein was added per well. For one sample per gel, half the sample was added in an 
adjacent well to the full volume of sample to serve as a standard (see below). Proteins were 
transferred onto a nitrocellulose membrane for ~2 hours at 35V at 4°C. Following transfer, 
membranes were blocked for 1 hour at room temperature with gentle shaking in 5% milk in 
TBST (TBS + 1% Tween 20).  
Membranes were probed with primary antibodies diluted in TBST with 5% BSA 
overnight at 4°C. The next day, membranes were subjected to 3 five-minute washes in TBST, 
incubated for 1 hour at room temperature with LI-COR IRDye secondary antibodies in 5% 
BSA/TBST in the dark, and washed three times again. Following incubation with secondary 
antibodies, membranes were kept in TBS in the dark.  
Membranes were imaged using an Li-Cor Odyssey CLX scanner and band intensities were 
quantified using Image Studio Lite software (ver. 4.0.21). Briefly, after background subtraction, 
the signal from the lane in which a half volume of sample was loaded was assigned a value of 
"0.5" using the "concentration standard" feature. Similarly, the signal from the lane 
corresponding to full volume of sample was assigned a value of "1". The program's linear 
interpolation feature was then used to assign values to the remaining bands on the blot.  
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For most experiments, bands of interest were normalized to the average of the 
corresponding ERK1 and ERK2 signals, though sometimes Ponceau stain was also used as a 
loading control 
8.10 Subcellular fractionation 
To prepare crude mitochondrial and cytosolic fractions from cells, the following protocol 
was followed. Cells and lysates were kept on ice for the duration of the procedure, and all 
centrifugation steps were performed at 4°C. First, cells were sprayed from the dish in PBS and 
pelleted by centrifugation. Cells from four wells of a 24-well plate were combined in one tube. 
70 µL fractionation buffer was added to the cell pellet. The fractionation buffer consists of 220 
mM mannitol, 70 mM sucrose, 20 mM Hepes-KOH (pH 7.5), 2 mg/ml BSA, 1 mM EDTA. Halt 
protease/phosphatase inhibitor was added to the buffer right before use. 
 Cells were lysed by passage through a 27G needle thirty times, until there were about 8 
broken nuclei for every unbroken cell. To remove cell debris & nuclei, samples were centrifuged 
at 1,000 x g for 10 minutes. The supernatant was set aside and the nuclear fraction was washed 
with 60 µL fractionation buffer and centrifuged a second time. The supernatant from this second 
spin was combined with the supernatant from the first spin and centrifuged at 10,000 x g for 10 
minutes to separate the mitochondria-rich pellet from the cytosolic fraction. The mitochondria-
rich pellet was washed three times by resuspending the pellet in 60 µL fractionation buffer and 
re-pelleting at 10,000 x g for 10 minutes. Then, the mitochondrial pellet was resuspended in 13 
µL Cell Lysis Buffer (Cell Signaling) with cOmplete Mini Protease inhibitor. The mitochondrial 
and cytosolic fractions were supplemented with NuPAGE Reducing Agent and LDS sample 
buffer, boiled for 20 minutes at 95°C, and used for Western blotting following the standard 
protocol. 
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8.11 qPCR 
Analysis of mRNA by qPCR was performed as in [265]. Briefly, total cellular RNA was 
extracted using TRI reagent (Molecular Research Center). cDNA was synthesized using the first-
strand cDNA synthesis kit (Origene). qPCR was performed using FastStart SYBR Green Master 
Mix (Roche) and an Eppendorf Realplex Mastercyler. The following cycling protocol was used: 
1 cycle at 95°C for 10 min and 40-45 cycles of amplification: 95°C for 15 s, 58–60°C for 30–60 
s, 72°C for 30–60 s. Relative mRNA amounts were determined using the delta-delta Ct method 
with 18S rRNA as the housekeeping gene. The following primers were used: Parkin: F: 
GGCCTTTGCAGTAGACAAAA; R: ACCACAGAGGAAAAGTCACG; 18S: F: 
TTGATTAAGTCCCTGCCCTTTGT; R: CGATCCGAGGGCCTCACTA; PINK1: F: 
AAAGGCCCAGATGTCGTCTC; R: GCTTAAGATGGCTTCGCTGG; NOX1: F: 
AATTCCAGCGTGCACACAAC; R: GACGTCAGTGGCTCTGTCAA; NOX2: F: 
CCATCCATGGAGCTGAACGA; R: GTCATAGGAGGGTTTCCGGC; p22phox: F: 
TTGTTGCAGGAGTGCTCATC; R: CTGCCAGCAGGTAGATCACA; DUOX1#1: F: 
CCGTTTCTTGGGAGGTCCAGCGAT ; R: CGTGGTAGCCGAAGAAGACACCCAG; 
DUOX1#2: F: TCAAGGGGAGTGGATTTGGCTTCGG; R: 
CATCCACGACTCGGATCTGTCCAGG; DUOX1#3: F: AGTACGACCTGGTGCTGTTG; R: 
TTGTCGAAGAGTCCAGTGGC; DUOX2#1: F: TGCTCTCAACCCCAAAGTG; R: 
TCTCAAACCAGTAGCGATCAC; DUOX2#2: F: CAGCGCTACGACGGCTGGTTTA; R: 
CCCAAGCACTGTGCGGTTGT; DUOX2#3: F: 
CCTGTTACTGTGATTGACTACTTTGAGG; R: CTGTCTGGAAGCAGCTGGACAGTG. 
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8.12 High Performance Liquid Chromatography 
 HPLC analysis would not have been possible without the generous assistance of Dr. 
Eugene Mosharov.  
 Cells were washed twice with cold PBS, detached from wells via forceful pipetting, and 
pelleted at maximum speed in a table-top centrifuge for 5 minutes at 4°C. The supernatant was 
then removed and the cell pellet was resuspended in 75 µL PBS.  25 µL of this cell mixture was 
removed, pelleted, and resuspended in 40 µL Cell Lysis Buffer with protease inhibitors. These 
samples were then sonicated, and the Bradford assay was performed to determine protein 
concentrations. The remaining 50 µL of cell mixture was mixed with an equal volume of 0.5 M 
trichloroacetic acid and vortexed for 10 seconds. These samples were then centrifuged at 10,000 
x g for 2 minutes at 4°C, and the supernatant was transferred to a new tube. This supernatant was 
used for HPLC. 
 Supernatant samples were separated on a VeloSep RP-18, 3 µm, 100 x 3.2 mm column 
(Chrom Tech, Apple Valley, MN) using an Agilent Technologies (Palo Alto, CA) 1100 series 
quaternary pump. The mobile phase consisted of 45 mM NaH2PO4, pH 3.2, 0.2 mM EDTA, 1.4 
mM heptanesulfonic acid, and 5% methanol. L-DOPA peaks were detected using an ESA 
(Chelmsford, MA) Coulochem II electrochemical detector at 350 mV oxidation potential. 
Relative L-DOPA levels were calculated by normalizing the area under the L-DOPA HPLC peak 
to the protein concentration from the same sample. 
8.13 Lucigenin Assay 
 Cells were washed 3 times with cold PBS, then harvested in Krebs-HEPES buffer 
("reaction buffer") with Halt protease/phosphatase inhibitor and 5 mM EDTA (100 µL was used 
to harvest cells from one well of a 12-well plate. The composition of the reaction buffer is: 20 
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mM HEPES, 99 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1 mM KH2PO4, 1.9 mM CaCl2, 25 
mM NaHCO3, 11.1 mM glucose, pH 7.44. Following harvest, cells were incubated on ice for 10 
minutes to allow for cell swelling from isotonic buffer. Then, cells were subjected to 3 snap 
freeze-thaw cycles using liquid nitrogen. Cell lysis was confirmed by looking at lysates under a 
microscope. Next, protein concentrations of homogenates were assessed using the Bradford 
assay. Protein concentrations were equalized using reaction buffer. Fresh stocks of lucigenin (5 
mM, 1000X) and NADPH (5 mM, 50X) were prepared in reaction buffer for each experiment. 
Cell lysates were combined with lucigenin and added to a white-walled microplate with or 
without 50 µM VAS3947. After a 5-minute incubation period in the dark, NADPH was added to 
start the lucigenin reactions and luminescence measurements were immediately started using a 
microplate reader. An integration time of 2 seconds was used. 
8.14 Immunofluorescence 
 Cells were fixed for 15 min in 4% paraformaldehyde that was not more than 10 days old and 
then washed 3 times with 1X PBS. Cells were then blocked with Superblock blocking buffer 
supplemented with 0.3% Triton X-100 for 1-2 h at room temperature and incubated overnight at 4°C 
with primary antibody in Superblock/Triton X (chicken anti-GFP, 1:1000, #A10262, Thermo Fisher 
Scientific) with gentle shaking. The next day, primary antibody was washed off in 3 8-minute washes 
with gentle shaking using 1X PBS. Cells were then incubated with fluorescent secondary antibody in 
Superblock/Triton X for 1 hour with gentle shaking (AlexaFluor-488 anti-chicken, 1:1000, #A11039, 
Thermo Fisher Scientific). Cells were then washed 3 X 8 minutes in 1X PBS with gentle shaking. 
Hoechst 33328 was added in the first wash (1:2500). Cells were kept in 1X PBS before imaging 
using an inverted fluorescence microscope. 
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8.15 Quantification of cell death 
 Cell death was assessed by adding a lysis buffer to cells (150 µl lysis buffer per cm2) that 
disintegrates the plasma membrane while keeping nuclei intact and counting viable nuclei 
manually using a hemacytometer or in an automated fashion using a Moxi Z Mini Automated 
Cell Counter. At least 200 nuclei were counted per condition. 10X lysis buffer recipe: 5 g of 
cetyldimethyl-ethanolammonium bromide, 0.165 g of NaCl, 2.8 ml of glacial acetic acid, 50 ml of 
10% Triton X-100, 2 ml of 1 M MgCl2, 10 ml of 10X PBS, and 35.2 ml of H2O. 
8.16 Statistical analysis 
 Statistical analysis was performed using GraphPad Prism 6 and using an online multiple 
comparison correction resource (http://alexandercoppock.com/statistical_comparisons.html) 
developed by Alexander Coppock as described in: Coppock, Alexander. 2015. "10 Things to 
Know About Multiple Comparisons."  EGAP Methods Guides.  
For most experiments, values were normalized to the control condition in that experiment before 
replicate experiments were combined. Paired t-tests were performed in most cases, followed by 
Holm correction for multiple comparisons. In time-course analyses, unpaired t-tests at each time 
point followed by Holm-Sidak correction for multiple comparisons were used. For analysis of 
differences between parkin mutants, one-way ANOVA of stressor-treated mutants was 
performed, followed by Holm-Sidak correction for multiple comparisons. For analysis of the 
cycloheximide experiment, repeated measures 2-way ANOVA of data from the 12-48 hour time 
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